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Cationic liposomes of dimethyldioctadecylammonium bromide (DDA) incorporating 
the glycolipid trehalose 6,6-dibehenate (TDB) forms a promising liposomal vaccine 
adjuvant. To be exploited as effective subunit vaccine delivery systems, the 
physicochemical characteristics of liposomes were studied in detail and correlated with 
their effectiveness in vivo, in an attempt to elucidate key aspects controlling their 
efficacy. This research took the previously optimised DDA-TDB system as a 
foundation for a range of formulations incorporating additional lipids of 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), by incrementally replacing the cationic content within DDA-
TDB or reducing the total DDA-TDB dose upon its substitution, to ascertain the role 
of DDA and the effect of DDA-TDB concentration in influencing the resultant 
immunological performance upon delivery of the novel subunit TB vaccine, Ag85B–
ESAT-6-Rv2660c (H56 vaccine).  
 
With the aim of using the DPPC based systems for pulmonary vaccine delivery and the 
DSPC systems for application via the intramuscular route, initial work focused on 
physicochemical characterisation of the systems with incorporation of DPPC or DSPC 
displaying comparable physical stability, morphological structure and levels of antigen 
retention to that of DDA-TDB. Thermodynamic analysis was also conducted to detect 
main phase transition temperatures and subsequent in vitro cell culture studies 
demonstrated a favourable reduction in cytotoxicity, stimulation of phagocytic activity 
and macrophage activation in response to the proposed liposomal immunoadjuvants.  
 
Immunisation of mice with H56 vaccine via the proposed liposomal adjuvants showed 
that DDA was an important factor in mediating resultant immune responses, with 
partial replacement or substitution of DDA-TDB stimulating Th1 type cellular 
immunity characterised by elevated levels of IgG2b antibodies and IFN-γ and IL-2 
cytokines, essential for providing protective efficacy against TB. Upon increased 
DSPC content within the formulation, either by DDA replacement or reduction of 
DDA and TDB, responses were skewed towards Th2 type immunity with reduced 
IgG2b antibody levels and elevated IL-5 and IL-10 cytokine production, as resultant 
immunological responses were independent of liposomal zeta potential.  
 
The role of the cationic DDA lipid and the effect of DDA-TDB concentration were 
appreciated as the proposed liposomal formulations elicited antigen specific antibody 
and cellular immune responses, demonstrating the potential of cationic liposomes to be 
utilised as adjuvants for subunit vaccine delivery. Furthermore, the promising 
capability of the novel H56 vaccine candidate in eliciting protection against TB was 
apparent in a mouse model. 
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1.1. Vaccines 
1.1.1. Vaccines for the prevention of disease 
The scientific foundation that shaped the concept of vaccination was fashioned by 
Edward Jenner in the eighteenth century when he recognised that patients with 
smallpox could be protected when vaccinated with the related cowpox virus. This led 
to the development of an effective vaccine which ultimately led to the abolition of 
smallpox by the end of the twentieth century, whilst also inspiring the intention of 
providing protection against exposure to contagious diseases (Seder & Hill, 2000; 
Plotkin, 2005).   
 
Indeed, vaccination as a deliberate endeavour was initiated by Louis Pasteur when he 
discovered attenuation upon inadvertently inoculating an aged chicken cholera culture 
into chickens, exemplifying his belief that “chance favours the prepared mind” 
(Plotkin, 2005). Subsequent work conducted by Pasteur, when developing vaccines 
against anthrax and rabies, verified the hypothesis that the attenuation of pathogens 
could be affected by environmental factors such as extreme temperature, oxygen and 
chemicals. Another major breakthrough in the field of vaccination can be attributed to 
the recognition of antibody and cellular responses of the adaptive immune system, 
pioneered by Paul Ehrlich and Ilya Mechnikov, who were both acknowledged for their 
work on immunity when receiving the prestigious accolade of a Noble Prize early in 
the twentieth century. Such a discovery prompted vaccinologists to focus on eliciting 
adaptive immune responses (Plotkin, 2005). 
 
As we have entered the 21
st
 century, vaccines can be regarded as an efficient and 
essential means of health care and their impact is evident, particularly in the 
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developing world (O’Hagan et al, 2001). Moreover, they provide the ultimate 
biomedical guarantee of disease prevention, and although universal eradication of 
disease is not feasible, control of disease is, and this can only be managed if 
vaccination coverage is sustained. Moreover, vaccination provides various benefits to 
individuals, families, employers, governments and societies. Indeed, the importance of 
vaccination is widely endorsed by the specialised United Nations (UN) agency of the 
World Health Organisation (WHO), and the World Bank suggests that immunisation 
must be one of the main public health initiatives that governments should invest in 
(Taylor et al, 2009).  
 
The basic principle of vaccination allows an individual to attain immunity against an 
infectious agent without enduring an initial infection, which is essential as the first or 
innate response to a natural infection is not fast enough to deter the onset of major 
symptoms. In contrast, memory cells of an adaptive immune response can induce rapid 
and robust protective reactions when exposed to an infectious agent for the second 
time (Perrie, 2006). The innate and adaptive immune responses will be discussed in 
further detail in section 1.2. 
 
1.1.2. Types of vaccines 
Vaccines can be categorised into three main types; live, inactivated and subunit, as 
summarised in Table 1.1. The most widely used vaccines are of an inactivated nature 
as they can advantageously obliterate infected areas whilst maintaining present 
immunogenicity against certain infectious diseases. However, in comparison to 
vaccines of a live, attenuated form, although its administration is safe, the use of 
inactivated vaccines has many associated disadvantages as it is less potent, largely 
Chapter 1 – General Introduction 
    
 
 26 
limited to a humoral immune response, requires additional dosages and incurs 
undesirable host reactions and reversion to virulence (Black et al, 2010). 
 
Table 1.1. The categorisation of the main types of vaccines into live, inactivated and subunit form. 
In addition, experimental DNA vaccines, therapeutic cancer vaccines and toxoid vaccines using 
detoxified exotoxins have also been created (O’Hagan et al, 2001; Perrie, 2006). 
 
Live vaccines have an adjuvant capacity based upon the developed capability of the 
immune system to detect signs of potentially hazardous microbes, contributing 
immensely to disease control. Despite drawbacks of certain live vaccines for example, 
mutations of the polio virus and virus perseverance, its application continues to 
markedly reduce the effects of associated diseases (Minor, 2002; Oxman et al, 2005). 
A further example of a live, attenuated vaccine is Bacille Calmette-Guérin (BCG) 
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which is economical to process and dispense and efficacious in a variety of situations, 
particularly in strong and fatal instances of infant tuberculosis (Bloom & Fine, 1994). 
However, the unpredictable variability and lack of protection against certain diseases, 
for example with pulmonary tuberculosis in adults, render live vaccination unsafe, 
particularly to those whose immune systems are constrained (Chambers et al, 2003). 
            
In general, for a vaccine to be regarded as effective it must meet certain criteria; to 
stimulate an adequate immune response, sustain safe administration, comply with 
issues of risk-benefit and be patient friendly in order to ultimately provide a safe 
means of health care. Upon understanding these identified desired attributes, of all 
vaccines currently in use, subunit vaccines have the best safety profile (Perrie et al, 
2008). Moreover, the development of subunit vaccines containing selected purified 
antigens potentially reduces side effects, crucially eradicates reversion to virulence and 
the need for culturing harmful pathogens whilst eliciting specific immune responses, 
generating a safer, more immunologically defined form of vaccination (Black et al, 
2010; Mohammed et al, 2010). 
 
However, in spite of a favourable safety profile and relatively economical production 
costs for this next generation of vaccines containing purified recombinant proteins, 
compared to more traditional forms of vaccination, when administered alone, they are 
insufficient as the associated immunogenicity is limited. As a result, co-administration 
with appropriate immunostimulatory adjuvants is required to induce protective and 
prolonged immunity (Reed et al, 2008; O’Hagan & Gregorio, 2009). 
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In general, scientific and technological advances have provided numerous 
developments in the production and delivery of vaccines. Such breakthroughs have 
contributed to significantly minimising preventable deaths and the spread of disease 
worldwide. Table 1.2 shows selected examples of currently available vaccines 
prioritised for necessity. 
 
Table 1.2. Examples of currently available vaccines categorised into order of priority. Vaccines of 
public health interest and those in use by UN agencies were defined and prioritised by The World 
Health Organisation and the United Nations International Children's Emergency Fund (UNICEF) 
according to the following criteria; demand within their specific markets, volume of supply and the 
unique associated profile of the available products (WHO, 2008).  
 
 
Furthermore, infectious diseases where vaccines are still required include Malaria and 
human immunodeficiency virus (HIV), in which increases in infection rates are still 
currently being recorded. These diseases together with tuberculosis (TB) collectively 
form the devastating trio of “global killers” that urgently require prevention (Perrie et 
al, 2008). With conventional in-depth scientific knowledge of immunological 
mechanisms and host pathogen interactions, a push towards the ever-present challenge 
of formulating vaccines continues, as an answer to questions posed by today’s 
potentially fatal yet preventable diseases (Bramwell & Perrie, 2005). 
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1.2. Stimulating the immune system 
With ever increasing knowledge of immunological processes, a more rational vaccine 
design aspires to induce specific, protective, and prolonged immunity upon vaccination 
(Lima et al, 2004). In general, immunity can be divided into two main responses of the 
innate and adaptive immune system. 
 
1.2.1. Innate immunity: the first line of defence 
Although we frequently encounter microorganisms, disease is only ever caused 
occasionally, as the majority of organisms are rapidly identified and destroyed by non-
antigen specific defence mechanisms. This initial stage of the host response upon 
infection forms the innate immune response which is a universal host defence 
stimulated upon infection. Only when an infectious agent manages to break this initial 
defence mechanism is an adaptive immune response triggered. Despite the innate 
immune system lacking the specificity of the adaptive immune system, it is capable of 
differentiating between self and non-self molecules and is vital to eliciting adaptive 
immunity (Janeway & Medzhitov, 2002; Storni et al, 2005).  
 
The first line of defence initiated upon intrusion of microorganisms involves responses 
such as mucosal secretions, fever and phagocytic cells that fight pathogens in a non-
specific manner. Antigen presenting cells (APCs) such as macrophages and dendritic 
cells (DCs), which are specialised phagocytes widely dispersed throughout the body, 
actively engulf, ingest and process potential antigens via phagocytosis, a mechanism 
that precedes antigen presentation and activation of T and B lymphocytes to generate 
an adaptive immune response. As a result, these activated cells collaborate with 
activated macrophages to destroy intra and extra-cellular pathogens (Gordon, 2002; 
Storni et al, 2005).  
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A crucial factor to the stimulation of innate immune responses is the detection of 
components commonly attached to the pathogen that are also foreign to the host and 
these components are known as pathogen-associated molecular patterns (PAMPs). 
After an infection, macrophages and DCs express mediating pattern recognition 
receptors (PRRs) such as toll-like receptors (TLRs) on their surface, bind such PAMPs 
and activate a signalling pathway to stimulate the host defences to respond to 
pathogens. Adaptive immunity is also initiated whilst activating APCs by eliciting pro-
inflammatory cytokine secretion and upregulating co-stimulatory molecules (Werling 
& Jungi, 2003; Akira, 2003; Kawai & Akira, 2011). 
 
TLR’s can be categorised into two main groups based on their cellular localisation: 
TLRs 1, 2, 4-6 become expressed on the plasma membrane for the detection of 
bacterial components and TLRs 3, 7-9 become expressed within intracellular 
compartments and function as nucleic acid sensors (O’Hagan & Gregorio, 2009). 
Furthermore, stimulation of TLR’s activate NFκB and mitogen-activated protein 
(MAP) kinases which are transcription factors that respond to produce key mediators 
of innate immunity such as interleukin (IL)-6 and interferon-gamma (IFN-γ) cytokines 
(Storni et al, 2005). 
 
1.2.2. Adaptive immunity: a specific and highly specialised response 
Adaptive or acquired immunity follows the innate immune response which induces the 
proliferation of pathogen-specific T or B lymphocytes together with T and B cell 
memory, providing long-term protection against disease (Storni et al, 2005). In 
instances of viral infections, both cell mediated and humoral responses are essential to 
controlling infection. However, cellular immunity is crucial to mediating protection 
against intracellular pathogens such as mycobacterium tuberculosis (MTB). 
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To initiate an immune response, a vaccine formulation should trigger distinct signals 
of the immune system. APCs within all tissues in a non-immunostimulatory phase 
collect antigens from the local environment. Detection of PAMPs (stranger model) 
and/or damage associated molecular pattern (DAMP) molecules (which act as a danger 
model or non-infectious signal 0 response) induce APCs to migrate to draining lymph 
nodes with maturation signified by enhanced presentation of antigenic material to 
major histocompatibility complex (MHC) class I and class II receptor molecules that 
subsequently become presented to the immune system. For the activation of protective 
T cells, the presentation of antigen to naive T cells constitutes the first of two main 
signals required (Figure 1.1) (Lima et al, 2004; Reed et al, 2008).  
 
 
Indeed, the presentation of antigen alone is insufficient to cause naive T cells to mature 
into effector T cells. As a result, an ideal vaccine should contain an 
immunopotentiating agent or adjuvant compound besides antigen in order to activate 
APCs via up-regulation of CD28 and CD80/CD86 co-stimulatory molecule expression, 
which constitutes signal 2 (Figure 1.1), a necessary action that ultimately prevents 
lymphocytes becoming anergic. Upon receiving signal 1 and 2, APCs can initiate key 
T cell responses to antigen such as cell survival, differentiation of naive T cells to 
develop into effector T cells and cytokine secretion (Rescigno et al, 1999; Lima et al, 
2004; Reed et al, 2008).  
 
CD4+ T cells identify antigens that have been processed by APCs, for example by 
DCs, macrophages and B cells, that express MHC class II molecules (Figure 1.2) and 
upon such recognition, activation of CD4
+
 T cells and T helper (Th) differentiation can 
take place into Th1 and Th2 type subsets (Seder & Hill, 2000). These two subsets 
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secrete a variety of cytokines and a typical Th1 type cytokine is IFN-γ which induces 
phagocyte-mediated defence against infection, particularly with intracellular microbes. 
In contrast, Th2 type cytokines such as IL-4 and IL-5, down regulate Th1 type immune 
responses and activate B cells to stimulate antibody synthesis (Lima et al, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The main signalling events required to initiate T cell activation. Resting APCs can 
present antigen material to naive T cells which represents the first signal, but naive T cells do not 
become activated until APCs express co-stimulatory molecules (Figure adapted from Lima et al, 2004).  
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Alternatively, antigens that become processed and presented via cells that express 
MHC class I molecules are identified by CD8
+
 T cells that also mediate their effector 
function upon cytokine secretion, of which IFN-γ and tumour necrosis factor (TNF)-α 
is fundamental to the activation of APCs, particularly macrophages (Figure 1.2). In 
addition, the mechanism of cytotoxic killing is mediated by the release of granzyme 
and perforin granules from CD8
+ 
T cells (Seder & Hill, 2000). 
 
 
 
 
Figure 1.2. Schematic overview of T cell activation and effector function. A: antigen processing and 
recognition by T cells, B: Th1 and CD8+ T cell effector function (Figure from Seder & Hill, 2000). 
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1.2.3. Immunological memory 
The immune response predominantly involves the distinction between self and non-
self coupled with immunological memory, which is the conceptual basis for 
preventative vaccination and possibly the most significant consequence of adaptive 
immunity. In terms of cellular memory, CD4+ and CD8+ memory T cells express 
specific cell-surface markers which signify previous activation and consequently, are 
more easily activated than naive T cells. Therefore, memory cells react to previously 
encountered pathogen or antigen, i.e. during a secondary response, in a stronger and 
faster manner in comparison to naive T cells, reflecting the pre-existence of clonally 
expanded antigen-specific lymphocytes. In addition, memory cells can be categorised 
into ‘resting’ and ‘effector’ cells: resting memory cells such as CD4+ or CD8+ T cells 
must be re-stimulated with antigen prior to activation, whereas the equivalent effector 
cells more readily secrete cytokines or directly partake in cell mediated cytotoxic 
activity (Seder & Hill, 2000; Storni et al, 2005). 
 
1.2.4. The emergence of Th17 
 
As highlighted earlier, T helper cells are typically believed to differentiate into either 
Th1 or Th2 type cell subsets, with the former required to clear intracellular pathogens 
and the latter fundamental in clearing extracellular organisms. However, distinctive to 
Th1 or Th2 cells, interleukin 17 producing Th17 cells are now acknowledged as a third 
and separate subset (Bettelli et al, 2006; Hirota et al, 2011). Moreover, it is believed 
that Th17 cells are highly pro-inflammatory and may play a crucial role in mediating 
host defence against extracellular pathogens that are not sufficiently cleared by 
initiated Th1 and Th2 type immune responses (Bettelli et al, 2007).  
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In addition, Th17 cells secrete cytokines such as interleukin 21 and 22 that induce an 
abundance of inflammatory and anti-microbial reactions in alternative cell types, for 
example in myeloid and epithelial cells. Th17 type responses have been implicated in 
fuelling protective immune responses against bacterial and fungal pathogens and 
inflammatory effects of these responses may also become implicated, leading to the 
development of autoimmune diseases (Vautier et al, 2010). 
 
In summary, defence-system mechanisms of the body that must be induced are 
antigen-presenting cells (APCs), thymus-derived lymphocytes (T cells), and bone-
marrow derived lymphocytes (B cells). Immunopotentiators stimulate antigen 
presenting cells that express TLRs in order to screen the environment for pathogens 
and TLR activation results in enhanced recruitment of innate immune cells to the 
infection site together with pro-inflammatory cytokine and chemokine production, 
facilitating an antigen specific adaptive immune response. Furthermore, to counter 
undesirable efficacy levels, utilisation of adjuvant systems are established in 
improving the immunogenicity of vaccines by providing protection and competent 
antigen targeting for antigen presenting cells (Perrie et al, 2008; Mastelic et al, 2010). 
An overview of the components responsible for inducing an immune response is 
displayed in Table 1.3. 
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Table 1.3. Functional elements critical to inducing immunity. (Table adapted from O’Hagan et al, 
2001). 
 
 
Response 
 
Function  
 
 
Antigen Presenting Cells  
 
 
Engage, process and present antigens as 
peptides via the major histocompatibility 
complex class I and class II pathways. 
 
B lymphocytes 
 
Responsible for producing antibodies 
and the function of APCs. 
 
PAMPs 
 
Molecules that associate to 
pathogens for recognition by 
innate immune system cells. 
 
PRRs 
 
Expressed by innate immune 
system cells to recognise PAMPs. 
 
T lymphocytes  
CD8
+
 (MHCI) 
 
Cytotoxic T lymphocytes (CTL) 
that terminates infected cells. 
 
CD4
+
 (MHCII) 
 
Promotes B cell and CTL 
activation and differentiation. 
 
Co-stimulatory signals 
 
Required for proficient antigen 
presentation and T cell stimulation. 
 
Adjuvants 
 
Increases co-stimulatory  
molecule expression to activate 
APCs for effector T cell differentiation. 
 
Th1 
 
Secretes IFN-γ which is pivotal to APC 
activation and ultimately mediates 
termination of intracellular pathogens. 
 
Th2 
 
 
Secretes IL-4 and IL-5 which 
aids  antibody stimulation and 
down regulates Th1 responses. 
 
Th17 
 
Secretes IL-17, 21 and 22, forming the 
later discovered third subset of T helper 
cells key to inflammatory responses. 
Chapter 1 – General Introduction 
    
 
 37 
1.3. Vaccine adjuvants 
Immunological adjuvants were principally defined by Ramon, (1924) as “substances 
used in combination with a specific antigen that produced a more robust immune 
response than antigen alone” and such a definition qualifies an extensive array of 
materials (Vogel & Powell, 1995). Indeed adjuvants must be appropriately formulated 
to maintain the stability of vaccine antigen and crucially help to stimulate broad and 
sustained immune responses, to ultimately maximise the vaccine effect (Reed et al, 
2008; Mbow et al, 2010). Furthermore, adjuvants can be applied to improve immune 
responses to vaccine antigens in many ways such as; elevating the immunogenicity of 
weak antigens, modulating and prolonging stimulated immune responses, invigorating 
cellular immunity, increasing cost-effectiveness by minimising antigen required per 
vaccine dose, preventing competition between antigens when combination vaccines are 
administered and enhancing vaccine efficacy in infants, elderly or immuno-
compromised individuals (O'Hagan et al, 2001; Reed et al, 2008). 
 
However, despite the promising potential of vaccine adjuvants, their mechanisms of 
action remain insufficiently understood which has delayed the progress and approval 
of novel adjuvant development. Furthermore, immunisation triggers an intricate 
cascade of responses which makes it difficult to distinguish the principle effects of the 
adjuvant in vivo (O'Hagan et al, 2001; O'Hagan & Gregorio, 2009). 
 
Indeed, numerous adjuvants have been developed previously but have failed to attain 
acceptance for routine vaccination due to issues of safety, such as acute toxicity and 
potentially delayed adverse effects. As a result, the benefits of vaccine adjuvants ought 
to be considered against the risk of any associated adverse reactions, which the 
European Medicines Agency (EMEA) when evaluating medicines for human use have 
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outlined, stating that safety is favoured above efficacy when a vaccine is being 
designed for a healthy population and increased toxicity is only ever acceptable when 
targeting protection against high risk patients and if there is considerable benefit from 
the vaccine (EMEA, 2005).  
 
In spite of these concerns, adequate data on adjuvants is now emerging, particularly in 
regards to their immunostimulatory impact and associated safety profile. Such 
information demonstrates the capability of next generation adjuvants in being safely 
administered to diverse human populations and allow for many vaccines combined 
with innovative adjuvants to attain licensure (O'Hagan & Gregorio, 2009). 
 
Adjuvants may be largely classified into two main groups based on their key 
mechanisms of action: delivery systems, which deliver antigens to immune cells and 
immunostimulatory adjuvants, which directly affect immune cells, generating their 
activation (O'Hagan & Valiante, 2003; Reed et al, 2008). Table 1.4 highlights some 
examples of approved vaccine adjuvants tested in each category. 
 
Table 1.4. Examples of tested vaccine adjuvants within the broadly classified adjuvant groups of 
delivery systems and immunostimulatory adjuvants.  
 
 
Adjuvant Type 
 
Vaccine Adjuvant 
 
 
 
Delivery systems 
 
 
 
Nano and microparticles, emulsions,  
immune stimulating complexes,  
virus-like particles, mineral salts. 
 
 
Immunostimulatory adjuvants  
 
 
MPL and its synthetic derivatives, DDA, 
TDM, TDB. 
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1.3.1. Delivery systems 
Delivery systems are predominantly particulate in nature and in general, increase 
cellular infiltration at the site of injection which facilitates and enhances antigen 
uptake into antigen presenting cells or directly transports antigen to the lymph nodes. 
Consequently, fundamental antigen presenting cells such as DCs migrate to the lymph 
nodes and present antigen to naive T cells for their activation (O'Hagan et al, 2001). 
 
1.3.1.1. Nano and microparticles 
Small solid particles such as nanoparticles (10-1000 nm) and microparticles (1-100 
µm) are formed from a variety of biocompatible and biodegradable polymers and can 
provide a lasting depot-effect, proficient targeting and is ideal for single dose multi-
release vaccines (Cox & Coulter, 1997). Antigen uptake by APCs can be increased 
upon antigen association with polymeric microparticles and also by polymers or 
proteins that self-assemble into particles. Biodegradable and biocompatible polyesters 
such as polylactide-co-glycolides (PLG) are suitable for micro particulate development 
as adjuvants and have been used in humans as sustained release drug delivery systems, 
with their adjuvant effect a result of uptake into APCs and local lymph nodes upon 
intramuscular injection (O'Hagan et al, 2001).  
 
Lipid nanoparticles, of which the most widely used are liposomes, demonstrate great 
potential as particulate delivery systems. The selected liposomal composition affects 
resultant interactions with immune systems cells and therefore, can be designed to 
elicit desired biological responses (Bramwell & Perrie, 2006), as liposomal adjuvants 
are capable of stimulating enhanced and diverse immune responses (Perrie et al, 2008). 
The use of liposomes as delivery systems will be discussed in greater detail in section 
1.4. 
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1.3.1.2. Oil and water emulsions 
Emulsion adjuvants have been successfully formulated as delivery systems with the 
licensed MF59 oil in water emulsion (O/W) adjuvant used in Europe since the late 
nineties, forming part of a safe and potent vaccine that provides protection against the 
influenza virus (O’Hagan, 2007). MF59 comprises an oil (squalene)-in-water nano-
emulsion and is understood to act via a depot-effect to induce cytokine secretion by 
monocytes, macrophages and granulocytes. MF59 administered with other antigens 
can induce higher, more balanced levels of antibody titres than Alum, however like 
Alum, MF59 is predominantly a Th2 inducer and fails to elicit increased CD4+ Th1 
type immune responses (Reed et al, 2008). 
 
1.3.1.3. Immune stimulating complexes  
 
Immune stimulating complexes (ISCOMs) were initially described by Morein et al, 
(1984) as novel structures that facilitated antigenic presentation of membrane proteins 
and to date, have been widely applied as adjuvants in veterinary vaccines (Reed et al, 
2008). ISCOMs are cage-like particles approximately 40 nm in size that entrap protein 
antigen through hydrophobic interactions and due to their particulate nature, ISCOMs 
entice more efficient uptake from APCs through the process of endocytosis (Reed et 
al, 2008). Furthermore, when immunogen are integrated into ISCOMs, they can 
effectively elicit Th1 and Th2 type immunity, provide proficient targeting and 
presentation and strong cytotoxic T-lymphocyte (CTL) responses (Cox & Coulter, 
1997). 
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1.3.1.4. VLP and IRIV 
Viruses like particles (VLPs) are self-assembling particles consisting of at least one 
viral protein, forming nanoparticles of approximately 20-100 nm. VLP vaccines for 
hepatitis B virus (HBV) and HPV have been produced for commercial use (Reed et al, 
2008) and immunopotentiating reconstituted influenza virosomes (IRIVs), which are 
proteoliposomes made from phospholipids, influenza hemagglutinin and selected 
antigen, become processed by APCs upon delivery by hemagglutinin receptor-
mediated endocytosis (Reed et al, 2008). Moreover, IRIVs are registered in Europe, 
Asia and South America as part of the Hepatitis A vaccine as during clinical 
development, it stimulated faster immunity and fewer adverse reactions upon injection 
in comparison to conventional Alum-containing vaccines (Holzer et al, 1996). Both 
VLPs and IRIVs promote uptake by APCs via receptor mediated endocytosis and are 
capable of inducing cellular and humoral immune responses (Gluck et al, 2004). 
 
1.3.2. Immunostimulatory adjuvants and their combination with delivery systems 
Although particulate adjuvant delivery systems may promote antigen uptake and 
presentation, this may not necessarily elicit an immune response and as highlighted 
earlier, the presence of antigen alone simply initiates “signal 1” leading to 
“immunological tolerance”. In order to stimulate an immune response, “signal 2” must 
be triggered, in which co-stimulatory molecules and cytokines, that are usually 
provided by APCs, prime T helper cells to initiate antigen specific protection via B cell 
proliferation and antibody production, whilst also assisting cytotoxic T lymphocyte 
responses (O'Hagan et al, 2001). 
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This broad adjuvant group of immunostimulatory adjuvants originate from pathogens 
such as bacterial cell wall components, which upon delivery, are capable of directly 
increasing responses to antigens, initiate signalling mechanisms upon induction of 
cytokine release or co-stimulatory molecules on APCs, and can be interpreted by the 
host as a threat of infection by the innate immune system. Indeed, such agents 
correspond to pathogen associated molecular patterns which interact with pattern 
recognition receptors expressed by phagocytes to activate pro-inflammatory pathways 
and mediate the onset of an adaptive immune response (O'Hagan et al, 2001; Reed et 
al, 2008). 
 
Conventional aluminium based mineral salts (generically referred to as ‘Alum’) as 
delivery systems are the most widely used vaccine adjuvants granted approval for 
human administration. Indeed, due to an acceptable safety record, Alum are 
components of many licensed vaccines, providing protection against diphtheria-tetanus 
(DT), hepatitis A virus (HAV), hepatitis B virus (HBV) and the human papilloma virus 
(Reed et al, 2008; Mbow et al, 2010).  
 
In general, alum absorption enhances the uptake of antigen at the site of injection and 
can induce local pro-inflammatory reactions which elevate the immunogenic effect 
(Mbow et al, 2010). However, in comparison to other adjuvants, limitations in the use 
of Alum are their inability to stimulate cell-mediated Th1 or CTL responses and 
coupled with relatively weak antibody initiation to protein subunits, they are 
inadequate in providing the type of immunity necessary to control the majority of 
intracellular pathogens responsible for major diseases such as tuberculosis, HIV and 
malaria (Gupta et al, 1998; Relyveld et al, 1998; Reed et al, 2008). 
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For potentially fatal infections such as tuberculosis, protective efficacy is only possible 
with a targeted approach whereby cellular responses are enthused. Therefore, novel 
adjuvants are required with the capacity to induce intricate immunological reactions 
that carry potent antigen specific T cell stimulation and antibody production (Agger et 
al, 2008). The current generation of vaccines increasingly consist of highly purified 
recombinant proteins but such antigens are often poorly immunogenic and thus, 
require co-administration with adjuvants to enable them to become potent vaccines 
(O'Hagan & Gregorio, 2009). Immunostimulatory adjuvants can be combined with 
particulate delivery systems in order to intensify responses, initiate a particular desired 
pathway, for example the induction of Th1 or Th2 type immunity, or acquire a mixture 
of such immunological responses (Cox & Coulter, 1997; O'Hagan et al, 2001). 
 
The combination of delivery systems and immunostimulatory agents to create adjuvant 
delivery systems provides a great challenge when producing vaccines that can combat 
pathogens that progress into chronic infections such as tuberculosis, HIV and Malaria, 
in which cell mediated immunity is required (O'Hagan et al, 2001). Thus, creations of 
innovative adjuvants that can promote vast targeted immune responses are highly 
advantageous and a necessity worldwide. As highlighted by Christensen et al (2007a), 
individually, antigens are not adequately immunogenic and in order to establish precise 
immune responses, co-administration of a successful adjuvant is vital. An essential 
function of vaccine adjuvants is to stimulate the activation of APCs and boost the 
differentiation of effector T and B cells. A focal point of modern adjuvant research is 
not just the initiation of potent immune responses but exclusively targeting APCs and 
associated receptors to achieve such a response, whilst being as non-toxic as possible. 
A promising example of such a combinational strategy of an immunoadjuvant delivery 
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system that can be utilised as a means of potent vaccine delivery are the use of cationic 
liposomes, which will be discussed in section 1.4. 
 
1.3.2.1. The use of Monophosphoryl Lipid A as an immunostimulatory adjuvant 
Monophosphoryl Lipid A (MPL), which is a non-toxic derivative of a bacterial 
lipopolysaccharide (LPS) of Salmonella Minnesota, is a strong inducer of Th1 type 
immune responses. The structure of LPS provides two major functions with its 
hydrophilic polysaccharide portion enhancing solubility and the hydrophobic lipid 
moiety, known as lipid A, responsible for the resultant endotoxic activity. Vaccines 
incorporating MPL have attained licensure in Europe as an allergy treatment due to its 
effectiveness in down-modulating Th2 responses to allergens and MPL is regarded as a 
safe, well-tolerated and potent vaccine adjuvant component (Reed et al, 2008). 
 
1.3.2.2. The future of adjuvants and the success of AS04: a combined vaccine adjuvant  
Many issues such as unacceptable adverse effects and associated toxicity of adjuvants 
have stalled the progress in the production of novel candidate adjuvants, with 
regulatory standards for adjuvant approval considerably higher since Alum was first 
approved. However, recent discoveries into the manner in which immune responses 
become activated have rejuvenated the invention of new and improved vaccine 
adjuvants (Reed et al, 2008).  
 
Fast moving and continual progress in molecular immunology is accommodating the 
screening process for new kinds of small-molecule immune potentiators (SMIPs). As a 
result, it is possible to foresee that in the coming years a variety of new molecules with 
the ability of inducing distinct immune responses will emerge and comprise new 
vaccine adjuvants against different types of pathogens (O’Hagan & Gregorio, 2009). 
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The PRRs that have been strongly linked to vaccines are TLRs that are expressed by 
immune cells such as DCs, macrophages and B cells and the future development of 
SMIPs that target TLRs shows great promise (O’Hagan & Gregorio, 2009), 
particularly as pathogenic actions may be replicated upon TLR activation, potentially 
facilitating adaptive immune responses. Indeed the first TLR targeting adjuvant that 
attained licensure for human use was MPL, which alongside aluminium hydroxide 
forms a vaccine adjuvant combination known as AS04, produced by GlaxoSmithKline 
(GSK), and is used in a licensed vaccine against hepatitis B, whilst also part of a 
human papillomavirus vaccine (Mastelic et al, 2010).  
 
The pharmaceutical industry has an established record in constantly providing safe and 
efficacious vaccines for developed and developing countries worldwide (Taylor et al 
2009), and it is feasible that new combinations of current adjuvants and innovative 
adjuvants targeting emerging molecular targets can enhance the efficacy of new 
preventive vaccines against infectious diseases (Mbow et al, 2010). When designing 
novel vaccine adjuvants, an optimal formulation would ideally be safe, stable before 
administration, be capable of eliciting antigen specific immunity and be well-defined 
chemically and physically in order to assure reproducible manufacturing and activity 
(Reed et al, 2008). Indeed, such attributes have been demonstrated upon the 
application of liposomal vaccine adjuvant delivery systems, whilst potentially 
providing protective efficacy against a variety of diseases. 
 
 
 
 
Chapter 1 – General Introduction 
    
 
 46 
1.4. Liposomes: an effective vehicle for drug delivery 
Liposomes were initially discovered in the 1960s by Bangham and Horne upon 
investigation of “bag-like” phospholipid configurations in water using an electron 
microscope and more specifically, liposomes are spherical vesicles comprising of one 
or more phospholipid bilayers encompassing an aqueous cavity (Rongen, 1997). 
Indeed, when phospholipids are placed in water, they arrange themselves in such a 
manner that protects the hydrophobic tails of the phospholipid molecule from water, 
whilst the hydrophilic heads are attracted to water and thus, aggregate into a dual or 
bilayer vesicular structure (Figure 1.3). 
 
Based on their sizes and according to associated physical structures, liposomes can be 
categorised into multi, large and small unilamellar vesicles (Figure 1.3). Large 
unilamellar vesicles (LUVs) and multilamellar vesicles (MLVs) approximately range 
from a few hundred nanometres to several micrometres in size and upon further 
treatment via sonication, small unilamellar vesicles (SUVs) are generated, typically 
less than 100 nm in size (Jones, 1995). 
 
The structural arrangement of liposomes makes them incredibly adaptable as vehicles 
for drug delivery as molecules can be associated to liposomes in many ways including 
encapsulation into the inner aqueous core, partitioning within lipid bilayer tails and 
electrostatic interaction with polar lipid head-groups. Hydrophilic molecules such as 
enzymes, DNA, vaccines and pharmaceutical compounds can be encapsulated into the 
inner core, and the bilayer structure can extend the longevity of encapsulated material 
by protecting them from destructive entities upon delivery, whilst drug release can be 
controlled, minimising any associated cytotoxic effects (Edwards & Baeumner 2006b). 
Chapter 1 – General Introduction 
    
 
 47 
 
 
 
 
                       
                                          
 
                                            
 
 
Figure 1.3. The classification of liposomes characterised by size and physical structure. Liposomes 
are flexible drug delivery vehicles as both lipid and water soluble molecules can become associated to 
the liposomal bilayer or aqueous compartment respectively (Figure adapted from Jones, 1995). 
Lipid bilayer 
Aqueous compartment  
Large unilamellar vesicle  
(LUV) – 50 to 10,000 nm 
Multilamellar vesicle  
(MLV) – up to 10,000 nm 
Small unilamellar vesicle  
(SUV) – up to ~100 nm 
Phospholipid molecule  
Hydrophilic 
head (polar) 
Hydrophobic 
tails 
(non-polar) 
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Physicochemical properties of lipids that form liposomes for example, surface charge, 
membrane fluidity and permeability can influence the nature and degree of liposome-
cell interactions upon administration and thus, liposomal composition has a great affect 
on the intracellular delivery of drugs (Sharma & Sharma, 1997). Indeed, liposomes can 
be prepared to attain a neutral, cationic or anionic surface charge and when used as 
immunostimulatory adjuvant delivery systems, can facilitate the association of a 
variety of proteins and particulate antigens whilst inducing potent immune responses 
specific to the delivered antigen. Furthermore, phospholipids with various polar head 
groups and hydrophobic regions of varying chain length and saturation can be selected 
to desirably modify the resultant liposomal properties (Edwards & Baeumner, 2006b), 
which makes liposomes extremely versatile structures that can be utilised for research, 
therapeutic and analytical applications (Edwards & Baeumner, 2006a). 
 
Initial work bringing liposomes into prominence as vehicles for drug delivery was 
conducted by Gregory Gregoriadis in the 1970s and their use as vaccine adjuvants was 
first described by Alison & Gregoriadis, (1974), demonstrating that entrapment of 
diphtheria toxoid in liposomes enhanced antibody responses. Since then, advances in 
liposomal technology and the understanding of in vivo liposomal behaviour both 
experimentally and clinically has prompted the design and approval of formulations to 
treat microbial infections and cancers, together with liposome based vaccines licensed 
for use in humans (Gregoriadis, 1991; Gregoriadis, 2000). In fact, ground breaking 
research has generated approval and licensure for the administration of liposomal-
based products against a variety of diseases, with some examples summarised in Table 
1.5. 
Chapter 1 – General Introduction 
    
 
 49 
Table 1.5.  Examples of commercialised liposome-based drugs on the market. The variety of diseases treatable illustrates the flexibility of liposomal systems. 
 
 
Marketed Product               
 
Company 
 
Target Disease 
 
Drug/therapeutic agent 
 
Formulation 
 
Route 
 
 
Caelyx
TM 
or Doxil
TM
 
 
Schering Plough 
(Caelyx) 
Ortho Biotech 
(Doxil) 
 
 
Kaposi’s sarcoma 
(KS), breast and 
ovarian cancer 
 
 
Doxorubicin 
 
80-100 nm liposomes composed 
of HSPC:Chol:PEG 2000-DSPE  
(56:39:5 molar ratio). 
 
 
Intravenous 
 
 
Myocet 
 
 
Zeneus  Pharma 
 
 
Metastatic breast 
cancer 
 
 
Doxorubicin 
 
 
HCl complexed with citrate 
encapsulated within 150 nm 
liposomes composed of PC:Chol 
(55:45 molar ratio). 
 
 
 
Intravenous 
 
 
Epaxal 
 
 
Berna Biotech 
 
 
Hepatitis A 
 
 
Inactivated hepatitis A 
virus 
 
150 nm immunopotentiating 
reconstituted influenza 
virosomes (IRIV) composed  
of DOPC/DOPE 
(75:25 molar ratio). 
 
 
 
Intramuscular 
 
 
AmBisome 
 
 
Gilead Sciences 
 
 
Fungal infection 
 
 
Amphotericin B 
 
< 100 nm sized Liposomes 
composed of HSPC, DSPG, 
cholesterol and amphoteracin B 
(2.0:0.8:1.0:0.4 molar ratio). 
 
 
 
Intravenous 
 
Visudyne 
 
Novartis 
 
Age-related macular 
degeneration 
 
Vereporfin 
 
Liposomes composed of  
BPD-MA:EPG:DMPC 
(1:3:5 molar ratio). 
 
 
Intravenous 
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1.4.1. Liposomes as vaccine delivery systems 
When defending against the onset of microbial infection, vaccines are a favoured 
alternative to treatment with a great ability of saving millions of lives (Gregoriadis et 
al, 2002). Proficient efficacy can be achieved by replicating natural infections without 
disease, with the objective of stimulating defence mechanisms involved in generating a 
consistent immune response. Despite the innovation of aluminium based adjuvants in 
the 20
th
 century, liposomes remain one of the few immunological adjuvants approved 
for human administration and liposome based vaccine delivery systems have been 
extensively recognised as potent stimulators of immunity (Bramwell & Perrie, 2005). 
 
Furthermore, the next generation of adjuvants was triggered by the innovation and 
application of muramyl dipeptide (MDP), which in the mid 70s, was recognised as a 
diminutive water soluble element of the mycobacterial cell wall that could potentially 
attenuate adjuvant like behaviour by stimulating immunity (Ellouz et al, 1974). 
Consequently, it was appreciated that the effectiveness of such mycobacterial 
constituents could not be maximised until they were attached to current adjuvants such 
as those derived from liposomes (Siddiqui et al, 1978). 
 
The versatility in the structural properties of liposomes coupled with their ability to 
accommodate a variety of drugs has facilitated the production of safe subunit vaccines. 
However, such vaccines are weakly or non-immunogenic and thus require co-
administration with immunological adjuvants in order to be effective. The use of 
liposomes provides a safe, versatile, universal adjuvant capable of eliciting humoral 
and cellular immune responses to antigens upon parenteral or enteral administration 
(Gregoriadis, 1990; Gregoriadis, 1991). 
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1.4.2. Cationic liposomal vaccine delivery systems 
Cationic liposomes are lipid-bilayer vesicles formed from positively charged 
amphiphilic lipid molecules (Lonez et al, 2008) yielding a net positive surface charge. 
Such systems have received great attention due to their biocompatibility and 
versatility, demonstrating potential for delivery of protein and DNA vaccines 
(Bramwell & Perrie, 2006). Moreover, DNA vaccines entrapped inside cationic 
liposomes protect DNA from nuclease degradation and are a viable system that can 
accommodate the delivery of DNA to APCs. Upon local injection, DNA containing 
liposomes become rapidly endocytosed by APCs that penetrate the site of injection or 
the draining lymph nodes (Perrie et al, 2001). Due to its convenience and efficacy, the 
use of cationic lipid mediated gene delivery to target cells or tissues in vivo, provides a 
viable means of gene therapy (Chrai et al, 2002; Liang & Chou, 2009).   
 
In addition, studies have demonstrated that co-administration of antigen with 
liposomes of a cationic nature elicit stronger antigen specific immunity in comparison 
to their anionic or neutral counterparts (Nakanishi et al, 1997; Perrie et al, 2001). It is 
understood that positively charged liposomes protect antigens from clearance within 
the body, whilst incorporating immune potentiators to enhance and modulate a desired 
response and delivering associated antigens to APCs and thus, are proficient vaccine 
delivery systems for specific disease targets (Christensen et al, 2007b). 
 
1.4.3. The promising potential of DDA-TDB as a liposomal adjuvant delivery system 
The cationic synthetic amphiphile of dimethyldioctadecylammonium (DDA) was first 
discovered as in immunostimulatory adjuvant in the 1960s by Gall, (1966) and the 
versatile adjuvanticity of DDA was recognised by Hilgers & Snippe (1992), 
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establishing its ability as a reasonable Th2 inducer and a powerful Th1 inducer. The 
primary adjuvant mechanism of DDA-based liposomes is to transport associated 
antigen to APCs, enhance antigen uptake and subsequent presentation of antigen 
material to T cells (Korsholm et al, 2007), as DDA can not only deliver associated 
antigen but also potentiate the immune response, acting as a combination of a vaccine 
delivery system and an immunostimulatory adjuvant. Moreover, the mechanism of 
action that provides DDA with immunopotentiating activity is due to its cationic 
surface charge and ability to incorporate antigens (Hilgers et al, 1985). Indeed, DDA 
consists of a positively charged hydrophilic polar dimethylammonium head group and 
two hydrophobic 18-carbon-long alkyl chains (Table 1.7) and in an aqueous 
environment, forms liposomal bilayer structures when heated beyond its main phase 
transition temperature (Carmona-Ribeiro & Chaimovich, 1983). 
 
 
TDB is a synthetic analogue of trehalose 6,6’-dimycolate (TDM), also known as cord 
factor, which is an immunostimulant found within the mycobacterial cell wall (Pimm 
et al, 1979; Lemaire et al, 1986). Due to its structure being composed of smaller fatty 
acid chains (Table 1.7) compared to its TDM counterpart, TDB yields a decreased 
level of toxicity (Pimm et al, 1979; Olds et al, 1980). However, due to its lipidic 
properties, TDB cannot be administered alone and therefore, integration into a delivery 
system is required (Vangala et al, 2007). Over the last decade, liposomes have been 
utilised as complex immunoadjuvant delivery systems for experimental subunit 
vaccines and the combination of DDA with TDB as a liposomal adjuvant system for 
subunit vaccine delivery was first considered by Holten-Andersen et al, (2004). TDB 
has been shown to provide a stabilising effect, alleviating the issue of physical 
instability associated with DDA vesicles whilst potentiating the immune response of 
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DDA, inducing cell mediated immune responses upon immunisation of mice with a 
TB vaccine antigen candidate, Ag85B–ESAT-6 (H1), characterised by elevated levels 
of the T-cell enhancing cytokine, IFN-γ (Davidsen et al, 2005). In addition, the DDA-
TDB immunoadjuvant delivery system (also referred to as cationic adjuvant 
formulation 01 or CAF01) has been shown to be a potentially viable adjuvant for a 
variety of diseases eliciting either cellular or humoral immunity or even a combination 
of such immune responses when providing protection against infectious diseases 
(Table 1.6).  
 
The DDA to TDB weight ratio of 5:1, previously optimised by Davidsen et al, (2005), 
provides the foundation of formulations to be tested in the present study as adjuvant 
subunit vaccine delivery systems, whilst also incorporating additional lipids of 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC), with the objective of applying the DPPC based systems for 
pulmonary vaccine delivery and the DSPC systems for immunological analysis in a 
mouse model. Phospholipids form the main constituent of the absorptive surfaces deep 
into the lung, for example in surfactants at the surface of pulmonary alveoli and within 
alveolar cell membranes (McAlister et al, 1996), and the phospholipid that 
predominantly comprises pulmonary surfactant is DPPC, which can facilitate the 
absorption of compatible liposomal systems (Wright, 1990). The long DSPC fatty acyl 
chains result in a higher transition temperature, possibly enhancing the structural 
rigidity of DDA-TDB upon incorporation, with the possibility of favourably reducing 
the overall toxicity of the formulation. Table 1.7 summarises further details on these 
additional lipids to be incorporated into DDA-TDB based liposomes as adjuvant 
formulations to be tested in this study, for delivery of a novel subunit vaccine against 
tuberculosis.
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Table 1.6.  The versatility of DDA-TDB: a cationic liposomal adjuvant delivery system capable of providing immunity against a variety of disease targets.  
 
 
Disease 
 
Desired protective 
immune response 
 
Vaccine Antigen 
 
Results/findings 
 
Reference 
 
Tuberculosis 
 
Cell mediated 
immunity 
 
Ag85B–ESAT-6 (H1) 
 
Immunisation with DDA/TDB at a 5:1 
weight ratio generated elevated levels of 
IFN-γ and low levels of IL-5, together with 
substantial IgG1 and IgG2 antibody titres.   
 
 
Davidsen et al, (2005) 
 
 
Malaria 
 
Humoral immunity 
 
Merozoite surface protein 1 
(MSP1) and glutamate rich 
protein (GLURP) 
Strong antigen specific IgG1 and IgG2 
antibody and IFN-γ cytokine responses and 
a Th2 humoral response characterised by 
MSP1 and GLURP specific IgG1 and IgG2 
antibody titres (upon incorporation of a 
non-ionic surfactant and cholesterol). 
 
 
Agger et al, (2008) 
+ 
Vangala et al, (2006) 
 
Influenza 
 
 
Cell mediated + 
humoral immunity 
 
Vaxigrip influenza 
split vaccine 
Elevated cellular and humoral immune 
responses, eliciting significantly higher 
IFN-γ and IgG antibodies compared to 
administration without the adjuvant. 
 
 
Christensen et al, (2010) 
 
 
Chlamydia 
 
 
 
Cell mediated + 
humoral immunity 
 
 
Major outer membrane protein 
(MOMP) 
Elevated levels of IgG1 and IgG2 antibody 
isotype titres, IFN-γ and TNF-α cytokines 
and a significantly reduced vaginal 
chlamydial load upon challenge when 
compared to naive control mice. 
 
 
Agger et al, (2008) 
 
Hepatitis B 
 
Cell mediated 
immunity 
 
 
Hepatitis B surface antigen 
(HBsAg) 
Strong antigen specific IL-2 and IFN-γ 
cytokine production and elevated IgG, 
IgG1 and IgG2a antibody isotype titres. 
 
Vangala et al, (2007) 
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Table 1.7.  DDA, TDB, DPPC and DSPC lipids used in the liposomal formulations and tested as novel adjuvants for TB subunit vaccine delivery. (Structures were 
obtained from www.avantilipids.com, 2011). 
 
 
 
Lipid 
 
 
Structure 
 
Molecular 
formula 
 
Molecular 
 weight 
 
Transition 
temperature 
 
Dimethyl- 
dioctadecylammonium (DDA) 
 
 
 
 
C38H80NBr 
 
630.95 g/mol 
 
47 °C 
 
 
 
 
Trehalose 6,6-dibehenate (TDB) 
 
 
 
 
 
 
 
 
C56H106O13 
 
 
 
 
987.433 g/mol 
 
 
 
 
/ 
 
 
1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) 
 
 
 
 
 
C40H80NO8P 
 
734.039 g/mol 
 
41 °C 
 
1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) 
 
 
 
 
 
C44H88NO8P 
 
790.14 g/mol 
 
 
55 °C 
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1.5. Vaccination for protection against tuberculosis 
Evidence of tubercular decay can be linked to ancient Egyptian times and was also 
prominent during the periods of ancient Greece and Imperial Rome (National Institute 
of Allergy and Infectious Diseases, 2008). Furthermore, TB has plagued humanity for 
centuries, attaining an epidemic status in Europe and North America in the 18
th
 and 
19
th
 century, with such an overwhelming outbreak of the infection prompting a 
reputation of being a “captain among these men of death." (Daniel, 2006). However, 
understanding the pathogenesis of TB was further developed by Jean-Antoine Villemin 
who demonstrated the contagious effect of the mycobacterium tuberculosis infection in 
1865, prior to Robert Koch recognising tubercle bacilli as the main causative agent in 
1882. Early in the 20
th
 century, Clemens von Pirquet created the tuberculin skin test 
and subsequently used it to exhibit the latent TB infection in healthy infant carriers. 
 
Tuberculosis is an infectious and airborne disease that results in approximately 2 
million deaths each year from the mycobacterium tuberculosis infection (WHO, 
2010a). Despite potentially curative pharmacotherapies being readily available for 
many decades, tuberculosis is still the primary cause of preventable deaths worldwide 
(Sosnik et al, 2010). In addition, with as many as 2 billion people potentially carrying 
the disease, such an incredibly high frequency of the latent infection facilitates the 
prevalence of TB in its active form, with inhalation of just a minute quantity of TB 
bacilli sufficient to incur infection (Gupta et al, 2007; WHO, 2010a). Although the 
number of TB related deaths has decreased by 35% since 1990, in 2009, almost 10 
million new cases of TB were reported, with an immense majority of deaths occurring 
in the poorer developing countries, particularly within the African region (Figure 1.4) 
(WHO, 2010b; Sosnik et al, 2010).  
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Figure 1.4. Estimated cases of tuberculosis reported in 2009 by country. A vast majority of global 
TB incidence is attributed to the developing world, particularly in Africa, where HIV is also prevalent. 
(Figure from WHO, 2010c). 
 
Following HIV/AIDS, TB is the second highest fatally infectious disease (Frieden & 
Driver, 2003) with HIV and TB forming a deadly combination, each accelerating the 
other’s progress, resulting in TB becoming the primary cause of death amongst HIV-
positive infected individuals (WHO, 2010a). In 1993, the World Health Organisation 
declared TB as an international emergency (WHO, 1993), with the latest global targets 
outlined by the WHO Stop TB partnership aiming to save five million lives between 
2011 and 2015, whilst stating that the objective to half global TB mortalities by 2015 
compared to 1990 remains successfully on course (WHO, 2010b). Although the 
occurrence of new TB cases declined in the 60s and 70s, this predicament was 
aggravated further by the onset of multi-drug resistant TB (MDR-TB), defined as 
resistance to first-line TB treatments of isoniazid and rifampicin and in extreme cases, 
extensively drug-resistant TB (XDR-TB) which is also resistant to fluoroquinolone 
and, as a minimum, one second-line injectable TB treatment (WHO, 2010c). Due to 
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the extent of TB prevalence, the necessity for a new vaccine strategy to combat the 
disease has been recognised as a global research priority (Anderson & Doherty, 2005). 
 
If left untreated, every actively infected person may transmit the disease to 10-15 
people each year. However, people infected with MTB do not necessarily have the 
active TB disease as a healthy patient can carry the TB infection in its latent form, yet 
fail to attain sterile eradication of the pathogen. Such latent carriers are susceptible to 
develop the active form of TB in their later life and represent approximately one third 
of the world’s population. The vast scale of TB incidence is evident as a TB bacillus 
infects a new individual every second (Kaufmann, 2010), with such alarming figures 
resultant of a deadly cycle of TB (Figure 1.5). 
 
Figure 1.5. The deadly cycle of tuberculosis. This figure portrays the estimated global levels of MTB 
and latent MTB incidence, new TB cases and TB related mortalities, forming a vicious cycle that 
amplifies the onset of infection (Figure from Kaufmann, 2010). 
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1.5.1. Tuberculosis infection    
The TB infection is activated upon inhalation of the mycobacterium into the 
respiratory system via aerosol particles. Subsequently, bacteria become non-
specifically phagocytosed by alveolar macrophages which lead to bacterial antigen 
presentation to T lymphocytes, prior to rapid proliferation of the pathogens by 
terminating host cells and spreading towards local lymph nodes within the lungs via 
lymphatic circulation. As a result, TB bacilli spread from the lungs to the central 
nervous system and other organs of the body such as the liver, kidneys etc (Smith, 
2003).  
 
Recent studies have indicated the potential influence of IL17-producing Th17 cells 
which draw in monocytes to where MTB replication takes place. This eventually 
generates a solid granuloma containing mononuclear phagocytes and T cells and such 
a formation restrains MTB but does not eliminate the infection, with this balanced 
coexistence symptomatic of the latent tuberculosis infection (LTBI). The active form 
of TB results from immune weakening which liquefies the granuloma as MTB 
multiplies and spreads to other organs, with patients enduring the extremely contagious 
active form of TB, which can ultimately lead to death (Parida & Kaufmann, 2010). 
 
It is understood that protection against TB is dependent on Th1 type CD4 T cells, 
whilst principle effector functions of T cells during an immune response to MTB are 
the secretion of cytokines, in particular IFN-γ and TNF-α, which are significant in 
mediating control of the infection (Quesniaux et al, 2010; Meraviglia et al, 2011). 
Where CD4 T cells are crucial to controlling the infection in the acute phase, CD8 T 
cell responses are essential to the latent phase of MTB (SSI, 2010). Indeed CD8+ T 
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cells also provide protection by secreting similar cytokines and by generating perforin 
and granulysin, substances that aid the termination of macrophages containing MTB, 
whilst also directly targeting the pathogen (Parida & Kaufmann, 2010).  
 
In summary, the main events that contribute to MTB infection can be categorised into 
a series of stages. The acute phase, whereby bacteria divide and multiply within organs 
until an immune response is strengthened, the latent phase, in which bacterial levels 
are stabilised from an active to dormant form of MTB, and a reactivation phase, which 
involves the recommencement of bacterial proliferation (SSI, 2010). 
 
1.5.2. Protection against TB: past, present and future promise 
Prior to establishing vaccination against TB, initial treatments were relatively basic. 
George Bodington and Hermann Brehmer were physicians that proposed the curative 
effects of dry and fresh air, which led to early medical facilities for TB being situated 
in alpine regions. Moreover, in conjunction with rest and a nutritious diet, TB infected 
individuals did respond favourably, yet such treatment methods probably contributed 
more to controlling the spread of infection by isolating patients (Campbell, 2005). 
 
Currently, the vaccine of choice against TB is the BCG vaccine which was commonly 
used after the first world war (Daniel, 2006) and to date, has been received by 4 billion 
people due to the protection it provides, particularly against TB in infants (Parida & 
Kaufmann, 2010). However, growing concerns over its safety, waning sensitivity and a 
highly variable protective efficacy (0-80%) against adult pulmonary TB have 
invigorated a push for a more potent vaccine alternative (Fine, 1995; Chambers et al, 
2003; Anderson & Doherty, 2005). 
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In addition, adverse effects of BCG vaccination are apparent upon alterations in 
resultant immune responses which can lead to the onset of autophagy, causing cell 
degradation and defence mechanisms to inhibit the protective action of BCG 
(Gutierrez et al, 2004). Furthermore, variations of numerous strains from the original 
BCG vaccine of 1921 add confusion to the consideration of an optimal strain of choice 
(Behr, 2002). For all such reasons, the use of BCG is widely alleged as being 
ineffective and coupled with its diminishing effect over time, the production of new 
and enhanced vaccines for TB is of great necessity. 
 
Vaccine development has been significantly advanced by determining genomic 
information via “reverse vaccinology”, which can generate novel and alternative 
solutions to vaccines that could not previously be developed, whilst evading the time 
consuming, conventional approach of pathogen cultivation (Rappuoli, 2001). Great 
efforts have been made to identify protective mycobacterial substances and it is 
understood that MTB carries and secrets numerous proteins that are potentially viable 
as components for a novel MTB vaccine (Brandt et al, 2000). Indeed, publication of 
the entire genome sequence for the greatest characterised MTB strain revealed 
approximately 4000 associated genes with the potential to encode as many proteins 
(Cole, 1998), providing a fundamental breakthrough that has facilitated the 
identification of revolutionary protein vaccine candidates and revitalised interest in TB 
vaccine research (Sable et al, 2007b). With the acknowledgment of a model vaccine 
candidate being able to provide protective efficacy in a variety of ethnic populations, 
multicomponent subunit vaccines combining defined MTB antigens is a desired 
approach for future development (Sable et al, 2007b). 
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TB is renowned as the principle cause of preventable deaths worldwide, yet attempts to 
surmount the infection by developing innovative treatments has hit many stumbling 
blocks along the way, for example poor aqueous solubility and stability, restricted 
bioavailability and minimal patient compliance (Sosnik et al, 2010). Exploration of 
novel vaccine candidates has predominantly focused on proteins secreted from 
dividing bacteria. A notable fusion protein that has shown the ability to stimulate a 
protective immune response against TB is Ag85B fused with ESAT-6 (Brandt et al, 
2000). Due to the intracellular nature of mycobacterium bacillus, cell mediated 
immunity is required in order to be effective. As highlighted earlier, the use of cationic 
liposomal adjuvants as part of a subunit vaccine delivery system facilitates protein 
antigen delivery whilst enhancing immunity. Moreover, the combination of DDA 
liposomes with the TDB glycolipid as a stable aqueous liposomal adjuvant system has 
been proven to induce cell mediated immunity upon immunisation of mice with a TB 
vaccine antigen candidate, Ag85B–ESAT-6 (H1), characterised by elevated levels of 
the T-cell enhancing cytokine, IFN-γ (Davidsen et al, 2005). 
 
The fusion of early secreted TB antigens Ag85B and ESAT-6 (forming H1 antigen) 
has been shown to be a competitive alternative to the current BCG vaccine, and as a 
booster, to enhance the protective efficacy of the currently available live TB vaccine. 
However, a post exposure vaccine that can provide protection against the late 
persistent stage of infection is still of high priority (Moreno-Mendieta et al, 2010). 
Thus, a vaccine comprising of antigens expressed by bacteria of the first growth phase 
and during the latent stage of TB could enhance long-term immunity when applied as a 
preventative vaccine. Such a multiphase vaccine can be efficient as a therapeutic 
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vaccine, particularly for those in developing countries who may already be latently 
infected prior to receiving a future TB vaccine (SSI, 2010). 
 
Numerous proteins harbour the potential capability to act as late antigens (recognised 
during latent infection) as they are predominantly expressed long after infection, in 
which the immune system has already elicited an initial adaptive defence, producing a 
hostile environment for mycobacteria to survive. Furthermore, in vitro hypoxic culture 
conditions that mimic an oxygen deprived atmosphere has been considered relevant to 
analysis of gene expression alterations, and Rv2660c has been identified as an antigen 
that is stimulated or upregulated in such an environment (Betts, 2002; SSI, 2010). 
 
The TB vaccine research group at the Statens Serum Institut (SSI) has implemented an 
antigen discovery program, screening over 250 TB vaccine mycobacterial antigen 
candidates, with the most promising preventative antigens being part of the Ag85 and 
ESAT-6 family (SSI, 2010). However, recently a multi-stage TB vaccine that 
combines the early secreted TB antigens that form the H1 vaccine with the later 
expressed Rv2660c antigen forming the H56 vaccine, has successfully protected 
against TB before and after exposure, managing reactivation and reducing the bacterial 
load in mice (Aagaard et al, 2011). In addition, the H56 vaccine was capable of 
controlling bacterial growth on par with BCG, whilst exceeding the vaccine 
performance of BCG and H1 at later time points upon challenge, eliciting elevated 
IFN-γ levels specific to all three vaccine components (Aagaard et al, 2011). With new 
and upcoming preclinical advances in TB vaccination coupled with the global priority 
of reducing TB incidence, Kaufmann (2010) reviewed key medium to long term 
vaccination strategies against TB and summarised them into three main stages (Table 
1.8), which if applied, could contribute towards crucially eradicating the pathogen.
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Table 1.8. Future vaccination strategies against tuberculosis. The three main stages of a TB vaccine strategy is summarising information reviewed by Kaufmann, (2010). 
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1.6. Aims & Objectives 
The aim of this work was to investigate the physicochemical characteristics of DDA-
TDB based cationic liposomes as adjuvant delivery systems for subunit antigen, upon 
incorporation of DPPC, for potential pulmonary vaccine delivery or DSPC, for 
immunological analysis upon delivery of H56 vaccine, a novel subunit TB vaccine 
antigen. Moreover, the role of DDA within the formulation was assessed by 
incrementally replacing cationic content with DPPC or DSPC lipid, alongside the 
substitution of DDA-TDB to ascertain the effect of DDA-TDB concentration, whilst 
evaluating the potential of such systems to activate antigen presenting cells in vitro, 
using a macrophage cell line as a general model to observe the viability of the 
proposed liposomal formulations for administration in vivo. In order to accomplish 
these aims the objectives were to: 
 
 Physicochemically characterise the outlined systems, upon incorporation of DPPC 
or DSPC into DDA-TDB, for particle size, zeta potential, short term stability, 
surface morphology, antigen retention/release and interactions with serum proteins. 
 Conduct thermodynamic analysis to attain the main phase transition temperature, 
whilst determining the interdigitation of the multiple lipid formulation components. 
 Determine the associated cytotoxicity of the proposed liposomal immunoadjuvants 
upon macrophages and their ability to stimulate phagocytic activity and the 
activation of macrophages in vitro.   
 Characterise the performance of the liposomal adjuvants as vaccine delivery 
systems in vivo, in order to fully appreciate the resultant immunological effect of 
DDA and TDB adjustment and additional lipid incorporation into DDA-TDB. 
 Assess the suitability of the DPPC based cationic systems for pulmonary delivery.  
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2.1. Materials 
Tris (Ultra Pure) was purchased from ICN Biomedicals (Aurora, OH). Phosphate 
buffered saline (PBS) tablets and D-glucose (glucose monohydrate) were purchased 
from Sigma-Aldrich Co. Ltd. (Dorset, UK). Methanol (extra pure), chloroform (extra 
pure) and hydrochloric acid (used to adjust the pH of Tris buffer), were purchased 
from Fisher (UK). Dimethyl dioctadecylammonium bromide (DDA), ,’-trehalose 
6,6’-dibehenate (TDB), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) were obtained from Avanti Polar 
Lipids (Alabaster, AL). The purity of all compounds used was > 99%, determined by 
HPLC. SDS-PAGE 12% Tris-glycine gels (1.0 mm X 12 well) and the protein 
molecular weight standard (broad range – 11 polypeptides, MW 6500-205,000 
Daltons) were purchased from Invitrogen (Paisley, UK). The bicinchoninic acid 
protein assay kit including reagents, bicinchoninic acid solution and copper sulphate 
solution and the β-N-Acetylglucosaminidase (NAG) assay kit was obtained from 
Sigma-Aldrich Co. Ltd. (Dorset, UK). The cell titer 96
®
 AQueous non-radioactive cell 
proliferation (MTS) assay was purchased from Promega (UK). A mouse TNF-α 
ELISA development kit was obtained from R&D Systems Europe Ltd. (Abingdon, 
UK). Fetal bovine serum (FBS) was obtained from Biosera (East Sussex, UK). For the 
radioactive studies, IODO-GEN® pre-coated iodination tubes were purchased from 
Pierce Biotechnology (Rockford, IL). Sephadex® G-75 was purchased from Sigma-
Aldrich Co. Ltd. (Dorset, UK).  I
125
 (NaI in NaOH solution), [
3
H] thymidine and 
ultima gold scintillation fluid were obtained from Perkin Elmer (Waltham, MA). 
Dialysis cellulose ester (CE) membrane tubing (Molecular weight cut off (MWCO): 
100,000) was purchased from Spectra/Por® Biotech (Breda, Netherlands). Ag85B-
ESAT-6-Rv2660 (H56 antigen) was supplied by Statens Serum Institut (SSI), 
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(Copenhagen, Denmark) at a concentration of 0.7 mg/ml. All other reagents used were 
of analytical grade.   
 
2.2. Methods 
2.2.1. Production of liposomes via lipid hydration    
DDA-TDB based liposome formulations were prepared by the method of lipid 
hydration based on studies by Bangham et al, (1965) and modified as described by 
Davidsen et al, (2005). Firstly, weighed amounts of powdered lipids were dissolved in 
a chloroform:methanol solvent mixture (9:1, v/v) and pipetted into a round bottomed 
flask, fixed to a final concentration of 1.25 mg DDA and 0.25 mg TDB per ml. 
Removal of the solvent was achieved via rotary evaporation of the mixture contained 
in the round bottomed flask together with subsequent nitrogen streaming which 
produces a fine lipid layer at the base of the flask. Multilamellar vesicles were 
produced by hydrating the remaining lipid film in 10 mM Tris buffer (pH 7.4). The 
lipid film was hydrated for twenty minutes with intermittent vortexing, in conditions 
10 ºC above the main phase transition temperature for the lipids used, providing total 
hydration (Davidsen et al, 2005). Independent batches of the vesicle systems were 
prepared and hydrated in either Tris buffer (10 mM, pH 7.4), dextrose (5% w/v) or 
phosphate buffered saline. Figure 2.1 summarises the technique of lipid hydration. 
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Figure 2.1. The production of liposomes via lipid hydration. Upon the addition of powdered lipids 
(A) in chloroform:methanol (9:1, v/v), the solvent was removed yielding a dry lipid film (B) before 
rehydration in an aqueous medium (C) producing liposomes upon cooling (D). 
 
The incorporation of increasing amounts of DPPC or DSPC to DDA-TDB at various 
molar % ratios from 0 to 75% were investigated (Table 2.1) (All lipids were dissolved 
in chloroform:methanol solutions - 9:1 v:v ratio). 
  
Table 2.1. Incorporation of lipids for the substitution of DDA-TDB. Values of weight or moles upon 
the addition of DPPC or DSPC to the DDA-TDB adjuvant system are represented to the final volume of 
1 ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DDA-TDB based 
Formulation 
(mol%) 
 
 
DDA 
Weight (mg) 
/Moles 
 
TDB 
Weight (mg) 
/Moles 
 
Lipid  
Weight (mg) 
/Moles 
 
0% 
 
1.25 / 1.98x10
-6 
 
 
0.25 / 2.53x10
-7 
 
0 / 0 
+ 25% DPPC 
 
0.94 / 1.49x10
-6
 0.18 / 1.78x10
-7
 0.41 / 5.58x10
-7
 
+ 50% DPPC 0.62 / 9.81x10
-7
 0.13 / 1.34x10
-7
 0.82 / 1.12x10
-6
 
+ 75% DPPC 
 
0.31 / 4.91x10
-7
 0.07 / 6.69x10
-8
 1.23 / 1.67x10
-6
 
+ 25% DSPC 0.94 / 1.49x10
-6
 0.18 / 1.78x10
-7
 0.44 / 5.58x10
-7
 
+ 50% DSPC 0.62 / 9.81x10
-7
 0.13 / 1.34x10
-7
 0.88 / 1.12x10
-6
 
+ 75% DSPC 0.31 / 4.91x10
-7
 0.07 / 6.69x10
-8
 1.32 / 1.67x10
-6
 
Organic 
solvent 
Dry lipid 
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lipids 
B C 
 
Solvent 
removal  
Hydrate 
above Tm 
Vortex to 
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A 
Aqueous 
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2.3. Dynamic light scattering: characterisation of liposome systems 
2.3.1. Determination of particle size 
The particle size of all liposome systems was measured using a ZetaPlus instrument 
(Brookhaven Instrument Corporation, Worcestershire, UK) via dynamic light 
scattering, which is a simple, efficient technique that can accurately measure particle 
sizes in the range of 2 to 3000 nm. For samples that are of sub-micron particle size, 
dynamic light scattering (DLS), also known by the techniques of photon correlation 
spectroscopy (PCS) and quasi elastic light scattering (QELS), is the most suitable 
instrumentation. 
 
Based on the principle of Brownian motion, when particles are suspended in an 
aqueous medium, the rate of particle diffusion is relative to their size with small 
particles diffusing faster than larger particles. The time disparity of subsequent 
scattered intensity is detected by studying their auto-correlation, thus ascertaining a 
diffusion coefficient from which particle size can be measured. The instrument passes 
a laser through the liposome sample which is scattered by the particles in multiple 
directions and is subsequently measured by a photomultiplier tube. A unique auto-
correlation function is processed and this function, exclusive to the sample population, 
ultimately gives an accurate calculation of particle size. The PCS technique calculates 
scattered light intensity that varies over time intervals. Thus, intensity autocorrelation 
function is produced upon calculating an average of the intensity products within 
dispersions as a function of time. Therefore, the scattered diffusion rate represents the 
particle size (Brookhaven Instruments Corporation, 2004). 
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2.3.2. Determination of zeta potential 
Zeta potential is the difference in electrical potential, measured in millivolts (mV), 
present between the stern plane of counter ions encompassing a colloidal particle and 
its dispersion medium. At the particle surface, the net charge impacts ion dispersal in 
the adjacent area, in turn increasing the volume of counter ions at the surface. This 
forms an electrical double layer at the particle-liquid interface (Figure 2.2). This liquid 
layer that encompasses the particle is split into two sections, an inner region, the stern 
plane, containing strongly associated ions, and an outer diffuse layer, with less firmly 
bound ions, with the zeta potential measured at the boundary of the shear plane 
(Kaszuba et al, 2010) (Figure 2.2). Thus, zeta potential can indirectly signify the 
surface charge of a particle, which is significant to the characterisation and 
management of colloidal stability, an imperative factor to be controlled when 
optimising physically stable delivery systems (Brookhaven Instruments Corporation, 
2004). 
 
The measured electrical charges greatly affect the interactions between particles in the 
dispersed phase and the resultant physical stability of the systems, especially of those 
in the size range of colloidal particles. For dispersed systems utilised as vehicles of 
drug delivery, such as liposomes for example, the in vivo fate, and thus the resultant 
protective efficacy, is considerably influenced by surface charge (Li & Tian, 2006). 
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Figure 2.2. A schematic illustration of the zeta potential of a particle. The electrical double layer 
that surrounds a particle with a net surface charge (in this instance a positive charge) and the electrical 
potentials encompassing the particle provides the zeta potential, which is measured at the surface of the 
shear plane. 
 
Overall, through the use of dynamic light scattering, the average diameter and zeta 
potential of the liposomal formulations were measured using a ZetaPlus analyser 
(Brookhaven Instrument Corporation). Particle sizes were averaged for their mean 
after three minutes, with three measurements averaged across one minute intervals. 
When measuring the particle size and zeta potential, approximately 100 µl of sample 
was suspended in 2 ml of the corresponding 1/10 diluted buffer solution (e.g. 1 mM 
Tris buffer, pH 7.4) with readings taken at room temperature. The zeta potential results 
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Stern potential 
Zeta potential 
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(Potential) 
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were mean averages taken from ten readings made for each formulation in triplicate. 
Standard control readings were taken regularly and recorded for particle size (499 nm 
+/- 5 nm; Brookhaven) and zeta potential (-68 mV +/-6.8 mV; Malvern). 
 
2.4. Differential Scanning Calorimetry (DSC) of liposomal dispersions 
The gel-to-liquid phase transition temperatures were attained for the liposomal 
dispersions via DSC and thermograms were acquired using a Pyris Diamond DSC 
(Perkin Elmer Instruments LLC, USA). A scan rate in the range of 2-20 °C/min is 
generally utilised for liposome samples. In this study, with a greater resolution 
associated to slower scan rates, a scan rate of 10 °C/min (600 °C/h) was applied, for a 
balance between enhanced sensitivity and resolution (Taylor & Craig, 2003), over the 
range of 25 °C to 75 °C. All scans were carried out in triplicate, as it is a standard 
approach to run at least two additional DSC scans to verify reproducibility (Feitosa et 
al, 2006).  
 
The conditions and settings were adjusted accordingly to optimise the application of 
differential scanning calorimetry of fluid liposomal dispersions. Suspensions were 
contained in air tight pans which were sealed immediately upon loading to reduce the 
effect of evaporation, with a sample load weight of approximately 10 mg. A reference 
pan filled with an equal volume of either water or buffer is beneficial compared to 
empty pans, with the corresponding buffer used as a reference. This yielded an 
improved baseline, achievable through a comparable thermal composition with the 
sample. Pyris software, version 5.00.02 (Perkin Elmer Instruments LLC, USA) was 
used for all data analysis. 
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2.5. Protein loading studies 
2.5.1. Separation of liposome associated and non-associated protein 
To separate the liposome associated antigen from the free, non-associated antigen, 
liposomes were centrifuged at 125000 g (45000 RPM) for sixty minutes at room 
temperature (RT) to pellet the liposomes. The supernatants were then collected and the 
pellets were re-suspended back into their original volume, using the corresponding 
buffer. 
 
2.5.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Gel electrophoresis occurs when a charged particle moves through an electrical field. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is utilised 
to ascertain the molecular weight for specific polypeptide chains. Initially, native 
proteins are denatured into individual polypeptides through the addition of the 
detergent sodium dodecyl sulphate, which breaks down hydrophobic bonds. Further 
breakage into disulfide bonds is achieved upon the application of mercaptoethanol. In 
this induced environment, polypeptide chains are generated by proteins that transform 
into inadvertent coils which attach to an abundance of SDS at a constant weight ratio 
of SDS detergent per gram of polypeptide. As a result, the charges of the polypeptides 
become redundant in comparison to the negative charges of the SDS, generating a 
consistent negative charge for the polypeptides. Therefore, with an identical 
charge/mass ratio, each SDS-protein complex has an equal electrophoretic mobility. 
When such complexes undergo electrophoresis on a polyacrylamide gel, a sieving 
motion aids sample separation and protein mobility can take place based on their 
respective molecular weights. The larger molecules take longer to migrate down the 
gel and, alongside a known standard marker, unknown proteins can be established for 
an approximate molecular weight (Stenesh, 1998). 
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Upon centrifugation, as highlighted earlier, which is conducted to separate the 
liposome associated protein from the non-associated protein, the resultant samples in 
an equal volume of SDS sample buffer were heated at 90 °C for three minutes in order 
to denature the proteins to their individual polypeptides. Subsequently, 10 µl of pellet 
and supernatant samples from each formulation were analysed via SDS-PAGE for 
semi-quantification of the protein concentrations present. 
 
2.5.3. Bicinchoninic acid (BCA) assay: quantification of non-adsorbed protein 
Determination of protein can be pivotal to biochemical research and the BCA assay 
allows for protein recognition, achieved by the development of a Cu
2+ 
protein complex
 
in an alkaline environment, prior to Cu
2+ 
reduction to Cu
1+
. Furthermore, the volume of 
this reduction reaction is directly proportional to any protein present. The formation of 
a purple-blue complex is resultant from BCA that binds with Cu
1+
 in alkaline 
conditions. Consequently, protein determination can occur and the colour change 
reaction provides a means of observing the reduction of alkaline Cu
2+ 
from proteins. 
Indeed, the BCA assay holds numerous advantages over alternative protein 
determination assays including: 
 
 Ease of application, 
 Stability of colour complexes formed, 
 Can be applied to an array of protein concentrations. 
 
The BCA assay has a working range of 0.5 to 30 µg/ml of protein, with triplicate 25 µl 
supernatant solutions (from liposome samples adsorbed with OVA at 1 mg/ml) added 
to 200 µl of BCA reagent per well, tested to ascertain the level of non-adsorbed protein 
from the proposed liposomal formulations. Overall, unknown OVA protein 
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concentrations present within the supernatants were quantified by the BCA protein 
assay in accordance with the associated protocol (Sigma-Aldrich Co. Ltd. Dorset, UK). 
 
A protein standard concentration curve for OVA from 0-1 mg/ml (Figure 2.3) was 
formed and plotted to establish the equation of the line, upon which the percentage of 
free protein within the sample supernatants could be determined from the known 
concentrations. Indeed, upon reduction of Cu
2+ 
to
 
Cu
1+ 
from proteins in the alkaline 
solution, the presence of bicinchoninic acid yields blue or violet complexes. This in 
turn allows for quantification of total protein from sensitive colorimetric detection, 
with mean absorbance values measured at the wavelength of ~560 nm (Pierce 
Biotechnology Inc, 2005). 
 
 
 
 
Figure 2.3. An example OVA protein standard curve for the BCA assay. Results represent the mean 
average from three readings for each concentration upon the net absorbance read at the wavelength of 
~560 nm. 
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2.6. Quantification of adsorbed OVA protein via radiolabelling 
2.6.1. Radiolabelling OVA 
 
For the studies of antigen retention and release over time, OVA protein was 
radiolabelled with iodine 125 (I
125
). OVA and I
125
 was added to a pre-coated iodination 
tube and allowed to bind for up to one hour, with swirling taking place at regular 
intervals. In order to generate an approximate 1-2 ml stock of radiolabelled OVA/I
125
, 
100 µl OVA (1 mg/ml) was mixed with 2 MBq I
125
. Sephadex G-75 (fractionation 
range for globular proteins of 3-80,000 MW) gel filtration media in water was formed 
in a 10 ml column and hydrated with Tris buffer. The radiolabel-OVA mixture was 
passed through the column, maintained with a stable flow rate of Tris buffer, for the 
collection of I
125 
in 80 samples of 0.5 ml.  
 
Upon sample collection, the extent of activity per iodine sample was measured using 
an auto-gamma counter for counts per second (CPS) and plotted (Figure 2.4), with 
confirmation of radiolabelled OVA determined by the BCA assay, whereby a colour 
change indicated the presence of protein (Figure 2.5). The samples that correlated to 
the uppermost gamma counts with a corresponding indication of protein presence were 
pooled together. This stock was subsequently diluted accordingly with Tris buffer in 
order to adsorb radiolabelled OVA to the liposome samples at the desired 
concentration. 
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Figure 2.4. Determination of γ-radiation activity for iodine labelled OVA samples eluted through a 
sephadex column. Each sample contained a volume of ~0.5 ml as 80 samples were passed through a 10 
ml column. OVA antigen was found to be associated to samples 11, 12 and 13, later confirmed with the 
BCA assay. The second visible peak is typical of free iodine, not associated to any protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Confirmatory BCA assay results for suspected protein labelled samples. A colour 
change from green to purple, indicative of protein presence corresponded to the 1
st
 peak of gamma 
counts associated to OVA/I
125
 samples of 11-13. A lack of protein was also confirmed in samples of the 
2
nd
 free iodine peak. 
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2.6.2. Determination of in vitro release via dialysis of liposomes adsorbed with 
OVA/I
125
 
Prior to the adsorption of radiolabelled OVA to the DDA-TDB based liposome 
systems, the release of radiolabelled OVA was assessed via dialysis experiments. This 
was firstly validated by ascertaining whether OVA alone would pass through the pores 
of the dialysis tubing in the absence of the liposomes. Such an experiment was 
conducted over a 72 hour time period with the tubing clipped and closed at either end 
with dialysis clips, prior to being immersed in 30 ml of Tris buffer or FBS/Tris in 
falcon tubes, at 37 °C in a shaking water bath. 
 
At regular intervals, 1 ml of sample was removed and measured for its iodine activity 
using an auto-gamma counter, giving results in counts per second. This allowed for the 
extent of radiolabelled OVA release at each designated time point to be calculated over 
time, from an initial measured total sample. Upon removal of a 1 ml sample, the media 
was changed with an identical volume of either Tris buffer or FBS/Tris as the same, 
original dialysis tubing was placed in a new falcon tube to be returned to the shaking 
water bath. After the final time point was measured, the remainder of I
125
 activity from 
within the dialysis tubing was then measured for gamma counts. This dialysis 
procedure was subsequently followed when applying the liposome/OVA/I
125 
samples 
to the tubing, to ascertain the release profiles over time for the various DDA-TDB 
based liposomal formulations. 
 
2.7. Serum stability studies: interaction of serum proteins with liposomes 
All of the proposed DDA-TDB based liposome systems were immersed in Tris buffer 
and/or in FBS, in a 50% v/v mixture with Tris buffer, in order to mimic in vivo 
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conditions. Measurements of particle size and zeta potential of the systems was carried 
out via dynamic light scattering using a ZetaPlus analyser (Brookhaven Instrument 
Corporation) as previously conducted. Upon the addition of each liposome batch in 
Tris buffer to an equal volume of FBS/Tris (50% v/v), samples were incubated in a 
water bath at 37 °C over 24 hours. At various intervals across this time period, the 
samples were centrifuged (Beckman Coulter - 125,000×g, 4 °C, 45 mins) to remove 
any unbound proteins, prior to measurements of particle size and zeta potential as 
previously conducted. 
 
2.8. Transmission electron microscopy (TEM) 
Transmission electron microscopy is one the main techniques of choice for the micro-
structural characterisation of materials. Conventional TEM consists of an array of 
advanced instrumentation including vacuum science technology, electronic and 
mechanical stability, electron sources and highly sensitive digital imaging, amongst 
many other processes (Zhang & Zhang, 2001). 
 
The transmission electron microscope directs a specialised beam of electrons (as 
opposed to light used in a light microscope), in conjunction with magnetic coils onto a 
specimen, with the chosen sample suspended within a vacuum. Electron interaction 
occurs as the specialised beam enters the specimen, forming a representative image. 
Contrast can be established through the use of heavy-metal stains that engage or 
diffract electrons, removing them from the electron beam as it enters the sample 
material. Such a powerful analytical tool is recognised in the potential resolution 
achievable with magnification as high as X1x10
6
. In addition, for biological 
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specimens, a transmission electron microscope possesses the resolving power to 
distinguish features down to a mere 2 nm (Alberts, 2004). 
 
In the current study, morphological examination was conducted using a “Jeol 1200EX” 
transmission electron microscope fixed with a LaB6 filament within an operating 
voltage range of 40 to x 120 kV. 10 µl of the liposome sample was positioned on a 
polymer filmed copper grid and was left to rest for two minutes. Surplus sample was 
removed using filter paper with subsequent application of uranyl acetate (10 µl). The 
copper grid was once more left for two minutes prior to cleaning with distilled water 
and air drying, producing a thin film. Upon sample preparation into a film, observation 
took place at 70 kV. 
 
2.9. Cell culture/in vitro studies 
A macrophage “J774” BALB/c mice cell line (Source: ECACC - European collection 
of cell cultures) was grown in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 1% Penicillin/Streptomyocin/L-Glutamine (PSG) and 10% (v/v) 
Foetal bovine serum. Incubation took place in sterile conditions at 37 °C, in humid 
conditions of 5% CO2. 
 
2.10. CellTiter 96 aqueous non-radioactive cell proliferation assay (MTS assay) 
The non-radioactive cell proliferation assay is a colorimetric technique that establishes 
the quantity of live, viable cells. The assay contains solutions of a tetrazolium 
compound; 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2Htetrazolium, inner salt; (MTS) with an electron coupling reagent, 
phenazine methosulfate (PMS). The bio-reduction of MTS by cells yields formazan 
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product, soluble within the tissue culture medium. Further processing is not required as 
complete absorbance of formazan at 490 nm is read directly from the plate. All 
metabolically functional cells contain dehydrogenase enzymes responsible for 
converting MTS into the soluble form of formazan (Figure 2.6). Therefore, the level of 
absorbance determined from the presence of formazan product is directly proportional 
to the volume of live cells in culture (Promega, 2007). 
 
Figure 2.6. The structure and conversion of MTS into formazan. MTS is converted by 
dehydrogenase enzymes present in active cells, responsible for the breakdown of MTS tetrazolium salt 
into the resultant formazan product (Promega, 2007). 
 
The MTS assay is required to understand the levels of cell proliferation possible with 
the outlined DDA-TDB based systems. As discussed by Lappalainen et al, (1994) 
when comparing cell proliferation assays using cationic liposomes, the necessity to 
ascertain cell proliferation and cytotoxicity is vital when formulating drug delivery 
systems. Although results obtained in vitro do not exactly correlate to the possible 
behaviour in vivo, such applications can indicate the functions and survival potential of 
components at a cellular level, within physiological conditions. The MTS and MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were applied to 
the cationic samples by Lappalainen et al, (1994), and proved to be almost identical in 
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results. However, as well as being convenient in use, non-radioactive and flexible, the 
use of the MTS assay is justified as it has favourable advantages over the MTT assay 
including; 
 
 Efficiency - No washing or harvesting of cells together with solubilisation steps 
(used in the MTT assay) are required for this assay. 
 
 Safe - To solubilise the formazan product, which is quantitatively, a directly 
proportional indication of viable cells in culture, volatile organic solvents are not 
required (necessary for the MTT assay). 
 
 Flexible - The 96 well plates used to read and quantify the absorbance of remaining 
formazan product can be re-incubated for additional development of the reaction 
and measurement, as measuring absorbance is non-destructive (Promega, 2007). 
 
Cytotoxicity upon macrophages was determined by the MTS cell proliferation assay in 
conjunction with the DDA-TDB based systems. More specifically, the commercially 
available “CellTiter 96® AQueous One Solution Cell Proliferation Assay” (Promega, 
USA) was applied to the DDA-TDB formulations at 5.0 µg/ml (concentration 
calculated for the cationic component, DDA: total concentration = 6 µg/ml) on 96 well 
plates with 8x10
4 
cells/ml (8x10
3
 cells/well). The cell number and viability was 
determined accordingly to the desired concentration and plated out for each 
formulation, together with positive and negative controls (macrophage cells or DMEM 
respectively) in triplicate wells. The total volume per well was 100 µl. 
 
Upon 24 hours incubation at 37 °C in a humidified atmosphere of 5% CO2, ensuring 
adherent cells, the DDA-TDB liposomes were applied at the set concentrations (serum 
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free DMEM was used as serum binds to the cationic components in the formulation). 
The following day, upon incubation of the cells and sample, 20 µl of CellTiter 96
® 
AQueous One solution reagent per 100 µl was pipetted to each well and the plate was 
incubated at 37 °C, 5% CO2. Absorbance was read after one hour using a 96-well 
protein assay micro plate reader, recorded at the wavelength of 490 nm as displayed in 
the schematic in Figure 2.7.  
 
        
 
 
        
 
 
        
 
 
 
 
 
 
 
Figure 2.7. Schematic diagram summarising the main steps of the MTS cell proliferation assay. 
Initially, BALB/c cells were plated out to a set cell number and incubated overnight at the set 
humidified conditions. Upon sample preparation, adjustment to the desired sample concentration and a 
further night of incubation, the MTS reagent was added before determining absorbance at the set 
wavelength of 490 nm. 
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2.11. β-N-Acetylglucosaminidase assay 
N-acetyl-â-D-glucosaminidase (NAG) is a lysosomal enzyme of mammalian cells that 
contributes to the intracellular degradation of glycolipids and glycoproteins (Legler et 
al, 1991). The NAG assay occurs due to the hydrolysis of the NAG substrate, 4-
Nitrophenyl N-acetyl-â-D-glucosaminide (NP-GlcNAc), by the lysosomal enzyme. 
Such enzymatic hydrolysis of the NAG substrate emancipates p-nitrophenol ions 
(Figure 2.8). After ionisation, the product reactant can be colourimetrically determined 
using a micro plate reader, (Bio-Rad, Herts, UK) set to the wavelength of 405 nm 
(Sigma, 2009). 
                                     
 
Figure 2.8. The enzymatic hydrolysis of NAG substrate. Hydrolysis liberates p-nitrophenol with 
subsequent introduction of stop solution resulting in the formation of yellow p-nitrophenylate ions, 
measured at the wavelength of 405 nm (Sigma, 2009). 
 
A β-N-Acetylglucosaminidase assay kit (Sigma-Aldrich Co. Ltd., Dorset, UK) was 
conducted according to manufacturer’s instructions using 96 well cell culture plates 
with a BALB/c cell number of 8x10
4
/ml, as fixed previously for the MTS assay. With 
the desired cell number correctly determined, plated and incubated overnight at 37 °C 
in a humidified atmosphere of 5% CO2, liposomal DDA-TDB based formulations at a 
5 µg/ml sample concentration were introduced in triplicate, mirroring the first two 
stages of the MTS assay, as displayed previously in Figure 2.7.  
 
After a second overnight incubation of cells and liposome samples, at identical 
conditions (37 °C, 5% CO2), 10 µl from each well was transferred to a new plate with 
the addition of 90 µl of substrate solution (1 mg/ml of 4-Nitrophenyl-N-acetyl-β-D-
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glucosaminide (NP-GlcNAc) in 0.09 M citrate buffer). A blank control (100 µl of 
substrate solution), a standard control (300 µl of standard solution) and a positive 
control (98 µl of substrate solution + 2 µl of NAG control enzyme) were included in 
triplicate to the new 96 well plate. This plate was then incubated at 37 °C, 5% CO2 as 
previously conducted for 10 minutes. Following incubation, the reaction was stopped 
by adding 200 µl of stop solution per well, except the wells containing standard 
solution. The plate was then read on a micro plate reader at 405 nm. 
 
2.12. Determination of tumour necrosis factor-alpha (TNF-α) cytokine release 
Immunoassays consist of experiments that utilise antibodies as reagents and more 
specifically, enzyme immunoassays employ enzymes bound to a reactant that 
ultimately yields quantification, possible from a colour change reaction that 
materialises upon the introduction of substrate. In general, ELISAs consist of a 
stepwise introduction and subsequent reaction of reagents to a solid-phase bound 
substance, via incubation and separation of bound and unbound reagents upon 
washing. An enzyme labelled reactant causes a characteristic colour change that allows 
for quantification of the reaction to take place (Crowder, 2001). 
 
Macrophage activation was detected by the application of a mouse TNF-α ELISA 
development kit (R&D Systems Europe Ltd., Abingdon, UK). The general enzyme-
linked immunosorbent assay (ELISA) protocol and subsequent analysis was conducted 
in accordance with the manufacturer’s recommendations.  
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Initially for plate preparation, capture antibody was diluted to a working concentration 
of 0.8 μg/ml and was used to coat a 96 well plate prior to incubation overnight at room 
temperature (RT). Subsequent washing and blocking rendered the plate ready for 
sample addition after a repeated wash stage. 100 µl cell culture supernatants of the 
DDA-TDB based formulations and standards were added, and after 2 hours incubation 
at RT and a further wash stage, the introduction of 100 µl detection antibody (200 
ng/ml) allowed for the TNF-α cytokine to be detected. After 2 hours incubation at RT 
and a further wash stage, an enzyme marker, Streptavidin-HRP (horseradish 
peroxidase) was added prior to incubation at RT for 20 minutes (plates were covered to 
avoid exposure to light). After washing and introducing 100 µl of substrate solution, 
the plates were covered and incubated for a further 20 minutes. 50 µl of stop solution 
was then added to each well and the plates were gently tapped, to ensure thorough 
mixing and inhibit any further reaction.  
 
After all experimental steps were followed to develop and stop the reaction, the optical 
density was read immediately using a micro plate reader (Bio-Rad, Herts, UK). 
Absorbance readings were made at the wavelength of 450 nm for each well, including 
the seven point standards to produce a corresponding standard curve for mouse TNF-α 
concentration (pg/ml) against the optical density. The enzyme-linked immunosorbent 
assay (ELISA) process and all the protocol steps conducted are summarised in Figure 
2.9.   
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Figure 2.9. Schematic summary of the mouse TNF-α enzyme-linked immunosorbent assay 
(ELISA) development kit. ELISA plates were coated with capture antibody prior to numerous wash 
stages (with 0.05% Tween 20 in PBS as wash buffer) and blocking with reagent diluent. Washing prior 
to each stage of introducing sample, detection antibody and additional antibody conjugate for bound 
antibody recognition took place with incubation at room temperature. Addition of the activating 
substrate with further incubation and subsequent addition of stop solution completed the experiment, 
prior to reading absorbance at 450 nm. 
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2.13. In vivo studies: immunological analysis of DDA-TDB based liposomes 
All experimentation strictly adhered to the 1986 Scientific Procedures Act (UK) and 
was conducted in a designated establishment. For the main immunisation study, female 
C57BL/6 mice, 6-8 weeks old (acquired from Charles River, UK) were split into 11 
groups of 5. 
 
2.13.1. Immunisation of mice 
Vaccine preparations were made with DDA-TDB based liposomes incorporating 
Ag85B-ESAT-6-Rv2660 (Hybrid56) antigen to a final concentration of 0.1 mg/ml (5 
µg/vaccine dose). All mice, with the exception of the naive group, were immunised 
intramuscularly (i.m.) with the proposed vaccines (0.05 ml/dose) three times, with two 
week intervals between each immunisation. 
 
Blood samples were taken at regular intervals throughout the seven week study, prior 
to termination. Blood was drawn from the tail vein upon a small incision, obtaining 50 
µl with micropipette capillary tubes lightly coated in heparin solution (0.1% w/v in 
PBS). The blood was subsequently added to 450 µl PBS (giving a final dilution of 
1/10) and centrifuged using a micro centrifuge at 13,000 RPM for 5 minutes. The 
supernatants of each mouse sample was collected and transferred to a fresh eppendorf 
prior to storage at -20 °C for future analysis. As a result, assuming that the haematocrit 
or packed cell volume is approximately 50%, sera obtained from each mouse consisted 
of a final 20-fold dilution. 
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2.13.2. Splenocyte proliferation 
Upon experiment termination, mice were humanly culled prior to aseptic spleen 
removal and placement in ice-cold, sterile PBS. Spleen cell suspensions were produced 
upon light grinding through a fine wire mesh into 10 ml RPMI 1640 cell culture 
medium (W/O Glutamine) supplemented with 10% (v/v) FBS and 1% (v/v) PSG 
(BioSera, East Sussex, UK). The cell suspension was left for 5 minutes to settle before 
transferring the suspension to sterile falcon tubes, ensuring that the cellular debris was 
not disrupted. The cell suspension was then centrifuged at 1000 RPM for 10 minutes at 
15 °C. The resultant supernatant was then removed with the remaining pellet 
resuspended in 10 ml of fresh RPMI media, prior to further centrifugation at 1000 
RPM for 10 minutes at 15 °C. The supernatant was removed and the pellet was 
resuspended in 5 ml of fresh RPMI media. The single cell suspensions were 
subsequently used to evaluate splenocyte proliferation and antigen specific cytokine 
responses. 
 
For the analysis of splenocyte proliferation, H56 antigen was added to sterile 96 well 
cell culture plates (Greiner Bio-One Ltd, Gloucestershire, UK) at the concentrations of 
0, 0.05, 0.5, 5.0 and 25 μg/ml (adjusted to the desired concentration using 
supplemented RPMI) alongside a positive control of concanavalin A at 2 μg/ml. 100 μl 
of the splenocyte cell suspensions were subsequently added to each well prior to 
incubation at 37 °C, 5% CO2. Upon 72 hours incubation, 40 μl of [
3
H] thymidine at 0.5 
microcurie (μCi) in supplemented RPMI media was added to each well before 
incubation for 24 hours (37 °C, 5% CO2). All well contents were harvested on to 
quartz filter mats (Skatron/Molecular Devices, Berkshire, UK) using a cell harvester 
(Titertek Instruments, Alabama, USA). Individual discs representative of each well per 
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plate was passed through to 20 ml scintillation vials (Sarstedt, Leciester, UK) 
containing 5 ml of liquid scintillation cocktail (Ultima Gold, PerkinElmer, 
Cambridgeshire, UK). Incorporation of [
3
H] thymidine in the cultured cells was 
measured using a Tri-carb 3100TR liquid scintillation analyzer (Packard BioScience 
Co., Meriden, CT, USA), according to standard operating procedures. 
 
2.13.3. Evaluation of H56 antigen specific antibody isotypes 
Serum samples collected at regular time intervals over the seven week immunisation 
study were assessed for levels of IgG, IgG1 and IgG2b antibodies by applying an 
enzyme-linked immunosorbent assay (ELISA). The ELISA plates (96 well, flat 
bottomed, high binding, Greiner Bio-One Ltd, Gloucestershire, UK) were firstly 
coated with 60 µl/well of H56 antigen at 3 µg/ml in PBS, prior to overnight incubation 
at 4 ºC. All plates were washed three times with PBST wash buffer (40 g NaCI, 1 g 
KCI, 1 g KH2PO4, 7.2 g Na2HPO4,  (2H20) per 5 litres of ddH20, incorporating ~0.4 ml 
of Tween 20) using a plate washer (Microplate washer, MTX Lab Systems, INC., 
Virginia, USA) with subsequent blotting onto paper towels to remove any unbound 
antigen. In order to eradicate any non-specific antigen binding, the plates were blocked 
by coating each well with 100 µl of Marvel in PBS (dried skimmed milk powder, 4% 
w/v, Premier Foods, Hertfordshire, UK) and incubated for one hour at 37 ºC before the 
plates were washed again three times with PBST buffer. 140 µl of serum sample was 
serially diluted in PBS (70 µl sequentially across the plate) in dilution plates, added to 
the washed ELISA plates and then incubated for one hour at 37 ºC. The plates were 
then washed five times with PBST buffer before the addition of 60 µl/well of 
horseradish peroxidise (HRP) conjugated anti-mouse isotype specific 
immunoglobulins of IgG, IgG1 and IgG2b (AbD serotec, Oxfordshire, UK) upon 
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adjustment in PBS to the suggested dilutions of 1/750, 1/4000 and 1/4000, to identify 
anti-H56 antibodies. The plates were washed a further five times with PBST buffer 
prior to the addition of 60 µl/well substrate solution (colouring agent: 6x 10 mg tablets 
of 2,2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS; Sigma, Dorset, UK) 
in citrate buffer (0.92g Citric Acid + 1.956g NA2 HPO4 per 100 ml) incorporating 10 
µl of hydrogen peroxide (30% H2O2/100 ml) before incubation for 30 minutes at 37 
ºC. The absorbance was then read at the wavelength of 405 nm using a microplate 
reader (Bio-Rad Laboratories, model 680, Hertfordshire, UK). A known positive 
serum and pooled naive mice sera were used as a positive and negative control 
respectively. 
 
2.13.4. Quantification of cytokines via the ELISA (sandwich ELISA) 
The isolation of splenocyte cell suspensions and plating onto 96 well cell culture plates 
was conducted as summarised in section 2.13.2. The cells were subsequently incubated 
for 48 hours at 37 °C (5% CO2), prior to removal of supernatants and storage at -70 °C 
for future analysis. Quantification of the cytokines, IL-2, IL-5, IL-6, IL-10 and IFN-γ 
within cell culture supernatants took place using each specific DuoSet ELISA 
development kit (R&D Systems, Oxfordshire, UK). The plates were firstly coated with 
100 μl capture antibody per well (diluted in PBS to 1.0 μg/ml for IL-2 and IL-5, to 2.0 
μg/ml for IL-6 and to 4.0 μg/ml for IL-10 and IFN-γ) and incubated at room 
temperature overnight. The plates were then washed three times with PBST buffer 
before blocking with blocking agent (reagent diluent). The plates were subsequently 
incubated at room temperature for a minimum of one hour before washing a further 
three times with PBST buffer. 100 μl/well of sample or standards were then added to 
the plates which were covered with an adhesive strip and incubated for two hours at 
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room temperature. The plates were washed again three times with PBST buffer before 
adding 100 μl of detection antibody for the particular cytokine per well (diluted in 
reagent diluent to 100 ng/ml for IL-5 and IFN-γ, to 200 ng/ml for IL-6 and 400 ng/ml 
for IL-2 and IL-10) and incubating for two hours at room temperature. Upon washing 
three times with PBST buffer, 100 μl of Streptavidin-horseradish peroxidise (HRP) 
was added to each well at the working dilution of 1/200. The plates were covered to 
protect from direct light and then incubated at room temperature for 20 minutes. The 
plates were then washed a further three times in PBST buffer before the addition of 
100 μl substrate solution to each well (1:1 mixture of colour reagent A and B: 
stabilised hydrogen peroxide and stabilised tetramethylbenzidine (TMB) respectively). 
The plates were again covered to avoid exposure to direct light and then incubated at 
room temperature for 20 minutes. The experimental reaction was halted through the 
addition of 50 μl stop solution (2N H2SO4) to each well. The optical density of each 
well was immediately determined using a microplate reader at the wavelength of 450 
nm (Bio-Rad Laboratories, model 680, Hertfordshire, UK). 
 
2.14. Statistical analysis 
Data was tested using one-way analysis of variance (ANOVA) followed by the Tukey 
test in order to compare the mean values of different groups. Differences were 
considered to be statistically significant at p < 0.05, p < 0.01 or p < 0.001 in all studies. 
Each value was obtained from triplicate samples from each case and expressed as the 
mean ± standard deviation (SD), unless stated otherwise. 
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3.1. Introduction: characterisation of liposomal delivery systems 
Liposomes have been widely shown to be effective vaccine delivery systems (e.g. Alison 
& Gregoriadis (1974); Kersten & Crommelin, 1995), in particular DDA-TDB, which as a 
vaccine adjuvant, has the ability to stimulate cell mediated immunity when combined with 
a novel mycobacterial fusion protein antigen for TB (Davidsen et al, 2005). However, the 
mechanisms of action in correlation with the systems characteristics have yet to be fully 
investigated. Therefore, the aim of this study was to further characterise DDA-TDB 
liposomes and also consider modifications of the systems by incorporating additional 
lipids of DPPC or DSPC given that it has previously been reported that cationic agents are 
toxic to cells due to induced cell membrane interactions, which can lead to the inhibition 
of cellular regulation and modification (Farhood et al, 1992; Fischer et al, 2003). 
Consequently, in the current study, the cationic lipid presence within DDA-TDB was 
investigated upon replacement of DDA content, whilst in another set of formulations, the 
DDA:TDB ratio remained fixed at the ratio previously optimised for effective vaccine 
adjuvanticity (Davidsen et al, 2005), with their combined level reduced in concentration 
upon substitution with additional lipids. 
 
Liposomes are formed upon the introduction of lipids to an aqueous environment. 
However, when producing such vesicles, numerous variables must be taken into account 
and controlled. Hence, the characteristics of the formulations and any such variations that 
may affect the biological performance of these systems must be identified. The 
significance of managing key physicochemical properties for liposomal products has been 
acknowledged by the Food and Drug Administration (FDA), of which factors such as 
particle size, liposome structure, drug-lipid ratios, stability, extent of drug loading, in vitro 
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release rate, and phase transition temperatures, were highlighted as pivotal 
characterisation parameters for liposomal drug delivery systems (Janoff, 1999). 
 
To be exploited as effective subunit vaccine delivery systems, the physicochemical 
characteristics of liposomes must be studied in detail and correlated with their 
effectiveness in vivo, in an attempt to elucidate key aspects controlling their efficacy. 
There are a range of widely used methods that can be employed to study and characterise 
liposomes and within this study the following characteristics were considered: 
 Dynamic light scattering was used to determine particle size and zeta potential, as 
these are major factors that can greatly influence the ability of liposomal carrier 
systems and their capacity to bind antigen.  
 Morphological analysis was undertaken by transmission electron microscopy.  
 Antigen adsorption was assessed via the BCA assay for the quantification of non-
adsorbed protein, together with SDS-PAGE analysis, which allowed for visual 
evaluation and quantification of liposome associated protein. 
 Interactions of the liposomal systems with serum proteins and the modelling of 
release rates in physiological conditions were examined, to ascertain the potential 
of the proposed formulations as immunoadjuvants.     
 
The main adjuvant formulation consisted of DDA liposomes that incorporated TDB at 11 
mol%, remaining locked at a 8:1 molar ratio for DDA:TDB (equivalent to a 5:1 weight 
ratio), as previous studies by Davidsen et al (2005), have shown that this ratio is most 
Chapter 3 - Characterisation of the effect of introducing supplementary lipids to DDA-TDB liposomes 
 
 97 
beneficial to DDA liposomes in terms of alleviating their physical instability, whilst also 
eliciting strong Th1 type antibody and cytokine responses. 
 
3.2. Characterisation of liposomes composed of DDA and TDB 
To consider the characteristics of DDA-TDB liposomes a range of parameters were 
investigated and the effect of their formulation was considered. 
 
3.2.1. The effect of buffers on the cationic liposome characteristics 
Buffer solutions are expansively utilised in the field of drug delivery to control the pH of 
aqueous solutions and attain the greatest stability required to optimise physiological 
performance. The pH of blood is sustained at approximately 7.4 by primary and secondary 
buffer constituents located in the plasma and erythrocytes respectively (Florence & 
Attwood, 1998). Initial studies were conducted to examine the effect of buffer used to 
hydrate the lipid film in the production of DDA-TDB liposomes. Tris buffer (10 mM) was 
selected as it is commonly used as a pH buffer, due to easily dissolving in water and 
remaining stable in solution for many months (Leonard, 2010). However, Tris buffer is 
non-isotonic and therefore, isotonic solutions of Dextrose (5% w/v in water) and 
phosphate buffered saline (PBS) were also investigated for their effect upon rehydration of 
the dry lipid films, with the resultant liposomes characterised for their particle size and 
zeta potential. 
 
DDA-TDB liposomes formulated in either Tris buffer or 5% Dextrose were approximately 
500 nm, displaying no significant difference between one another (Figure 3.1). However, 
for DDA-TDB prepared in PBS, significantly larger vesicles (P < 0.01) were produced, in 
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the region of three micrometres, with typically heterogeneous liposomal populations 
expressed for all the systems as the polydispersity ranged between 0.31-0.43 (Figure 3.1). 
No significant differences between the zeta potentials of the systems prepared in Tris 
buffer, Dextrose or PBS were observed, with a recorded zeta potential of 45-50 mV 
(Figure 3.1). The observed particle sizes also generally correlated to the visual appearance 
of the systems which were comparably clear for DDA-TDB prepared in Tris or 5% 
Dextrose buffer, whilst hydration of the lipid film in PBS produced a cloudy, turbid 
appearance (Figure 3.1).  
 
Although the use of 5% Dextrose buffer resulted in the production of sub-micrometre 
sized liposomes, this buffer was disregarded for its future use due to the weak long term 
stability of sugars in solution. In addition, vesicles prepared in PBS were subject to salt 
induced aggregation, as saline based buffers contain neutralising counter ions that 
ultimately minimise the repulsion forces between neighbouring particles (Yan & Huang, 
2009). This effect has been shown to be immunologically beneficial, as a cationic 
liposomal vaccine delivery system was enhanced in terms of Th1 and Th2 type immunity, 
with such a salt-induced effect interfering with the electrostatic interaction between the 
cationic carrier system and the protein antigen, promoting antigen release and the 
activation of APCs (Yan & Huang, 2009). However, with the importance of long term 
stability of the pharmaceutical product, the immediate physical instability displayed in the 
liposomal system prepared in PBS prevents the use of this buffer. Therefore, Tris buffer 
was selected as the hydration medium for future preparations of the immunoadjuvants, 
and will require adjustment to make the buffer isotonic for future liposomal application in 
vivo. 
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Figure 3.1. The effect of hydrating medium during liposome production characterised for particle 
size, polydispersity and zeta potential, together with visual observations of liposomes prepared in A: 
Tris buffer, B: 5% Dextrose and C: PBS. Samples were suspended in a 1/10 dilution of the corresponding 
buffer for the DLS measurements. Results represent the mean average and standard deviation from at least 
three independent experiments. 
             
3.2.2. The effect of buffer concentration upon the measured zeta potential 
Prior to further characterisation of the proposed systems in the selected buffer, the effect 
of Tris buffer and PBS concentration on the zeta potential of DDA-TDB vesicles was 
measured. Studies by Perrie & Gregoriadis, (2000) had previously established a working 
dilution of 1 in 10 for measuring the zeta potential of cationic liposomes. This was due to 
the equipment available at such time being unable to analyse the zeta potential of samples 
in undiluted PBS. However, to investigate the effect of buffer concentration on the zeta 
potential of DDA-TDB vesicles measured with the Brookhaven ZetaPlus instrument, and 
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to decide upon an appropriate dilution for the suspension of liposome samples when 
taking future measurements, Tris buffer and PBS was serially diluted to a range of 
concentrations for measurements of zeta potential. This took place in ddH2O (0), pure 
buffer and buffer diluted to the ratios of 1/10, 1/100, 1/1000 and 1/10,000, with all 
dilutions (v/v) made with ddH2O. 
 
The measured zeta potential of DDA-TDB liposomes suspended in ddH2O was 33.1 mV 
(+/- 2.7) with DDA-TDB suspended in Tris buffer dilutions of 1/10,000 (0.001 mM), 
1/1000 (0.01 mM) and 1/100 (0.1 mM) significantly (P < 0.05) increasing the zeta 
potential to within the region of 40 mV (Figure 3.2 A). Furthermore, the zeta potential of 
the liposomes in 1/10 Tris (1 mM) and pure Tris buffer (10 mM) was significantly (P < 
0.001) increased further to 54.6 mV (+/- 4.4) and 56.0 mV (+/- 5.3) respectively, showing 
no significant difference between one another (Figure 3.2 A). The general trend apparent 
was that as the electrolyte concentration in the media in which the liposome sample was 
suspended in became more concentrated, closer to Tris buffer in its pure form, the 
resulting zeta potential measurements increased (Figure 3.2 A). Indeed, an increased zeta 
potential infers electrostatic stability of the colloidal suspension, resulting in mobile and 
charged particles, and as the zeta potential is determined from mobility (Brookhaven 
Instruments Corporation, 2010a), the rise in the zeta potential measured in the present 
study upon increased Tris buffer concentrations suggests an increased sample mobility, 
with elevated electrostatic repulsion forces present between the charged particles. 
 
Contrastingly, dilutions of PBS demonstrated an opposing influence on the zeta potential 
of DDA-TDB, with the zeta potential decreasing when measured in stronger 
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concentrations of PBS (Figure 3.2 B). This was apparent as the recorded zeta potentials in 
ddH2O, 1/10,000, 1/1000 and 1/100 PBS generated a strong cationic zeta potential for 
DDA-TDB of between 50-60 mV (Figure 3.2 B). However, at a 1/10 dilution of PBS (1 
mM), the measured zeta potential of DDA-TDB was significantly (P < 0.05) reduced to 
45.5 mV (+/- 2.6), followed by a further significant (P < 0.05) reduction to 28.7 mV (+/- 
2.5) when suspended in PBS (10 mM) (Figure 3.2 B), which was approximately half of 
the recorded zeta potential of DDA-TDB measured in ddH2O. The higher concentrations 
of PBS in turn increases the salt concentration of the liposomal suspension, with such 
conditions known to reduce the measured zeta potential (Brookhaven Instruments 
Corporation, 2010b), and the increased presence of phosphate ions may possibly be 
masking the determined zeta potential, reducing the electrostatic repulsion forces and 
mobility present between particles of the suspensions measured at the lower PBS 
concentrations. 
 
With the variability displayed in the resultant zeta potential of DDA-TDB vesicles 
suspended in different buffer concentrations, there was a necessity to standardise the 
concentration in which DDA-TDB based liposomes were suspended in for subsequent 
characterisation. With Tris being the buffer of choice at 10 mM when rehydrating DDA-
TDB vesicles and with no apparent difference between measurements made in pure Tris 
buffer (10 mM) and in the 1/10 dilution of Tris buffer (1 mM), for the future 
characterisation of particle size and zeta potential of the proposed DDA-TDB based 
systems, 1 mM Tris buffer was chosen as the concentration to suspend the liposome 
samples in for the DLS measurements using the Brookhaven ZetaPlus instrument. 
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Figure 3.2. The effect of Tris buffer or PBS concentration on the measurement of zeta potential for 
DDA-TDB liposomes. All vesicles were prepared in their corresponding buffer and serially diluted in A: 
Tris buffer or B: PBS. Dilutions were made with ddH2O and samples were tested in undiluted buffer and 
buffer diluted to 1/10, 1/100, 1/1,000 and 1/10,000 respectively. Results displayed are the mean average of 
at least three independent experiments, with error bars representing the standard deviation from the mean. 
 
3.3. Replacement of DDA within DDA-TDB with DPPC or DSPC lipid 
To investigate the role of the cationic component within DDA-TDB, previously shown to 
be an effective adjuvant system (Davidsen et al, 2005; Agger et al, 2008; Christensen et 
al, 2010), a series of formulations were prepared in which DDA was proportionally 
replaced with either DPPC or DSPC lipid, with the volume of TDB remaining fixed 
within the formulation (Table 3.1). 
A 
B 
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Table 3.1. The replacement of DDA within DDA-TDB with DPPC or DSPC lipid. The volume of TDB 
remained fixed at 50 µg per dose in all proposed formulations. The values of weight (µg) for DDA, DPPC or 
DSPC lipid and TDB for each formulation are stated as per dose (200 µl Tris buffer). 
 
 
 
 
 
 
 
 
 
 
 
 
These proposed systems in which DDA was replaced within DDA-TDB were firstly 
characterised for their particle size and zeta potential. DDA-TDB displayed an average 
particle size of ~500 nm, a polydispersity in the region of 0.3 and a cationic zeta potential 
of 50 mV (Figure 3.3), which was in good agreement with previous characterisation data 
(Davidsen et al, 2005; Christensen et al, 2007a; Henriksen-Lacey et al, 2010b). 
 
Cationic replacement of DDA-TDB, with either DPPC or DSPC lipid, generated 500-600 
nm sized vesicles when DDA was still present within the formulation (Figure 3.3). In 
contrast, upon complete DDA replacement, DPPC-TDB and DSPC-TDB liposomes were 
significantly (P < 0.05) larger in size than the DDA based systems, in the region of two 
micrometres (Figure 3.3). The polydispersity of all of the empty vesicle systems was 
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consistently in the proximity of 0.3, suggesting a characteristic heterogeneous liposomal 
population (Vangala et al, 2007). 
 
The measured zeta potential was approximately 50 mV for all of the formulations that 
contained DDA, coinciding with a sub-micrometre particle size (Figure 3.3). However, 
DPPC-TDB and DSPC-TDB liposomes were significantly (P < 0.05) reduced to a slightly 
neutral to anionic zeta potential in the region of -20 mV (Figure 3.3). Additionally, no 
significant difference was apparent between the formulations when either DPPC or DSPC 
lipid was used as the replacing lipid within DDA-TDB. 
 
In addition, coinciding with the particle size data attained, notable turbidity of the larger 
DPPC-TDB and DSPC-TDB liposomes was evident. This was particularly observed in 
comparison to the significantly smaller sized and comparatively clearer systems in which 
DDA was still present within the formulation (Figure 3.3). 
 
The impact of DDA upon the zeta potential was evident as removal of the cationic 
component ultimately diminished the positive charge of the formulation, which is vital to 
facilitating the surface adsorption of many anionic subunit proteins. Surface properties 
have an immense effect upon the rate, degree, and the mechanism of protein adsorption, 
with a net negative charge of proteins having an increased tendency to adsorb to cationic 
surfaces (Brash & Horbett, 1995).  
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Figure 3.3. Replacement of DDA within DDA-TDB characterised for particle size, polydispersity and 
zeta potential, together with visual observations with A: DPPC or B: DSPC. Vesicles were produced by 
lipid hydration in Tris buffer (10 mM, pH 7.4). Results represent the mean ± SE from three experiments. 
A 
B 
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Previous studies by Filion & Phillips, (1997) employed a similar experimental approach 
with the incorporation of DPPC lipid to a cationic dioleoylphosphatidylethanolamine- 
dioleoyldiacyltrimethylammonium propane (DOPE-DOTAP) system, taking place in the 
replacement of DOPE content. DOTAP provided a net cationic charge to the system and 
in terms of the measured zeta potential, increased incorporation of DPPC to the cationic 
liposomes prepared in 0.85% w/v sodium chloride (NaCl), retained a cationic zeta 
potential of over 40 mV. This trend of increasing the introduction of a neutral lipid to a 
cationic liposomal formulation, whilst maintaining the cationic properties of the multi-
lipid system, coincides with the consequent findings for the measured zeta potential in this 
present study. Indeed as DDA content within the main DDA-TDB formulation was 
reduced, no significant change in the measured zeta potential was observed, until complete 
cationic replacement occurred with DPPC or DSPC lipid. 
 
The incorporation of zwitterionic lipids in the replacement of DDA demonstrates potential 
in favourably reducing the toxicity of the DDA-TDB liposomes. This may be conducted 
whilst maintaining the ability to electrostatically surface adsorb protein antigen, and 
induce antigen specific immune responses, upon administration of the proposed adjuvants. 
 
3.4. Substituting DDA-TDB with DPPC or DSPC lipid 
Alongside the assessment of replacing cationic content within DDA-TDB, to further 
understand the role of DDA and TDB within the adjuvant system, another set of 
formulations were assessed. More specifically, formulations substituting DDA-TDB with 
DPPC or DSPC lipid, at the ratios of 25, 50 and 75 mol%, were prepared and 
characterised. 
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3.4.1. The effect of buffer upon DDA-TDB substituted with additional lipids 
Initial tests were conducted to investigate the effect of buffer upon the formation of DDA-
TDB based liposomes. Incorporation of DDA-TDB with DPPC or DSPC lipid at 25, 50 
and 75 mol% took place with Tris buffer or PBS used as the hydrating medium. These 
systems were directly compared to one another in terms of particle size and zeta potential, 
to establish whether the incorporation of zwitterionic lipids could stabilise the 
formulations and possibly prevent the aggregating effect seen previously when PBS was 
used as the hydrating medium in the preparation of DDA-TDB.  
 
The particle size of DDA-TDB in Tris buffer prior to substitution was ~500 nm as 
previously characterised in this study. Substitution of DDA-TDB in Tris buffer with either 
DPPC or DSPC at 25, 50 and 75 mol%, whilst retaining a mean sub-micrometre particle 
size, generated a significant (P < 0.05) increase in vesicle size from DDA-TDB, measured 
between to 650-800 nm (Figure 3.4). However, substitution with DPPC or DSPC at 25-75 
mol% displayed no significant change in the resultant zeta potential of the DDA-TDB 
based liposomes, remaining strongly cationic in the region of 50 mV when prepared in 
Tris buffer (Figure 3.4). 
 
In contrast, all equivalent DDA-TDB systems incorporating 25-75 mol% DPPC or DSPC 
in PBS demonstrated a significant (P < 0.001) increase in mean vesicle size from a sub-
micrometre size range in Tris buffer to 2-3000 nm when prepared in PBS (Figure 3.4). 
Upon incorporation of DPPC or DSPC at 25-75 mol%, no significant difference in the 
zeta potential was apparent between all of the systems regardless of the substituting lipid 
used, ranging between 45-55 mV, which was comparable to the equivalent systems in Tris 
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buffer (Figure 3.4 A and B). The polydispersity expressed for all systems was in the 
proximity of 0.3, regardless of the hydrating medium or the level of DDA-TDB 
substitution (Figure 3.4 A and B). 
 
The introduction of additional lipids, at a variety of mol% ratios, failed to prevent an 
instantaneous increase in vesicle size, as observed with DDA-TDB liposomes in PBS. The 
differences between the two tested buffers, particularly in terms of particle size, is evident 
when visually comparing the formulations upon incorporation of DPPC or DSPC, with 
turbidity visible in all formulations prepared in PBS, opposing the clarity of the equivalent 
Tris buffer samples (Figures 3.4 A and B). Although a strong cationic zeta potential was 
observed, the significantly larger vesicle sizes indicate possible aggregation and 
instantaneous physical instability upon formation in PBS, resulting in the selection of Tris 
buffer as the hydration medium of choice, to be used for the production of all subsequent 
liposomal formulations. Indeed, the impact on particle size observed upon preparation of 
vesicles in PBS may be attributed to salt induced aggregation, as with cationic liposome 
suspensions, aggregation may arise upon a reduction in electrostatic repulsions between 
particles as a result of neutralising counterions associating to charged lipid surfaces, with 
resultant clustered populations dictated by the ionic strength (Bordi & Cametti, 2002). 
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Figure 3.4. The effect of Tris buffer vs. PBS (10 mM, pH 7.4) in the hydration of DDA-TDB 
substituted with A: DPPC or B: DSPC and characterised for particle size, polydispersity and zeta 
potential with corresponding sample images. Each photo on the left was prepared in Tris buffer with 
liposomes prepared in PBS on the right hand side. Results represent the mean ± SD of three experiments. 
A 
B 
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3.4.2. Stability of DDA-TDB liposomes substituted with additional lipids 
3.4.2.1. DDA-TDB based formulations incorporating DPPC 
Whilst DDA-TDB liposomes provide a cationic charge ideal for antigen absorption, there 
may be issues of long term stability with such a combination (Davidsen et al, 2005). 
Furthermore, with a vast array of literature highlighting the potential of liposomal drug 
delivery, a lack of liposome based vaccines currently available could possibly be due to 
their weak physical stability in solution (Mohammed et al, 2010). The addition of 
zwitterionic lipids such as DPPC or DSPC may retain the stability of DDA-TDB whilst 
being biocompatible and desirably less toxic. As a result, DDA-TDB substituted with 0-75 
mol% DPPC or DSPC was measured over 28 days, at the storage temperatures of 4 ºC and 
25 ºC. 
 
DDA-TDB liposomes in Tris buffer were ~500 nm in particle size with a cationic zeta 
potential of approximately 65 mV, which was sustained over 28 days in both storage 
conditions (Figure 3.5). Upon DPPC incorporation at a 25, 50 and 75 mol% ratio to DDA-
TDB, the average vesicle size had risen significantly (P < 0.05) on day 0 to 650-800 nm, 
however no significant difference to DDA-TDB was observed in the measured zeta 
potential, as a strong cationic charge was consistently maintained, inferring a stable 
vesicle formulation (Figure 3.5). This remained the case for the duration of the 28 days, 
with no significant difference observed between all of the various substituted ratios 
analysed at 4 ºC and 25 ºC (Figure 3.5). The polydispersity for all of the tested systems 
remained in the region of 0.3. 
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Figure 3.5. Time development of particle size and zeta potential for DDA-TDB and its substitution with 25-75 mol% DPPC stored at 4 ºC (A & B) and at 
25 ºC (C & D). All formulations were produced by lipid hydration in Tris buffer (10 mM, pH 7.4). Results shown are the mean and standard deviation of three 
independent experiments. 
A 
C 
B 
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3.4.2.2. DDA-TDB based formulations incorporating DSPC 
Upon substitution with DSPC at 25-75 mol%, the resultant liposomes were 650-800 nm, 
which represented a significant increase (P < 0.05) from DDA-TDB, yet generated a 
comparably strong cationic zeta potential of ~65 mV and a polydispersity in the region of 
0.3, which was maintained throughout the study, displaying no significant difference 
between the varying levels of DPSC incorporation over 28 days at 4 ºC and 25 ºC (Figure 
3.6). Figure 3.7 visually demonstrates the clarity in all the tested formulations, with no 
apparent difference between samples at day 0 or day 28 when kept at 25 °C (with no 
observed difference to the corresponding samples stored at 4 ºC). 
 
Overall, DDA-TDB remained stable over 28 days, as shown by Davidsen et al, (2005), 
and such stability was also retained in the present study for both sets of formulations in 
which DPPC or DSPC was substituted into DDA-TDB, with no significant difference 
displayed between these systems. The consistently retained strong cationic charge when 
either lipid was incorporated into DDA-TDB confers stability of the systems, as it is 
understood that with a higher zeta potential, a suspension is more likely to remain stable 
as the charged particles possess greater repulsion forces against one another, ultimately 
overcoming a natural propensity to aggregate (Brookhaven Instruments Corporation, 
2004). Furthermore, as no difference was observed between DDA-TDB and its 
substitution with either lipid, the stabilising effect of TDB can be seen to be maintained, 
with trehalose possibly acting as a steric barrier inhibiting fusion between vesicles (Spargo 
et al, 1991), preventing particle aggregation. The retention of physical stability reiterates 
the use of TDB in the proposed adjuvants and the lack of difference between DDA-TDB 
and its substitution suggests that DPPC or DSPC slots into the liposomal system.
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Figure 3.6. Time development of particle size and zeta potential for DDA-TDB and its substitution with 25-75 mol% DSPC stored at 4 ºC (A & B) and at 
25 ºC (C & D). All formulations were produced by lipid hydration in Tris buffer (10 mM, pH 7.4). Results shown are the mean and standard deviation of three 
independent experiments. 
A 
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Figure 3.7. Images of DDA-TDB in Tris buffer and its substitution at 25-75 mol% with DPPC at A: 
day 0 and B: day 28 or with DSPC at C: day 0 and D: day 28, stored at 25 ºC. 
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3.5. Morphological analysis of DDA-TDB based liposomes 
Microscopic analysis was conducted via TEM in order to examine the general structures 
of the liposomal systems. As there can be a possible over dependence on physicochemical 
analytical techniques such as particle sizing via laser diffraction, the application of 
microscopic imaging analysis can confirm the structural integrity of the liposomes 
produced, a process often disregarded during characterisation (Bibi et al, 2011). 
 
3.5.1. TEM of DDA-TDB upon cationic replacement with additional lipids  
Initial analysis was conducted upon DDA-TDB partially replaced with DPPC or DSPC at 
150/100/50 µg/dose, or completely replaced producing DPPC-TDB and DSPC-TDB 
liposomes. It was observed that upon partial DDA replacement with either lipid, minimal 
differences between the two sets of formulations were apparent, producing spherical 
vesicles within a broad size range (Figure 3.8 A & B). With DDA still present in the lipid 
mixture of these selected formulations, the imaged vesicles corroborated with the 
characterisation data previously attained for the liposomes via DLS, with populations 
predominantly under a micrometre in particle size (Figure 3.8 A & B). 
 
Contrastingly, DPPC-TDB and DSPC-TDB liposomes were substantially larger than the 
systems containing DDA (Figure 3.8 C & D). Although spherical structures indicative of 
liposome formation was evident, these vesicles were beyond a micrometre in particle size, 
in good agreement with corresponding analysis determined via DLS. Additionally, these 
liposomes, characterised in the present study for attaining a slightly anionic zeta potential, 
were less isolated than the other cationic formulations, remaining in closer proximity to 
one another, suggesting a susceptibility to aggregate (Figure 3.8 C & D).   
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Figure 3.8. TEM micrographs of DDA-TDB replaced with either DPPC or DSPC lipid. Images 
represent the replacement of DDA within DDA-TDB liposomes that occurred partially with A: DDA-DPPC-
TDB and B: DDA-DSPC-TDB (at 150/100/50 µg/dose) or totally with C: DPPC-TDB and D: DSPC-TDB. 
All formulations were prepared in Tris buffer and produced by the method of lipid hydration. 
 
500 nm 500 nm 
1µm 1µm 
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3.5.2. TEM of DDA-TDB and its substitution with additional lipids 
DDA-TDB liposomes and its substitution with either DPPC or DSPC lipid at 50 mol% 
was also analysed (Figure 3.9 A-C). DDA-TDB was found to generate consistent 
formations of spherical vesicles with no apparent aggregation observed (Figure 3.9 A). It 
can be presumed that the larger hydrophilic trehalose head group of TDB escalates net 
hydration at the surface, which acts to minimise dehydration of the DDA head groups, 
thus reducing the effect of aggregation (Davidsen et al, 2005). The morphological features 
observed for DDA-TDB (Figure 3.9 A) are comparable to TEM imaging previously 
conducted for this cationic liposomal immunoadjuvant system (Davidesn et al, 2005; 
Vangala et al, 2007).  
 
Upon substitution of the DDA-TDB formulation with either DPPC or DSPC, the 
additional lipids appeared to be successfully incorporated and were similar in vesicular 
appearance to that of DDA-TDB, with abundant formations of a spherical nature and 
minimal aggregation. The morphological analysis conducted also coincided with the 
previously determined particle size findings, displaying a polydisperse population of 
liposomes with the majority of vesicles remaining within a sub micrometre particle size 
range (Figure 3.9 B & C).  
 
 
 
 
 
 
Chapter 3 - Characterisation of the effect of introducing supplementary lipids to DDA-TDB liposomes 
 
 118 
 
        
                A                                                                                 B 
 
 
 
 
 C 
Figure 3.9. TEM micrographs of A: DDA-TDB, B: DDA-TDB-50% DPPC and C: DDA-TDB-50% 
DSPC. All formulations were prepared in Tris buffer and produced by the method of lipid hydration.  
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3.6. Protein adsorption studies 
The ability of the proposed liposomal adjuvant systems to adsorb antigen was measured 
using ovalbumin (OVA) protein. OVA has a molecular weight of 45 kilodaltons (kDa) and 
an isoelectric point (pI) of 4.5, therefore carrying a net anionic charge at pH 7.4, 
facilitating electrostatic adsorption to the surfaces of cationic liposomes. Due to the great 
availability and low cost of OVA, it has been extensively utilised as a protein standard in 
an array of immunological studies (Huntington & Stein, 2001). Proficient liposomal 
delivery can be determined by the ability of the delivered protein to associate with 
liposomes, for example via surface adsorption. As a result, OVA was used to determine 
the loading characteristics of selected liposomal systems in Tris buffer, providing a 
protein model with a comparable molecular weight to the candidate antigen to be used in 
future immunological studies.    
 
Furthermore, OVA was added to the liposomes at a wide range of concentrations, from 10 
µg/ml to 1 mg/ml, potentially saturating the systems, to investigate the effect of protein 
adsorption upon the physicochemical properties of the liposomes. The selected liposomal 
systems, which represented cationic replacement and substitution of the DDA-TDB 
adjuvant, were measured for particle size, zeta potential and levels of protein adsorption. 
Subsequently, the interaction of the carrier systems with serum proteins was also assessed, 
whilst the potential in vivo preparations were examined for antigen retention/release over 
time in replicated physiological conditions, by dialysis of the liposomes adsorbed with 
radiolabelled OVA. 
 
 
Chapter 3 - Characterisation of the effect of introducing supplementary lipids to DDA-TDB liposomes 
 
 120 
3.6.1. Physicochemical characterisation of liposomal systems in dosage form 
3.6.1.1. Liposomal interactions with serum proteins and OVA-I
125 
release over time 
Upon administration, a delivery system will encounter an abundance of blood components 
such as blood cells and an array of serum proteins. Such interactions with particulate 
delivery systems, such as liposomal adjuvants, can affect their deposition (Opanasopit et 
al, 2002). Following on from the characterisation of the proposed DDA-TDB based 
carriers systems, these formulations, prepared by lipid hydration in Tris buffer, were 
suspended in the mediums of Tris buffer or 50% foetal bovine serum (FBS) and assessed 
for their stability and serum interactions in terms of particle size and zeta potential over 24 
hours, and radiolabelled antigen retention/release over 72 hours via dialysis, all at 37 °C. 
The FBS media consisted of 50% FBS and 50% Tris buffer (v/v) as blood plasma 
represents ~50% of total blood volume, thus mimicking the physiological conditions that 
the liposomal immunoadjuvants may encounter upon injection.  
 
Prior to the dialysis of the liposomal systems upon electrostatic adsorption of OVA-I
125
, as 
a control experiment, the release of OVA-I
125 
alone was tested in Tris buffer and FBS/Tris 
over 72 hours, and the dialysis tubing was appropriately selected for OVA due to its well 
defined pore size (50-100,000 MW). The majority of OVA-I
125 
was released as an initial 
burst with ~80% release, quantified by measured gamma counts in relation to the total, in 
both Tris buffer and FBS/Tris. Almost all of the OVA-I
125 
was released after 4 hours in the 
absence of liposomes, with total clearance
 
taking place
 
at 72 hours (Figure 3.10). 
Additionally, minimal counts of the remaining sample in the dialysis tubing at the end of 
the experiment correlated to the total counts introduced at the beginning. These findings 
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validated the approach for subsequent experiments into the extent of radiolabelled antigen 
adsorption and retention over time.  
 
Alongside the assessment of serum interactions, the liposomal systems were 
physicochemically characterised in Tris buffer upon antigen adsorption at 10 µg/ml. 
Liposomes of DDA-TDB, substitution with 50 mol% DPPC or DSPC and partial DDA 
replacement with DSPC at 150/100/50 µg/dose generated a sub micrometre particle size 
and a cationic zeta potential of 50 mV, whilst DSPC-TDB was 2 to 3 micrometres with an 
anionic zeta potential of approximately -20 mV (Figures 3.11: A, C, E, G and I). The 
addition of OVA at 10 µg/ml was not significantly different to the equivalent empty 
systems characterised earlier (see Figures 3.3 and 3.4). Furthermore, no fluctuations in 
particle size or zeta potential were apparent for each of the systems over 24 hours when 
placed in Tris buffer (Figures 3.11: A, C, E, G and I). 
 
However, DDA-TDB exposed to FBS produced a particle size of ~2000 nm after 3 
minutes (0.05 hours) and remained at 2-3 micrometres in the serum-induced environment 
over 24 hours, which was significantly (P < 0.01) greater than DDA-TDB in Tris buffer. 
This indicated instantaneous serum binding to the cationic liposomes, coinciding with a 
significantly (P < 0.001) reduced zeta potential, from a strongly cationic charge in Tris to 
approximately -25 mV in FBS (Figure 3.11 A). Corresponding antigen release was 
calculated using OVA radiolabelled with I
125 
and adsorbed to each liposomal formulation 
at 10 µg/ml. A vast majority of OVA-I
125
 adsorbed to DDA-TDB remained associated to 
the vesicles in both Tris buffer and FBS/Tris, with OVA retention consistently maintained 
over the 72 hour time period (Figure 3.11 B). Calculated antigen release was ~5% after 3 
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minutes in Tris buffer and FBS/Tris, and this high level of antigen retention was sustained 
with an approximate 10% loss at 24 hours. Minor further losses were observed in the 
following 48 hours as antigen retention was ~85%, with no difference apparent between 
OVA release in the Tris and FBS/Tris environments (Figure 3.11 B).  
 
Upon incorporation of DPPC or DSPC to DDA-TDB, at either 50 mol% substitution or 
partial DDA replacement with DSPC at 150/100/50 µg/dose, and exposure to FBS, no 
significant change in particle size took place until the first few hours, whereby a 
substantial rise in vesicle size occurred to beyond a micrometre (Figures 3.11: C, E and 
G). The elevated vesicle size was maintained over time with a further significant (P < 
0.01) increase to beyond 2 micrometres observed for the substituted DDA-TDB systems 
between 4 and 24 hours (Figures 3.11: C, E and G). All of the cationic systems in FBS 
were significantly (P < 0.01) larger in particle size after 24 hours compared to the Tris 
buffer counterparts, with an instantaneous and significantly (P < 0.001) reduced zeta 
potential of -25 mV (Figures 3.11: C, E and G), as the initial cationic charge was masked 
upon interaction with serum proteins of the FBS environment.  
 
These particular formulations containing additional zwitterionic lipids by either 
substitution or replacement showed antigen retention at a lower range to that of DDA-
TDB, with release profiles comparable to one another (Figures 3.11 D, F, and H). These 
cationic adjuvants released 10-15% OVA-I
125
 in both Tris buffer and FBS/Tris after three 
minutes, with the majority of antigen release occurring within the first 1-2 hours of 
incubation. This period coincided with the point at which the particle size increased upon 
serum interaction, as DPPC or DSPC incorporation slightly delayed the observed increase 
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in particle size in comparison to the instantaneous aggregating effect seen on DDA-TDB. 
Furthermore, at 24 hours, a 20-30% antigen loss was observed with minor further losses as 
approximately 70% OVA-I
125
 was retained at 72 hours (Figures 3.11 D, F and H). 
 
DSPC-TDB liposomes demonstrated no significant difference in terms of particle size and 
zeta potential, regardless of the medium used, as the liposomes remained in the proximity 
of 2-3 micrometres, whilst consistently attaining a zeta potential in the region of -20 mV 
over 24 hours in Tris buffer or FBS (Figure 3.11 I). The slightly anionic DSPC-TDB 
liposomes appeared to interact with the plasma proteins of FBS in a different manner to 
that of the cationic liposomes with minimal association to the serum proteins, as no 
significant affect on the vesicle size and zeta potential characteristics were observed. The 
lack of cationic charge in DSPC-TDB was reflected in the inability to electrostatically 
adsorb antigen, as OVA-I
125
 was rapidly released (Figure 3.11 J). More than half of the 
total antigen associated to DSPC-TDB was released within the first hour, and this high 
level of antigen release continued, leading to a substantial calculated antigen loss of ~85% 
after 72 hours. Such findings are in complete contrast to the cationic systems tested, as the 
anionic liposomes failed to retain antigen in both Tris buffer and the simulated in vivo 
conditions of FBS (Figure 3.11 J).    
 
As highlighted earlier, incorporation of TDB alleviates the physical instability of DDA 
liposomes (Davidsen et al, 2005), however, when placed in FBS, the particle size and zeta 
potential was still greatly affected as DDA-TDB aggregated upon binding to plasma 
proteins. Incorporation of DPPC or DSPC lipid, in the substitution or partial replacement 
of DDA-TDB, also failed to prevent the eventual aggregation of the cationic liposomes.
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Figure 3.10. OVA/I
125
 release profile in Tris buffer or FBS. All of the I
125
-labelled OVA was released over the tested 72 hour time period. 
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Figure 3.11. Vesicle size, zeta potential and antigen release of liposomes adsorbed with 10 µg/ml OVA in Tris or FBS. The size/zp and antigen retention 
profiles are for A&B: DDA-TDB, C&D: +50% DPPC, E&F: +50% DSPC, G&H: DDA-DSPC-TDB (150/100/50 µg/d) and I&J: DSPC-TDB, with the mean 
average displayed (n=3 ± SD). 
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Cationic liposomal systems of DDA and DDA-TDB have been previously studied for 
their interactions with serum proteins, in which the visual appearance of aggregating 
particles was apparent and confirmed by particle sizes measured at 2 µm over 24 hours 
(Henriksen-Lacey et al, 2010a). The zeta potentials observed in this study upon 
exposure to serum proteins are also in good agreement with the literature for such 
cationic liposomal systems, with DDA and DDA-TDB adjuvants found to decrease 
considerably to a negative zeta potential in the region of -30 mV (Henriksen-Lacey et 
al, 2010a). In addition, the instantaneous serum effect upon liposomes has also been 
shown to alter the zeta potential of cationic liposomal systems made of DOTAP lipid 
for DNA delivery, attaining an anionic zeta potential upon introduction to a serum 
induced environment (McNeil & Perrie, 2006). 
 
The effect of vesicle stability as a result of serum interactions has been previously 
studied (Ostro, 1983; Gregoriadis, 1988), whereby interactions of plasma proteins with 
liposomes were considered to be a charge dependent reaction, as highlighted in this 
current study with the cationic DDA-TDB based systems aggregating and attaining an 
anionic zeta potential upon exposure to FBS. These findings also correlate to studies 
by Foradada et al, (1997), in which cationic stearylamine containing liposomes were 
susceptible to aggregation when fused with serum, evident from an immediate increase 
in vesicle size, determined by photon correlation spectroscopy. Adsorption of serum 
proteins to cationic vesicle surfaces take place via electrostatic interactions, which 
conceals the surface charge and ultimately facilitates particle aggregation. The cationic 
charge dependent effect generating vesicle aggregation supports the results of this 
current study, as FBS had no effect upon the negatively charged DPPC-TDB or DSPC-
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TDB liposomes, as an anionic zeta potential was maintained after being subjected to 
FBS.  
 
Serum proteins can induce either liposomal breakdown or adsorb to the liposomal 
surface. Taking into account that the zeta potential represents the magnitude of 
potential at the hydrostatic plane of shear, the resultant serum induced net negative 
zeta potential of the proposed adjuvants can indicate liposomes coated in protein, as 
opposed to disrupted vesicles (Foradada et al, 1997). 
 
3.6.2. Physicochemical characterisation of liposomes adsorbed with OVA at 1 mg/ml 
3.6.2.1. Vesicle size, zeta potential and protein adsorption upon DDA replacement 
DDA-TDB liposomes and its partial DDA replacement, in conjunction with varying 
levels of either DPPC or DSPC incorporation, were in the region of 2000 nm when 
adsorbed with OVA at 1 mg/ml (Figure 3.12), which in comparison to the equivalent 
empty systems and upon OVA adsorption at 10 µg/ml (see Figures 3.3 and 3.11), were 
significantly (P < 0.01) larger in vesicle size. Furthermore, the previously attained 
strong cationic zeta potential of the systems was significantly (P < 0.05) reduced to a 
zeta potential of between 0 and -30 mV (Figure 3.12). Contrastingly, DPPC-TDB and 
DSPC-TDB liposomes were not significantly affected upon OVA loading at 1 mg/ml, 
in comparison to the equivalent systems prior to OVA adsorption, with a recorded 
vesicle size of 1-2 micrometres and an anionic zeta potential in the region of -25 mV 
(Figure 3.12), and was therefore not saturated with OVA at this elevated level of 
protein addition. Corresponding values of polydispersity for the systems was within a 
wider range of 0.2-0.6, which still represented a heterogeneous sample population 
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(Figure 3.12), with no differences apparent between the systems when DPPC or DSPC 
was used to replace the cationic content in DDA-TDB. 
 
 
 
 
Figure 3.12. Particle size, polydispersity and zeta potential upon replacement of DDA in DDA-
TDB with DPPC or DSPC and adsorption of OVA at 1 mg/ml. Results represent the mean average ± 
standard deviation of three independent experiments. 
 
The BCA assay was subsequently carried out on the DDA-TDB based formulations 
adsorbed with OVA at 1 mg/ml to quantify the level of non adsorbed protein, free in 
the supernatant of the liposomes pelleted upon centrifugation. It was observed that 
upon increased replacement of DDA with DPPC or DSPC lipid, the percentage of 
quantified non-associated OVA also increased, as more protein failed to bind to the 
liposomal systems (Figure 3.13). This was expected as electrostatic adsorption of the 
protein to the liposomes is dependent on the presence of DDA, providing the net 
cationic properties of the liposomal system from its positively charged head groups.  
 
Indeed for DDA-TDB liposomes, low levels of non-associated OVA were found as 
approximately 5% protein was quantified within the supernatant (Figure 3.13). Upon 
partial DDA replacement with either lipid at 150/100/50 µg/dose, the volume of free 
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OVA significantly (P < 0.01) increased to within the region of 35% (Figure 3.13). 
Further replacement of DDA content at 50/200/50 and 25/225/50 µg/dose, generated a 
further significant (P < 0.01) increase in non-associated protein, quantified at ~80% 
(Figure 3.13). Additionally, DPPC-TDB and DSPC-TDB liposomes were unable to 
retain antigen as ~95% of OVA was found free within the supernatant solution (Figure 
3.13), with the vast quantity of unbound protein resultant of a diminished cationic zeta 
potential. Additionally, as previously observed, no differences were apparent between 
the systems when either DPPC or DSPC was used as the replacing lipid. 
 
Following on from protein quantification via the BCA assay, upon centrifugation, the 
pellet and supernatant samples of the various liposomal systems surface adsorbed with 
OVA at 1 mg/ml were assessed by SDS-PAGE. It was observed that the presence of 
non-adsorbed OVA increased as DDA was continually replaced with either DPPC or 
DSPC lipid, signified by an increased intensity of banding in the gel for the 
supernatants of each formulation, as displayed in Figure 3.14 for DDA replacement 
within DDA-TDB with DSPC. Furthermore, no apparent differences were observed in 
the retention properties of the systems when either DPPC or DSPC was used to replace 
DDA-TDB, and such findings confirmed the trends observed in the BCA assay data 
for the corresponding formulations. 
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Figure 3.13. Quantification of non-adsorbed OVA protein in the supernatants of DDA-TDB and 
its cationic replacement with DPPC or DSPC lipid, pelleted upon centrifugation. Results are based 
on triplicate readings from at least three independent experiments with error bars representative of the 
standard deviation from the mean average. 
 
 
      
 
Figure 3.14. SDS-PAGE analysis upon OVA protein adsorption at 1 mg/ml for the cationic 
replacement of DDA-TDB with DSPC. The allocated lanes represent the protein standard marker (M), 
the pellet (P) and supernatant (S) samples for 1: DDA-TDB, 2: DDA/DSPC/TDB at 150/100/50 
µg/dose, 3: 50/200/50 µg/dose, 4: 25/225/50 µg/dose and 5: DSPC-TDB. 
 
 
 
 
    M              P      S     P           S       P     S      P     S       P      S   
                                                                       1            1         2               2          3         3              4                      4             5                   5                                                                         
Chapter 3 - Characterisation of the effect of introducing supplementary lipids to DDA-TDB liposomes 
 
 132 
The level of unbound OVA quantified for DDA-TDB was similar to the findings of 
previously related studies by Korsholm et al, (2007), in which protein adsorption at 1 
mg/ml to DDA liposomes, which also have a comparably strong cationic zeta 
potential, resulted in a vast majority of protein binding, quantified as high as 90%. 
Furthermore, it is evident that DDA is required to provide the net cationic charge 
essential in facilitating the adsorption and retention of anionic protein antigen, and 
although previous characterisation data in the present study displayed no significant 
difference in the cationic zeta potentials of the partially replaced formulations, the 
variation in antigen adsorption was dependent upon DDA presence. 
 
3.6.2.2. Vesicle size, zeta potential and protein adsorption upon DDA-TDB 
substitution 
Substitution of DDA-TDB with 25, 50 and 75 mol% DPPC or DSPC and adsorption of 
OVA at 1 mg/ml produced a mean particle size in the region of 2000 nm, and a neutral 
to anionic zeta potential (Figure 3.15). This significant change in particle size and zeta 
potential reflected the saturation of the substituted systems with OVA, resulting in 
liposomal aggregation, as antigen addition at 1 mg/ml was close to the total lipid 
weight of the cationic DDA-TDB based systems. The polydispersity of all 
formulations was recorded between 0.3-0.6 (Figure 3.15).  
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Figure 3.15. Particle size, polydispersity and zeta potential upon substitution of DDA-TDB with 
DPPC or DSPC and adsorption of OVA at 1 mg/ml. Results represent the mean average ± standard 
deviation of three independent experiments. 
 
The incorporation of DPPC or DSPC at 25, 50 and 75 mol% to DDA-TDB liposomes 
demonstrated that upon increased substitution, a higher level of non-adsorbed OVA 
was quantified by the BCA assay (Figure 3.16). With DDA-TDB representing the peak 
of assumed antigen retention, substitution with 25 and 50 mol% DPPC or DSPC 
generated a significantly (P < 0.01) higher level of free OVA antigen, quantified at 
~35% (Figure 3.16). Further substitution, with either DPPC or DSPC at 75 mol%, 
generated 50%-60% non-adsorbed OVA, which was an approximate 10-fold increase 
in the volume of unbound antigen when compared to the levels observed from DDA-
TDB (Figure 3.16). 
 
Subsequent SDS-PAGE analysis displayed a trend of an increased intensity of banding 
for the supernatant samples as DDA-TDB was continually substituted with DPPC or 
DSPC at 25, 50 and 75 mol%, displayed in Figure 3.17, for systems substituted with 
DPPC (similar banding was also observed with the equivalent DSPC systems). Such 
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behaviour mirrors the results achieved when DDA was continually replaced, whilst 
coinciding with the trend demonstrated upon quantification via the BCA assay.   
 
 
Figure 3.16. Quantification of non-adsorbed OVA protein in the supernatants of DDA-TDB and 
its substitution with DPPC or DSPC lipid, pelleted upon centrifugation. Results are based on 
triplicate readings from three independent experiments with error bars of the standard deviation from the 
mean average.  
 
 
Figure 3.17. SDS-PAGE analysis upon OVA protein adsorption at 1 mg/ml for DDA-TDB and its 
substitution with DPPC. The allocated lanes represent the protein standard marker (M), the pellet (P) 
and supernatant (S) samples for 1: DDA-TDB, 2: DDA-TDB-25%DPPC, 3: DDA-TDB-50%DPPC and 
4: DDA-TDB-75%DPPC. 
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Protein aggregation can either be beneficial or detrimental to a vaccine delivery 
system, depending on the processes involved for a particular type of response required. 
The manner in which antigen presentation occurs to the immune system is crucial to 
accomplish functional immunity. It has been shown that an antigen is capable of 
improved immunity when administration takes place as an aggregated, colloidal form, 
for example as a protein micelle (Morein et al, 1978), whilst it is also believed that 
most adjuvants utilised till the mid 90s, activated an enhanced inflammatory response 
at the site of injunction, essentially providing a depot effect in order to induce stronger 
antigen specific immunity (Badiee et al, 2007).  
 
Contrastingly, competent antigen deposition has also been achievable at the site of 
injection upon administration with non aggregated, cationic DDA based liposomal 
delivery systems (Henriksen-Lacey et al, 2010a), and with a greater understanding of 
Th1 and Th2 type immune responses, it is apparent that each vaccine requires a 
specific adjuvant to maximise a desired immune response (Campos-Neto, 2002). Thus, 
aggregation is not always necessary if an appropriate adjuvant-antigen complex is 
employed, as seen with the application of the promising TB fusion antigens of Ag85B–
ESAT-6 or Ag85B–ESAT-6-Rv2660, providing antigen specific antibody and cellular 
immune responses upon delivery of DDA-TDB adjuvant liposomes adsorbed with the 
TB fusion proteins, at 10 and 100 µg/ml respectively (Davidsen et al, 2005; Aagaard et 
al, 2011). 
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3.7. Further replacement of DDA within DDA-TDB 
3.7.1. Physicochemical characterisation upon further DDA replacement 
An additional set of experiments was carried out to test the level of DDA content 
within DDA-TDB upon further cationic replacement. This was conducted to ascertain 
whether the characterised responses were due to a decreased level of DDA presence, or 
from the increased incorporation of further lipids. DDA-TDB was assessed upon 
further cationic replacement with DDA-DSPC-TDB at 100/150/50 µg/dose, alongside 
DDA-TDB at a reduced DDA:TDB weight ratio of 2:1 (Table 3.2), which represented 
additional varying levels of DDA or DSPC content, to possibly aid the understanding 
of the role of DDA within the TDB enriched liposomal immunoadjuvant system. 
 
DSPC was selected as the replacing lipid as no difference was apparent between the 
introduction of DPPC or DSPC throughout the previous characterisation studies 
completed to date. DDA-TDB and DSPC-TDB (both at a 5:1 weight ratio) was also 
assessed in conjunction with these additional formulations for comparison, with all 
systems initially characterised for their particle size and zeta potential before and after 
antigen loading at 1 mg/ml OVA, followed by the quantification of non-associated 
protein via the BCA assay, allowing for comparisons to be made with the related 
DDA-TDB replacement formulations of this study. 
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Table 3.2. Further DDA-TDB based formulations proposed to test whether responses were due to 
DDA replacement or a reduced DDA presence within the system. The weight ratios of 5:1 and 2:1 
for DDA-TDB, alongside partial and total DDA replacement with DSPC was tested as the volume of 
TDB remained fixed throughout all of the formulations. 
 
 
 
 
DDA-TDB was characteristically 500 nm in particle size with a zeta potential of 50 
mV, which was not significantly different to DDA-TDB at the reduced weight ratio of 
2:1 (Figure 3.18). Further replacement of DDA with DDA-DSPC-TDB at 100/150/50 
µg/dose produced a significantly (P < 0.05) larger vesicle size compared to DDA-
TDB, measured  at ~700 nm, yet the zeta potential remained unchanged from DDA-
TDB at both weight ratios, at 50 mV (Figure 3.18). This increased size and sustained 
cationic zeta potential was comparable to the related DDA replacement formulation at 
150/100/50 µg/dose measured earlier, which incorporated a slightly elevated level of 
DSPC in replacement of DDA. As previously observed, DSPC-TDB was ~2 µm in 
size with a zeta potential of -20 mV, and the polydispersity of all empty systems was 
in the proximity of 0.3 (Figure 3.18). 
 
Upon surface adsorption of OVA at 1 mg/ml, DDA-TDB together with DDA-DSPC-
TDB at 100/150/50 µg/dose and DDA-TDB at a 2:1 weight ratio had changed 
significantly (P < 0.01) in mean particle size to 2-3 micrometres and to a neutral to 
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anionic zeta potential (Figure 3.18). The exception to this trend was the lack of change 
observed with DSPC-TDB, as a particle size of 2 micrometres and an anionic zeta 
potential was sustained upon OVA addition, with all systems expressing a 
polydispersity of around 0.4-0.6 (Figure 3.18). 
 
OVA adsorption at 1 mg/ml induced liposomal aggregation in the cationic 
formulations, as previously seen in this study for the other related DDA-TDB based 
systems, as when compared to their empty counterparts, larger particles with a 
diminished cationic charge were produced. The strong cationic zeta potential recorded 
for these outlined further DDA replaced formulations prior to protein addition, 
inevitably facilitated OVA adsorption and retention, and due to their cationic nature, 
such liposomes are able to electrostatically bind the anionic protein (Korsholm et al, 
2007).  
 
Indeed, the saturated concentration of OVA protein resulted in a neutralised zeta 
potential and an increased particle size for the cationic systems, indicative of particle 
aggregation. This was also visibly reflected in the formulations as the aggregated 
samples upon protein adsorption appeared to be more turbid than the equivalent empty 
systems, with the exception of DSPC-TDB, which displayed no observable effect upon 
OVA adsorption at 1 mg/ml (Figure 3.18).  
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Figure 3.18. Particle size, polydispersity, zeta potential and images of DDA-TDB, DDA-DSPC-
TDB (100/150/50 µg/dose), the reduced weight ratio of DDA-TDB at 2:1 (100/50 µg/dose) and 
DSPC-TDB, before and after OVA adsorption at 1 mg/ml. Results represent the mean ± SD from 
three experiments.  
 
The BCA assay was subsequently applied to quantify the volume of non-adsorbed 
protein in the supernatants of the additional DDA replacement formulations, pelleted 
upon OVA adsorption at 1 mg/ml. This was conducted as the level of antigen to be 
delivered and its association to the vesicles, via surface adsorption for example, 
indicates the potential efficiency of a liposomal delivery system (Korsholm et al, 
2007), and these experiments also provided a further point of comparison with the 
previously characterised DDA-TDB based formulations in which DDA content was 
replaced. 
 
DDA-TDB (5:1) generated the lowest level of non-associated OVA at ~10% (Figure 
3.19) and as DDA content decreased within the formulation, more antigen became 
free, as compared to the DDA-TDB liposomes, DDA-DSPC-TDB at 100/150/50 
µg/dose and the reduced weight ratio of DDA-TDB (2:1) generated significantly (P < 
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0.01) higher levels of non-adsorbed antigen at 30-40%, which was half the level 
attained in the supernatants of DSPC-TDB, in which ~80% of quantified OVA was 
non-associated from the slightly anionic system (Figure 3.19). Additionally, no 
significant difference was exhibited between these two additional replacement systems 
tested. Overall, the further replaced formulations appear to have comparable 
characteristics to DDA-TDB and its partial DDA replacement, with these outlined 
systems to be further characterised and immunologically assessed, in order to fully 
appreciate the role of the cationic lipid DDA vs. DSPC content within the proposed 
TDB based liposomal adjuvants. 
 
 
Figure 3.19. Quantification of non-adsorbed OVA protein in the supernatants of DDA-TDB, 
DDA-DSPC-TDB (100/150/50 µg/dose), the reduced weight ratio of DDA-TDB at 2:1 (100/50 
µg/dose) and DSPC-TDB, pelleted upon OVA adsorption at 1 mg/ml. Results are based on triplicate 
readings of three independent experiments, with error bars representative of the standard deviation from 
the mean average. 
 
3.8. Conclusions 
Upon initial studies into the effect of buffer on the hydration of the lipid film, Tris was 
selected as the most suitable medium, with DLS measurements made with samples 
suspended in 1 mM Tris buffer. The liposomes characterised upon incorporation of 
DPPC or DSPC, by cationic replacement or substitution of DDA-TDB, produced 
vesicles in a sub-micrometre size range with a cationic zeta potential. The exceptions 
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were observed with DPPC-TDB and DSPC-TDB, which were significantly larger with 
an anionic zeta potential. Furthermore, the substituted systems were physically stable 
over 28 days as no fluctuations in mean particle size or zeta potential was apparent, 
with TEM demonstrating heterogeneous populations of vesicles whilst corroborating 
with the particle size analysis. 
 
A DDA dependent effect upon the levels of liposome associated and non-associated 
antigen was observed with DDA-TDB, followed by its partial replacement or 
substitution retaining the highest levels of antigen coupled with relatively low OVA 
release in the replicated physiological conditions, whilst demonstrating interactions 
with serum proteins. The necessity of DDA was further demonstrated with the lack of 
OVA retained in the DSPC-TDB liposomes, coinciding with rapid and continual 
antigen release. 
 
With the aim of investigating the physicochemical characteristics of the liposomal 
adjuvants used to deliver antigens, these outlined formulations may be developed into 
potential vaccine delivery systems, as the characterised attributes displayed upon 
partially incorporating or replacing DDA content have been encouragingly comparable 
to the recognised DDA-TDB adjuvant. The findings reported in this chapter for the 
multi-component liposomal formulations can be further assessed for their 
thermodynamic properties to confirm lipid interdigitation, with further in vitro 
evaluation into associated cytotoxicity and activation of macrophages, prior to 
immunological characterisation in response to a novel vaccine antigen, to determine 
whether the main DDA-TDB formulation can possibly be enhanced, whilst fully 
appreciating the role of DDA and the effect of additional lipid incorporation in the 
proposed liposomal immunoadjuvants. 
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4.1. Introduction 
4.1.1. Differential scanning calorimetry for thermodynamic analysis 
Differential scanning calorimetry (DSC) is a widely used method of thermal analysis 
that has been applied to investigate and characterise a range of pharmaceutical systems 
(Giron, 2002). The thermal examination of materials can give a range of thermal 
properties including phase transitions and heat capacity changes, which are key factors 
of the drug delivery formulation process, allowing indications of system stability at 
various temperature conditions. DSC is commonly applied for such investigations due 
to its ease of use, speed of application and for laboratory analysis, its relatively low 
costs (Demetzos, 2008). Differential scanning calorimetry measures the heat flow that 
enters or exits a material at a given heating or cooling rate from which the heat 
capacity (Cp) at a continuous pressure can be determined. The heat capacity is 
representative of the quantity of heat input necessary to increase the temperature of a 
sample by one degree Celsius at a constant pressure (Demetzos, 2008).  
 
As a function of time and temperature, DSC is a technique capable of measuring the 
heat flow and temperature of a given sample. Thermal transitions such as the melting 
of crystalline materials, crystallisation of melts, glass transitions of amorphous 
materials and phase transitions from a crystalline to a liquid crystalline form can be 
detected and quantified using DSC (Gill et al, 1993). All thermal transitions are 
influenced by the chemical structure and physical nature of the material, making the 
application of DSC a useful tool, for example in the thermal characterisation of 
liposomal dispersions. Quality control in liposome production can also be achieved, 
particularly in multicomponent systems when determining the effect of additional 
components to main phase transitions, leading to an improved understanding of the 
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thermodynamic behaviour of lipids used in liposomal formulations (Biltonen & 
Lichtenberg, 1993).      
 
4.1.2. Thermal characteristics of liposomes 
Thermal transitions of vesicular systems such as liposomal dispersions can be obtained 
for characterisation via DSC. The features that define a typical melting transition in a 
thermogram for a liposomal dispersion are shown in Figure 4.1. One of the major 
features of interest is the main phase transition temperature (Tm), representing the peak 
melting temperature, which is the uppermost, maximum point of the endothermic peak. 
The energy of the main melting point is taken from the area under the peak in J/g. This 
area is proportional to the energy associated to the main phase transition (Chapman & 
Urbina, 1974). 
 
For the analysis of lipid dispersions, in the studies within this chapter, a heat, cool, re-
heat method was applied to remove any thermal history and ascertain the main melting 
point of the proposed systems. The endothermic event of melting to a liquid phase, 
whereby energy is absorbed, is characterised by a single, upward deviation from the 
baseline (heat flow displayed as endo up on the Pyris Diamond DSC system, Perkin 
Elmer Instruments LLC, USA). Contrastingly, an exothermic event such as 
crystallisation, in which energy is released, is displayed as an inverse of a Tm peak 
when cooling (Figure 4.1), as the system returns to a gel phase after attaining fluidity, 
prior to a final re-heating stage (PerkinElmer, 2010). 
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Figure 4.1. A typical DSC thermogram of a liposomal dispersion. An endothermic main melting 
event indicative of a main transition from a gel-to-liquid crystalline state and an exothermic 
crystallisation is evident in the opposing deviations from the baseline (Figure adapted from Taylor & 
Craig, 2003). 
 
Upon the addition of thermal energy to lipid bilayers (e.g. to multilamellar liposomes), 
the major change in state that takes place is the gel-to-liquid crystalline phase 
transition, which is effectively a melting transition, from a crystalline to a liquid 
crystalline state (Figure 4.2). The transition of lipid bilayers is influenced by the level 
of Van der Waal interactions between the hydrocarbon chains of adjacent lipid 
molecules. These interactions are determined by the length of lipid chains, with longer 
chain lipids having an increased area in which to interact, in turn strengthening this 
interaction and ultimately resulting in decreased lipid mobility. Therefore, shorter 
tailed lipids are more fluid than their longer tailed counterparts (Rawicz et al, 2000).  
 
The amphiphilic structure of a lipid molecule, consisting of a polar head group and two 
attached non-polar tails, together with the phase transition behaviour of hydrated lipids 
is displayed in Figure 4.2. It is understood that longer chain phosphatidylcholines 
remain in a consistently, well ordered gel state with extended acyl chains and 
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predominantly motionless head groups at the water interface (Fuldner, 1981). 
However, upon heating (towards a liquid crystalline state), a cooperative melting of the 
acyl chains results in a disordered hydrocarbon arrangement as the mobility of the acyl 
chains is increased (Koyama et al, 1999; El Maghraby et al, 2005). 
 
 
Figure 4.2. Schematic representation of phospholipid acyl chain arrangements from a gel-to-liquid 
crystalline state. A lipid molecule (A), e.g. the saturated DPPC lipid, produces a well-ordered bilayer of 
molecules when in a gel state (B), which later becomes altered upon heating to a liquid crystalline state 
(C) (Demetzos, 2008).  
 
Therefore, depending on the structural attributes of the lipids forming the liposomal 
suspension, its bilayers may be in a rigid, gel state or a fluid, liquid crystalline state at 
a given temperature. Liposomes are in a liquid crystalline phase when the vesicle 
suspension is at a temperature above its main phase transition temperature, and in a 
rigid state when at a temperature below the crystalline transition temperature. 
 
Indeed the greatest modification to vesicle bilayers takes place in the main phase 
transition from a gel-to-liquid crystalline state (Lentz et al, 1976). Hence, the choice of 
phospholipids and introduction of additional lipids can affect the main phase transition 
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and in turn, vesicle bilayer fluidity. This can favourably influence the system by 
increasing the overall transition temperature of the lipid bilayer, decreasing bilayer 
fluidity and consequently preventing leakage of encapsulated components at 
physiological temperature (Sharma & Sharma, 1997). 
 
The crystalline state of lipid bilayers, i.e. their bilayer fluidity, is a key influencing 
factor upon the in vivo behaviour of liposomes. Early work by Senior & Gregoriadis, 
(1982) demonstrated that drug retention in liposomes in vivo was dependent on the 
phase transition temperature of the lipids used. Lipids with various chain lengths and 
resultant phase transitions were tested such as, dilauroyl phosphatidylcholine (DLPC) 
(C12, Tm of -1 °C), dimyristoyl phosphatidylcholine (DMPC) (C14, Tm of 23 °C), and 
DPPC (C16, Tm of 41 °C), quickly released entrapped drug, whereas DSPC liposomes, 
which possesses a longer fatty acid chain and thus a higher Tm, (C18, Tm of 55 °C), 
were shown to retain increased amounts of entrapped drug (carboxyfluorescein) 
(Senior & Gregoriadis, 1982).  
 
In the present study, the aim of this chapter was to investigate the effect of 
incorporating varying levels of DPPC or DSPC lipid to DDA-TDB based liposomal 
systems. This was achieved by identifying particular structural phases and determining 
lipid miscibility via DSC, indicated by the temperature at which the main phase 
transition from a gel-to-liquid crystalline state occurs for the proposed multicomponent 
adjuvants. Cationic replacement or substitution with the further lipids took place upon 
the main DDA-TDB liposomal formulation, previously shown to be an effective 
adjuvant (Davidsen et al, 2005). 
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4.2. DSC of DDA and the effect of TDB on the gel-to-liquid phase transition  
DSC was initially carried out on DDA and DDA-TDB liposome dispersions in order to 
establish a method for analysis and characterise the main gel-to-liquid phase transition 
temperature of these systems. The thermograms and thermodynamic parameters 
characterised for both DDA and DDA-TDB are summarised in Figure 4.3. An 
endothermic event for the main thermal transition can be seen with DDA dispersions 
in the region of 47 °C within the heat capacity curve. Upon 11 mol% TDB addition 
(5:1 weight ratio) to the DDA liposome formulation, the onset of Tm is lowered by 
approximately 5 °C with a noticeable broadening of the peak. 
 
 
 
 
 
Figure 4.3. DSC thermograms and corresponding thermodynamic parameters of the gel-to-liquid 
phase transition of DDA and DDA-TDB vesicles. Liposomes were produced via lipid hydration in 10 
mM Tris buffer (pH 7.4). DSC Thermograms were made at 10 °C/min (600 °C/h) over the tested 
temperature range of 25-75 °C. One of three thermograms for each vesicle system is shown with the 
results representative of the mean ± the standard deviation of three independent liposome batches. 
 
   Liposome                 Onset  
                                       (°C) 
   
Peak Max  
(°C) 
       
        Delta H  
           (J/g) 
 
   
       DDA                    46.1 ± 0.6 
 
 
  47.1 ± 0.6 
 
        1.9 ± 0.2 
   DDA-TDB               41.6 ± 0.4 
 
  42.8 ± 0.6         1.3 ± 0.8 
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These results are in line with previous studies (Davidsen et al, 2005) in which the Tm 
for DDA was detected at 47 °C, and the integration of the TDB glycolipid acyl chains 
into the hydrophobic region of DDA bilayers changed the lipid chain arrangements, 
signified by a broader, highly significantly down shifted Tm (P < 0.01) to ~42 °C, also 
in good agreement with previous studies (Christensen et al, 2007a). With TDB 
substituted into DDA, a broadened DSC peak at the main phase transition 
demonstrates the concept of multiple cooperative heat transitions hypothesised by 
Davidsen et al, (2005). This is possibly resulting from alterations to the local lipid 
bilayer configuration as the 22-carbon acyl chains of TDB are accommodated within 
the hydrophobic core of DDA bilayers, affecting the lipid chain packing characteristics 
(Davidsen et al, 2005).    
 
4.3. Investigations using Nano DSC 
DDA-TDB liposomes were also tested for their main phase transition using a new 
Nano DSC (TA Instruments). This system is described as being able to precisely 
control the temperature of the sample and provide higher sensitivity and 
reproducibility of data with greater baseline stability than conventional DSC (TA 
Instruments, 2011). Such attributes allow for samples at lower concentrations to be 
used, with DDA-TDB scans prepared in dosage form (1.25/0.25 mg/ml) as opposed to 
the higher concentrations used to maximise the thermal events for the other equivalent 
scans of this study via DSC. Furthermore, the Nano DSC scans were made at a scan 
rate of 2 °C/min, providing a good balance between signal to noise ratio and 
resolution, maximising the thermal event and hence a more prominent Tm. 
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The heat-cool-reheat conditions for DSC can offer valuable characterisation 
information of the thermodynamic behaviour for a given sample. This is achieved as 
cooling and subsequent reheating removes the original thermal history of a sample, 
replacing it with a solid, more controlled thermal history, allowing increased 
sensitivity, highlighting any thermal events that may not be apparent during the first 
heat (Sichina, 2000). 
 
The DDA-TDB liposomal sample was firstly heated and cooled which displayed a pre-
transition in the region of 30 °C and a subsequent main transition, of a large 
magnitude, split into two domains beyond 40 °C. However, upon cooling, a single 
crystallisation peak was observed, suggesting a more homogenous sample. 
Subsequently, the same sample was reheated to examine the reproducibility of the 
transition and confirm the main melting point of the lipid dispersion. This first reheat 
displayed a pre-transition prior to a two domain main transition (Figure 4.4), as 
characterised in the first heat. However, a further heat (second repeated heat), with a 
new thermal history, showed no pre-transition and a prominent, single domain, main 
phase transition (Figure 4.4). This single transition peak of the repeated heat, 
positioned between the previously observed twin domain, displays homogeneity within 
the sample. 
 
Reproducibility of phase transitions was achievable in both heating and cooling of the 
sample and once initially melted and cooled, subsequent melting and re-crystallisation 
was identical in behaviour, characterised for the main melting point of the DDA-TDB 
liposomal dispersions. The magnitude of the main phase transition was large and 
prominent for the sample scans and as the area associated to the transition was not 
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significantly altered (found to be consistently in the region of 23.5 mJ) between each 
repeated scan (additional repeated scans not shown), no physical or chemical 
degradation of the liposome system was apparent, as a function of repeated heating, in 
the tested temperature range. 
 
 
 
Figure 4.4. Nano DSC thermogram of the gel-to-liquid phase transition of a DDA-TDB liposomal 
dispersion. The liposomes were produced via lipid hydration in Tris buffer (10 mM, pH 7.4) with the 
scans made at 2 °C/min (120 °C/h) over the tested temperature range of 20-70 °C. 
 
From the successful reproduction of these highlighted results, the DSC method applied 
for liposomal dispersions in this study was validated. The heat, cool, re-heat 
instrumental approach removed any thermal history allowing for the main phase 
transition to be successfully characterised. Further confirmation of the main melting 
point of DDA-TDB determined via Nano DSC also corroborated with the findings of 
conventional DSC instrumentation. The analysis of DDA and DDA-TDB thus 
effectively acted as a control for subsequent thermodynamic studies of the novel 
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formulations in this study, which included a variety of phospholipid combinations 
incorporating DPPC or DSPC lipid. 
 
4.4. DSC of DDA-TDB based liposomes replacing DDA with DPPC or DSPC lipid 
DSC was conducted upon the DDA replacement formulations, previously 
characterised for vesicle size, zeta potential, antigen retention and release (see Chapter 
3), in order to ascertain the temperature point at which the main transition from a gel-
to-liquid phase occurred for the DDA-TDB based lipid mixtures. With a fixed weight 
of TDB present within the formulation, the cationic DDA component within the 
DDA:TDB 5:1 weight ratio was replaced with DPPC or DSPC lipid. These lipids are 
from the phospholipid family of saturated phosphatidylcholines, and only differ by the 
number of carbon atoms within their acyl chains: DPPC and DSPC lipids contain two 
16 and 18-carbon alkyl chains respectively (see Chapter 1, Table 1.7 for schematic 
structures of DPPC and DSPC). 
 
DSC thermograms were attained across a temperature range of 25-75 °C at a scan rate 
of 10 °C/min to characterise the main gel-to-liquid crystalline phase transition (Tm) 
(Figure 4.5). The main melting point attained for pure DPPC liposome dispersions was 
42.3 °C ± 0.2 °C (Figure 4.5). When DPPC completely replaced DDA in the liposomes 
(DPPC-TDB; 250/50 µg/dose), the main melting point was not significantly different 
in comparison to pure DPPC lipid, remaining in the region of 42 °C. When DDA was 
introduced alongside DPPC and TDB at 50/200/50 µg/dose, the measured peak max 
temperature for the main phase transition dropped significantly (P < 0.01) by 
approximately 4 °C, as the liposomal system incorporated multiple phospholipid 
components, coinciding with an evident broadening of the peak. Interestingly, for the 
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phospholipid mixture of DDA-DPPC-TDB at the weight ratio of 150/100/50 μg/dose, 
no endothermic peak indicative of a main phase transition was detected in the tested 
temperature range (Figure 4.5). 
 
Results for liposome suspensions prepared from pure DPPC dispersions correspond 
with previously conducted DSC studies into such liposomes (McMullen et al, 1995; 
Biruss et al, 2007; Bolean et al, 2010), noting the main phase transition for DPPC at 
42 °C. Hoyrup et al, (2001) analysed phospholipid mixtures composed involving 
DPPC and stearoylmyristoyl-sn-phosphatidylcholine (SMPC), adjusting the SMPC 
concentrations to examine bilayer interactions via DSC. SMPC is an asymmetrical 
phospholipid as it consists of two chains of unequal carbon lengths (C18/C14). Such 
lipids are common in biological membranes and interestingly, miscibility with 
symmetrical phospholipids is possible, whilst raising the main melting point. 
Furthermore, with the presence of DPPC lipid, all tested ratios yielded a maximum Tm 
beyond 40 °C, where pure DPPC liposome dispersions were expected to generate a 
highly cooperative phase transition. As DPPC was increasingly introduced within the 
SMPC-DPPC phospholipid mixture, the corresponding phase transitions of the systems 
were measured at higher temperatures (Hoyrup et al, 2001). For this current study, the 
general trend apparent was that with an increased incorporation of DPPC lipid in the 
replacement of DDA, the resultant main phase transition temperatures became closer 
to DPPC lipid in its pure form. In all instances, the main phase transition did not 
exceed that of DPPC alone which was characterised at approximately 42 °C (Figure 
4.5). 
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Figure 4.5. DSC thermograms and associated thermodynamic parameters of the gel-to-liquid 
phase transition of DDA-DPPC-TDB liposomes. Liposomes were made by lipid hydration and 
rehydrated in 10 mM Tris buffer (pH 7.4). DSC thermograms were taken at 10 °C/min (600 °C/h) over 
the temperature range of 25-75 °C. One of three thermograms per formulation is shown with results 
representative of the mean ± the standard deviation of three independent batches. 
 
 
 
 
 
  DDA-DPPC-TDB             Onset  
          (µg/dose)                     (°C) 
   
    Peak Max  
                 (°C) 
       
     Delta H  
        (J/g) 
 
   
        DPPC                       41.4 ± 0.3 
 
 
   42.3 ± 0.2 
 
    2.8 ± 1.4 
        0/250/50                   40.8 ± 0.1 
 
        50/200/50                 36.8 ± 0.8  
 
        150/100/50                 0.0 ± 0.0 
 
        250/0/50                   41.6 ± 0.4                 
 
   41.6 ± 0.1 
 
            37.4 ± 0.8        
 
               0.0 ± 0.0 
 
            42.8 ± 0.6 
    1.8 ± 0.5 
 
    0.8 ± 0.4                        
 
    0.0 ± 0.0 
 
    1.3 ± 0.8 
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When phospholipids are blended together, main phase transitions are known to occur 
over a wider range as opposed to phospholipids in their pure form (Taylor & Craig, 
2003). All lipid components that made up the mixtures in this study contained chains 
of equal length, comprising of an even number of carbon atoms. The single, well 
defined peaks represented a more stable system for the multi saturated lipid mixture, 
suggesting miscibility of all the components. Alternatively, DSC thermograms 
characterised by several endothermic peaks indicate liposomal instability in multiple 
lipid formulations, derived from potential heterogeneity in the molecular arrangement 
within the bilayer (Giatrellis et al, 2009). 
 
In the present study, similar experiments were also carried out with DDA replacement 
in DDA-TDB with DSPC lipid, with such liposome dispersions prepared in Tris buffer 
as previously conducted. The main phase transition of pure DSPC dispersions was 
characterised at 56 °C ± 0.2 °C (Figure 4.6), in accordance with findings previously 
reported in the literature (Koyama et al, 1999).  When TDB was mixed into the DSPC 
liposome formulation (DSPC-TDB; 250/50 µg/dose) no significant difference in the 
main melting points was observed (56.0 °C ± 0.2 °C vs. 55.1 °C ± 0.6 °C, respectively, 
Figure 4.6). In the multicomponent liposome systems containing DDA, DSPC and 
TDB at a ratio of 50/200/50 µg/dose again, the measured Tm was not significantly 
different from the DSPC-TDB formulation (Figure 4.6). However, when the amount of 
DDA increased to 150 µg/dose (total DDA-DSPC-TDB ratio of 150/100/50 µg/dose) 
no transition was measured within the tested temperature range (Figure 4.6). The 
absence of a thermal event replicates a stabilising cholesterol effect on the system, as a 
main phase transition is reported to be abolished upon bilayer incorporation of 
cholesterol (Chapman & Urbina, 1974), enhancing the orientational order of 
hydrocarbon chains in the liquid crystalline state and reducing the passive permeability 
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of lipid bilayers beyond the gel-to-liquid phase transition (McMullen & McElhaney, 
1996), evident upon increased integration of cholesterol concentrations up to 50% 
(Moghaddam et al, 2011). The broadening and eventual Tm elimination upon 
cholesterol incorporation organises membrane lipids into a state between a solid 
ordered gel phase and a liquid crystalline phase, producing an intermediate liquid-
ordered phase (Mannock et al, 2010). 
 
As highlighted earlier, when phospholipids are blended together, a characteristic 
singular, broader peak is observed, or indeed removed as in the case of DDA 
replacement with DPPC or DSPC at 150/100/50 µg/dose (Figures 4.5 & 4.6), via DSC. 
Contrastingly, when two lipids fail to interdigitate with one another, two separate well 
defined peaks can be expected (Feitosa et al, 2006). For example, the phase 
characteristics of DDA based cationic liposome mixtures were previously examined by 
Feitosa et al, (2006). Specifically, cationic lipid mixtures of DDA and 
didodecyldimethylammoinuim bromide (DODA) were investigated via DSC for the 
main transition temperature from a gel-to-liquid crystalline state, whereby DDA molar 
fractions of 0.2-0.8 within DDA-DODA liposomes at a net 1.0 mM lipid concentration 
were tested. Moreover, two distinct peaks were observed with individual melting 
points, representing two divided populations of DDA and DODA-enriched liposomes. 
These separate, independent peaks signified that the two lipids had a low affinity for 
one another and opposed the observed lipid mixtures of this study, whereby single, 
broadened peaks obtained for the lipid blends tested were symptomatic of multiple 
lipid incorporation. 
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Figure 4.6. DSC thermogram summary and corresponding parameters of the main gel-to-liquid 
phase transition of DDA-DSPC-TDB liposomes. Liposomes were made by lipid hydration in 10 mM 
Tris buffer (pH 7.4). DSC thermograms were taken at 10 °C/min (600 °C/h) over the temperature range 
of 25-75 °C. One of three thermograms per formulation is shown with results representative of the mean 
± the standard deviation of three independent batches. 
 
 
 
 
 
 
DDA-DSPC-TDB          Onset  
         (µg/dose)                 (°C) 
   
     Peak Max  
               (°C) 
       
          Delta H  
             (J/g) 
 
   
     DSPC                     55.4 ± 0.2 
 
 
    56.0 ± 0.1 
 
          1.8 ± 0.2 
     0/250/50                 55.1 ± 0.5 
 
     50/200/50               54.2 ± 0.4  
 
     150/100/50               0.0 ± 0.0 
 
     250/0/50                 41.6 ± 0.4                 
 
    55.1 ± 0.6 
 
             54.7 ± 0.6        
 
                0.0 ± 0.0 
 
42.8 ± 0.6 
          1.6 ± 0.4 
 
          0.5 ± 0.4                        
 
          0.0 ± 0.0 
 
              1.3 ± 0.8 
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4.5. DSC of DDA-TDB liposomes substituted with DPPC or DSPC lipid 
Differential scanning calorimetry was also conducted using an identical experimental 
approach on further liposomal formulations. More specifically, DSC was used to 
measure the thermodynamic effect of incorporating additional lipids upon substitution 
of the DDA-TDB adjuvant, rather than directly replacing the DDA component, i.e. the 
DDA-TDB ratio remained at a 5:1 weight ratio and the addition of DPPC or DSPC at 
mol% ratios of 25, 50 and 75 % in substitution of DDA and TDB occurred. 
 
In this series of formulations, liposomal dispersions with 25 mol% DPPC 
incorporation displayed a single, broadened peak indicative of a melting event of a 
phospholipid mixture (Figure 4.7). The temperature at which this main melting event 
occurred was not found to be significantly different to DDA-TDB alone, occurring at 
43 °C (Figure 4.7). Indeed, low levels of DPPC incorporation to DDA-TDB have been 
noted to have no significant effect on the main phase transition from a gel-to-liquid 
crystalline state (Henriksen-Lacey et al, 2010). With DDA-TDB substitution at 50 and 
75 mol%, a main melting point was determined in the region of 50 °C. Although both 
systems showed no significant difference to one another, these two uppermost 
substituted mixtures allowed for a significant (P < 0.05) increase in the measured Tm, 
of almost 10 °C, compared to DDA-TDB dispersions prior to further lipid 
incorporation (Figure 4.7). Here, a favourable increase in the main phase transition 
was achieved as the systems remained in the gel phase at higher temperatures prior to 
the main melting event, attaining structural rigidity whilst successfully interdigitating 
into a single mixture. The broadened shaped endotherms detected for such 
formulations suggest ideal mixing of the multiple lipid formulation components used 
in this study (Ali et al, 2000). 
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Figure 4.7. DSC thermogram summary and corresponding thermodynamic parameters measured 
for the main phase gel-to-liquid transition of DDA-TDB liposome dispersions substituted with 25, 
50 or 75 mol% DPPC. Scans of DDA-TDB and pure DPPC lipid have also been overlaid for 
comparison. Liposomes were produced via lipid hydration in 10 mM Tris buffer (pH 7.4) and 
thermograms were made at a scan rate of 10 °C/min (600 °C/h) over the tested temperature range of 25-
75 °C. One of three thermograms for each formulation is displayed with results representative of the 
mean ± the standard deviation of three independent liposome batches.   
 
 
 
     DDA-TDB                   Onset  
+ mol% DPPC                  (°C)       
   
      Peak Max  
    (°C) 
       
        Delta H  
           (J/g) 
 
   
 + 25% DPPC                42.1 ± 1.3 
 
 
       43.4 ± 1.5 
 
        0.5 ± 0.3 
 
 + 50% DPPC                49.0 ± 1.1 
 
 + 75% DPPC                50.1 ± 0.8  
 
       DPPC                     41.4 ± 0.3 
 
 DDA-TDB (0 %)         41.6 ± 0.4                 
 
       49.4 ± 1.8 
 
              51.1 ± 0.9        
 
              42.3 ± 0.2 
 
  42.8 ± 0.6 
        0.8 ± 0.4 
 
        1.2 ± 0.3                        
 
        2.8 ± 1.4 
 
        1.3 ± 0.8 
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DSC was also conducted upon DDA-TDB systems substituted with DSPC at 25, 50 
and 75 mol% (Figure 4.8). Upon incorporation of 25 mol% DSPC, an endothermic 
peak was evident, shifting to a significantly higher (P < 0.05) maximum temperature of 
60.2 °C ± 0.7 °C, from that of DDA-TDB. This contrasted with the Tm observed for 
the equivalent DPPC formulation, as the incorporation of DSPC, with its longer 
hydrocarbon chains, led to higher temperatures required to alter its well ordered gel 
state. Interestingly, when DDA-TDB was substituted with 50 mol% DSPC, no main 
melting event was detected within the tested temperature range. For DDA-TDB-75 
mol% DSPC, the main phase transition was also significantly modified (P < 0.05) by 
20 °C from DDA-TDB, characterised at a peak of 62 °C (Figure 4.8). This particular 
composition represented the uppermost incorporation of DSPC, and the main thermal 
event occurring over a wider temperature range suggests complete miscibility for the 
multicomponent adjuvant system (Taylor & Morris, 1995), with the configuration of 
DSPC within DDA-TDB possibly strengthening the hydrocarbon arrangement, thus 
requiring more energy to melt the hydrocarbon chains at the point of phase transition. 
 
It is understood that lipids with chain length differences encourage bilayer integration 
in lipid bilayer mixtures (Sisk, 1990). The differences in chain lengths are apparent 
when observing the phospholipid mixtures formed as a result of DDA-TDB adjustment 
in this study, from either its cationic replacement or substitution. An increased 
introduction of DPPC for example, with its 16 carbon chains that represented a small 
chain length difference between the 18 carbons of DDA within DDA-TDB, generated 
noticeably broader peaks. Furthermore, substitution with the longer chained DSPC 
lipid led to elevated phase transition temperatures whilst also displaying multiple lipid 
incorporation, characterised by single defined peaks. 
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Figure 4.8. DSC thermogram summary and corresponding thermodynamic parameters measured 
for the main phase gel-to-liquid transition of DDA-TDB liposome dispersions substituted with 25, 
50 or 75 mol% DSPC. Scans of DDA-TDB and pure DSPC have also been overlaid for comparison. 
Liposomes were produced via lipid hydration in 10 mM Tris buffer (pH 7.4) and thermograms were 
made at a scan rate of 10 °C/min (600 °C/h) over the tested temperature range of 25-75 °C. One of three 
thermograms for each formulation is displayed with results representative of the mean ± the standard 
deviation of three independent liposome batches. 
 
 
 
    DDA-TDB                 Onset  
+ mol% DSPC               (°C)       
   
   Peak Max  
 (°C) 
       
         Delta H  
            (J/g) 
 
   
+ 25% DSPC               59.6 ± 0.4 
 
 
   60.2 ± 0.7 
 
          3.3 ± 2.8 
 
+ 50% DSPC                0.0 ± 0.0 
 
+ 75% DSPC               61.6 ± 1.0  
 
      DSPC                    55.4 ± 0.2 
 
DDA-TDB (0%)         41.6 ± 0.4                 
 
     0.0 ± 0.0 
 
          62.5 ± 0.6        
 
          56.0 ± 0.1 
 
42.8 ± 0.6 
          0.0 ± 0.0 
 
          3.1 ± 0.9                        
 
          1.8 ± 0.2 
 
          1.3 ± 0.8 
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The exception to all of the tested substituted systems was seen with 50 mol% DSPC 
substitution of DDA-TDB, with thermal events abolished beyond detection, producing 
a possible intermediate fluid ordered phase (Henriksen-Lacey et al, 2011a). A 
comparable effect is seen from increased cholesterol incorporation into liposomal 
dispersions, such as systems composed of saturated phosphatidylcholines of DPPC, 
whereby phase transition peaks become broader until an eventual abolition of the 
cooperative gel-to-liquid crystalline phase transition of the bilayers is observed 
(Bolean et al, 2010). As highlighted earlier, this abolition of a phase transition occurs 
when cholesterol is incorporated at concentrations of 50 mol% (McMullen et al, 1993), 
which can minimise drug leakage from formulated vesicles (Bedu-Addo & Huang, 
1995). 
 
The broadening of the peaks attained in the thermograms of this study is indicative of 
lipid blends, particularly with lipids of apposing hydrocarbon chain lengths, whereby a 
difference of two carbon atoms in the phospholipid tails represents an ideal mixture of 
phases. However, as the difference in hydrocarbon chains of phospholipids become 
greater, the level of phase mixing declines, producing regions of immiscibility in the 
gel phase, notably seen with chain differences as high as six carbons (Mabrey & 
Sturtevant, 1976). This level of immiscibility was verified by Feitosa et al, (2006), in 
which DODA-DDA mixtures represented a difference in phospholipid chain lengths of 
six carbon atoms. Such dispersions generated two main melting events independent of 
each other, opposing the singular defined peaks of the phospholipid adjuvant mixtures 
assessed in this study. However, as highlighted previously, the effect of TDB on the 
phase behaviour of DDA liposomes suggested incorporation of the 22-carbon acyl 
chains of TDB at 11 mol%, into the 18-carbon alkyl twin tailed DDA lipid, producing 
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TDB enriched domains and a resultant broadened main phase transition (Davidsen et 
al, 2005).  
 
4.6. Conclusions 
In conclusion, liposomal dispersions of DDA, DDA-TDB and the replacement and 
substitution of DDA-TDB were analysed for their main phase transitions, which 
indicated lipid interdigitation of the proposed multicomponent delivery systems. DDA 
dispersions alone presented a sharp endothermic peak indicative of a main melting 
event, with the addition of TDB displaying incorporation within the DDA bilayers. 
Upon cationic replacement with an incremental increase of DPPC, the main phase 
transition temperature was characterised below that of DDA-TDB. In contrast, 
equivalent DDA replacement formulations with DSPC yielded higher phase transition 
events, beyond DDA-TDB upon incorporation of this longer chained phospholipid.  
 
Additionally, as the substitution of DDA-TDB increased with DPPC or DSPC lipid, 
detected thermal events were generally observed at higher temperatures, beyond DDA-
TDB dispersions alone and the pure substituted lipid used. All of the tested systems 
demonstrated thermograms typical of phospholipid mixing, with the exceptions of 
partial cationic replacement with either lipid (150/100/50 µg/dose) and 50 mol% 
substitution with DSPC, possibly enhancing the structural rigidity of the system, as the 
orientation of hydrocarbon chains is altered within the lipid mixture, providing a 
stable, fluid ordered phase, as any thermal events were undetectable in the tested 
temperature range. 
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As a result of DSC analysis, thermograms for the outlined adjuvant systems containing 
DDA with TDB and either DPPC or DSPC displayed single, broadened main gel-to-
liquid phase transition peaks indicative of phospholipid blends, suggesting that the 
multicomponent liposomal dispersions interdigitated with one another. Furthermore, 
these liposomal systems can be prepared at lower temperatures, and may be stable 
beyond physiological temperature, potentially prolonging drug retention, making their 
application beneficial as drug delivery systems. 
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5.1. Introduction 
5.1.1. Therapeutic applications of liposomal delivery systems 
Liposomal delivery systems have various uses in the modulation of the immune system, 
providing a potent means of drug delivery as they are non destructive to cell membranes, 
able to transfect numerous different cell types and are metabolically compatible, whilst 
facilitating the possibility of targeting desired tissues of interest in vivo (Smith et al, 
1993). The use of liposomal adjuvants are also advantageous as they are biodegradable, 
relatively non-toxic and FDA approved, whilst they can be easily manufactured and 
tailored in order to maximise efficacy from optimising antigen-liposome complexes (Fries 
et al, 1992).    
 
Cationic liposomal systems can be used to deliver peptides, proteins and DNA, whilst also 
acting as adjuvants in the enticement of immunological reactions, triggered from the 
effective delivery of antigens (O’Hagan & Singh, 2002). Furthermore, liposomes of a 
cationic nature have been utilised as potential delivery systems and immunological 
therapies, with the ability to function as immunomodulators in the enhancement of anti-
microbial, anti-viral or anti-inflammatory treatments (Filion & Phillips, 1997). 
 
5.1.2. Liposomes as immunoadjuvants 
Upon antigen delivery, activation of innate immune receptors associated to APCs, e.g. 
macrophages and DCs, engage with and present antigen material to T cells through 
pathogen recognition receptors, and are employed by APCs to identify pathogen-
associated molecular patterns (Akira et al, 2006). Such pathogen recognition receptors 
activate the transportation of APCs from the site of injection for example, to the T-cell 
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region of the draining lymph nodes for eventual stimulation of naive T-cells, pivotal to 
adaptive immunity and essential to humoral and cellular immune responses (Pulendran & 
Ahmed, 2006). 
 
With careful manipulation, liposomal immunoadjuvants can potentially target and 
associate with APCs, inducing cell mediated Th1 type immunity or a humoral Th2 type 
immune response in reaction to the presence of specific antigen (Gregoriadis, 1990; 
Galdiero et al, 1995). The main location in which liposomes congregate upon injection or 
infusion is that of the macrophages (Velinova et al, 1996), which can phagocytose a vast 
volume of antigen or liposome when presenting antigens (Filion et al, 1996). Key to cell 
mediated immunity induced from antigen delivery is the activation of macrophages and 
the release of cytokines, of which a major immunomodulator secreted is tumour necrosis 
factor alpha (TNF-α). This particular cytokine receptor, primarily generated by 
macrophages with an anti-viral and anti-tumoural activity, improves T and B lymphocyte 
responses and is a significant contributory factor of inflammatory reactions (Vassalli, 
1992). Such an inflammatory compound, discharged by the macrophage antigen 
presenting cell, therefore provides a definitive marker for macrophage activation.    
 
Before immunological evaluation of the DDA-TDB based formulations and their ability as 
drug delivery systems in vivo, it was necessary to assess the outlined systems in vitro, in 
order to determine their potential in stimulating targeted and protective immune responses. 
A mouse macrophage J774 cell line was selected as the experimental model as it is one of 
the most sustainable cell lines to culture, justifying its widespread utilisation as an in vitro 
model (Stumpo et al, 2003). Therefore, the aim of this chapter was to establish associated 
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levels of toxicity, phagocytic activity and to quantify secreted levels of the TNF-α 
cytokine in vitro, verifying liposomal cytotoxicity, uptake and expression. This was 
conducted in response to the proposed DDA-TDB based liposomal immunoadjuvants 
characterised earlier in this study upon introducing additional DPPC or DSPC lipids, in 
which DDA was replaced or DDA-TDB was substituted whilst the DDA:TDB ratio 
remained locked, in order to ascertain the effect of cationic content or adjuvant 
concentration respectively. 
 
5.2. Cytotoxicity studies: MTS cell proliferation assay 
Given the association of DDA with toxicity, investigations into the cytotoxicity of the 
DDA-TDB based formulations previously characterised in Chapter 3 took place. Indeed, 
these liposomal systems were assessed for their effect upon macrophage cell proliferation. 
 
5.2.1. Calibration of BALC/c cell number 
Prior to applying the MTS assay upon the DDA-TDB based formulations, the appropriate 
cell number to be used was determined by producing a cell calibration curve. Cell 
numbers ranging from 0-400,000 BALB/c cells per ml were tested to ascertain an 
optimum quantity of cells upon which the liposomal formulations could be introduced. As 
displayed in Figure 5.1, the measured absorbance, which is directly proportional to the 
volume of viable cells, steadily increased with a rise in cell number. The chosen number 
of cells to be used was deduced from where the linear range within the calibration curve 
started. This region can be seen to coincide with a BALB/c cell number of 8x10
4
/ml 
(8x10
3
/well/100 µl), and was therefore selected as a suitable cell number to be used for the 
subsequent in vitro experiments. 
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Figure 5.1. Calibration of BALB/c cell proliferation. MTS absorbance readings were taken over time for 
the BALB/c cell numbers of 0, 2x10
4
, 4x10
4
, 8x10
4
,
 
2x10
5
 and 4x10
5
/ml. The results displayed are the mean 
averages and the standard deviation of triplicate wells. 
 
5.2.2. Determination of liposome sample concentration 
With the cell number established, the concentration of the cationic component, DDA, was 
analysed upon resultant macrophage cell proliferation. The selected BALB/c cell number 
of 8x10
4
/ml was plated out and incubated overnight prior to the addition of DDA-TDB 
and DSPC-TDB liposomes, adjusted to the sample concentrations of 2.5, 5.0, 7.5, 10, and 
15 µg/ml. Subsequent incubation of the BALB/c cells and samples took place overnight 
before calculating the levels of cell proliferation. 
 
Upon the addition of the MTS reagent and after one hour of incubation, which allowed for 
the MTS reagent to be broken down into formazan product by dehydrogenase enzymes of 
viable cells, the cell viability was calculated. After introducing DSPC-TDB at 
concentrations of 2.5 up to 15.0 µg/ml, calculated BALB/c cell proliferation was 
consistently in the region of 90%, with no significant difference between the varying 
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sample concentrations, suggesting that this formulation had no impact on the measured 
cell viability in the tested concentration range (Figure 5.2). In contrast, DDA-TDB 
displayed a concentration dependent cytotoxic effect as DDA-TDB at a concentration of 
2.5 µg/ml generated cell viability at ~70%, which was reduced to around 50-60% at 
concentrations of 5.0 to 7.5 µg/ml, and finally at the highest concentration of 15 µg/ml, 
little viable cells could be measured (Figure 5.2). 
 
 
Figure 5.2. Effect of sample concentration on the cell viability of DDA-TDB vs. DSPC-TDB. The 
BALB/c cell number was adjusted to 8x10
4 
cells/ml and absorbance measurements were made for each 
concentration in triplicate, with error bars displaying the standard deviation from the mean average. 
 
Cationic liposomal systems disadvantageously confer a high toxicity to cells (Romoren et 
al, 2004), resulting from electrostatic interactions with cell membranes (Fischer et al, 
2003), and at increased concentrations, induces apoptosis of antigen presenting cells and 
suppresses the immune response (Ma et al, 2009), which unfortunately restricts their 
safety for clinical use (Lv et al, 2006). The addition of TDB to DDA vesicles not only 
physically stabilises DDA, it also comes with the desirable trait of being less cytotoxic 
due to a reduced fatty acid chain length, particularly in comparison to its 
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immunostimulating synthetic analogue, TDM (Pimm et al, 1979; Olds et al, 1980). 
Therefore, the cytotoxic effect observed in this study, upon an increased concentration of 
the DDA-TDB formulation, can be attributed to the cationic DDA lipid presence, 
opposing the DSPC based system composed of neutral lipids which generated consistently 
high cell proliferation levels, even at higher concentrations. 
 
5.2.3. Cell toxicity studies: DDA replacement within DDA-TDB 
The effect of the DDA lipid presence within DDA-TDB was assessed upon its gradual 
replacement with either DPPC or DSPC. DDA-TDB was used as a control formulation, 
with macrophage cells alone and the cell culture growth medium (DMEM), which was a 
negative control. Based on the preliminary studies conducted, the sample concentration 
was set to 5.0 µg/ml and was also compared against formulations at 10.0 µg/ml, with a 
BALB/c cell number of 8x10
4
/ml applied throughout all subsequent in vitro assays. 
 
As previously observed, DDA-TDB liposomes at 5.0 µg/ml produced a cell viability of 
50-60%, and at a concentration of 10 µg/ml the measured viability was dramatically 
reduced to half the recorded level, to within the region of 30% (Figure 5.3). Upon 
increasing the replacement of DDA with DPPC or DSPC lipid, a rise in cell viability was 
observed as the presence of the cationic component decreased with, in general, no 
significant difference between the DPPC and DSPC based formulations at 5 µg/ml (Figure 
5.3a and b), with cell viability ranging from approximately 60-90%. At the concentration 
of 10 µg/ml, cell viability for the DPPC based systems was significantly (P < 0.05) lower 
than their DSPC equivalents ranging from ~30-60% and ~40-90% respectively, however 
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at this increased concentration, a similar trend was still apparent, with increased 
replacement of DDA content with either lipid resulting in increased cell proliferation.  
 
Introducing zwitterionic lipids in the replacement of cationic content in the present study 
ultimately reduced the toxicity upon macrophages, in co-operation with previous studies 
by Filion & Phillips, (1997), whereby dioleoylphosphatidylethanolamine (DOPE) in 
conjunction with the cationic lipid of dioleoyldiacyltrimethylammonium propane 
(DOTAP) was replaced with DPPC. The gradual replacement of DOPE with DPPC 
notably diminished the toxicity upon macrophages as cell viability was enhanced, 
determined by lactate dehydrogenase (LDH) activity, an enzyme indicative of cell death. 
Although total replacement of DOPE (DPPC-DOTAP) was unable to completely eradicate 
the associated toxicity, the limit of toxicity was 15%, with the applied LDH assay based 
on murine macrophage death. Interestingly, the results of this study, which quantified the 
level of cell proliferation, and thus an inverse indicator of toxicity compared to the LDH 
assay, reached a limit of ~85% cell viability when DPPC completely replaced DDA in 
DDA-TDB. This corresponds to a presumed toxicity of 15% in terms of cell death, 
demonstrating a comparable reduction in toxicity upon introducing lipids such as DPPC. 
 
In addition, Manosroi et al, (2008), when formulating cationic liposomes for gene therapy, 
determined that an increased incorporation of DPPC and cholesterol to DDA vesicles 
reduced the toxic effect upon mouse melanoma cells. Moreover, based on the findings in 
this study in which an increased DDA-TDB concentration decreased cell viability, the 
level of cationic content can be understood to be the main factor influencing the 
cytotoxicity of the liposomal formulation. 
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A 
 
 
 
 
B 
 
 
Figure 5.3. Cell viability for DDA-TDB and the replacement of DDA with (A) DPPC or (B) DSPC. 
Formulations were set to a concentration of 5.0 and 10.0 µg/ml with 8x10
4
/ml BALB/c cells. Measurements 
were made on triplicate wells with results of the mean and standard error of three independent experiments. 
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5.2.4. Cell toxicity studies: substitution of DDA-TDB 
As established earlier, reducing the cationic DDA lipid content reduces the cytotoxic 
effect of the formulation. Subsequently, this second set of substituted systems was tested 
for their toxicity upon macrophage cells with the DDA:TDB ratio fixed, but upon 
increased substitution of the main DDA-TDB immunoadjuvant, became reduced in 
concentration. 
 
As previously observed, DDA-TDB generated a cell viability within the region of 50% yet 
substitution with 25 mol% DPPC or DSPC significantly (P < 0.05) elevated cell viability 
to within the region of 70% (Figure 5.4 A and B), which was not significantly different to 
the levels of macrophage cell proliferation observed upon further substitution with either 
additional lipid at 50 mol% (Figure 5.4 A and B). However, upon a further reduction of 
DDA-TDB concentration with 75 mol% incorporation of DPPC or DSPC lipid, a further 
significant (P < 0.05) increase in cell viability was recorded by approximately 10% 
(Figure 5.4 A and B). Furthermore, no difference in the substituted systems was apparent 
between one another when DPPC or DSPC was substituted into DDA-TDB.  
 
Moreover, an adjuvant concentration dependent effect upon the cytotoxicity of the 
formulation was apparent. Indeed, as 25, 50 and 75 mol% incorporation of either lipid 
indecently coincided with an approximate 25, 50 and 75% reduction in DDA content (see 
Chapter 2, Table 2.1), this impacted upon favourably reducing the associated cytotoxicity 
of DDA-TDB, whilst also corroborating with the effect of DDA previously observed 
when the cationic content was replaced within the formulation. 
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A 
 
 
 
B 
 
 
 
Figure 5.4. Cell viability of DDA-TDB substituted with (A) DPPC or (B) DSPC lipid. Formulations 
were set to a 5.0 µg/ml concentration with 8x10
4
/ml BALB/c cells. Measurements were made upon triplicate 
wells with results representing the mean average and standard error from three independent experiments. 
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5.3. Determination of phagocytic activity: β-N-Acetylglucosaminidase (NAG) assay 
It is important to understand the extent of phagocytosis induced by the proposed 
immunoadjuvants, primarily due to macrophages comprising an innate ability to non-
specifically phagocytosise an immense magnitude of particles such as liposomes, a 
process that T cells are unable to achieve (Adams & Hamilton, 1984). Macrophages are 
capable of consuming liposomal systems that carry protein antigen and subsequently 
present such material to T lymphocytes, advancing the initiation of an immunological 
response (Harding et al, 1991; Filion et al, 1996). Therefore, the NAG assay was applied 
to test the effect of liposomal sample concentration and the levels of phagocytic activity 
induced by the various DDA-TDB based formulations. 
 
5.3.1. Effect of sample concentration upon resultant NAG release 
Macrophages, also known as professional phagocytes, contain surface receptors capable of 
detecting foreign and dangerous particles (Robinson & Babcock, 1998; Ernst & Stendahl, 
2006) and can process high quantities of material (Cannon & Swanson, 1992). The 
process of endocytosis, whereby cells engulf and ingest particulates, can be categorised 
into two main types: phagocytosis (cellular eating) of large particles, typically greater than 
250 nm, and pinocytosis (cellular drinking) of smaller particles, soluble macromolecules 
or fluid and low molecular weight solutes, all of which are less than 200 nm in size 
(Silverstein et al, 1977; Kaisto, 2003). In order to measure the level of phagocytic activity 
in the present study, as all of the proposed liposomal adjuvant formulations were 
previously characterised to be greater than 250 nm in particle size and thus, will most 
likely become phagocytosed when encountered by macrophages, the release of NAG, 
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which is a lysosomal enzyme released by macrophages after phagocytosing particulate 
material (Mack et al, 1995), can be used as a marker of phagocytic activity. 
 
To optimise the concentration to be used within the assay, the effect of sample 
concentration on stimulating NAG activation was assessed at 2.5-15 µg/ml. As previously 
established for the MTS assay, the BALC/c cell number of 8x10
4
/ml was used for all 
NAG experiments with NAG enzyme release quantified in units per ml. DDA-TDB 
yielded the highest activation at 2.5 and 5.0 µg/ml, in the region of 0.8 units/ml (Figure 
5.5). However, beyond a sample concentration of 5.0 µg/ml, the level of calculated 
activity was significantly (P < 0.05) reduced, with DDA-TDB at 7.5, 10.0 and 15.0 µg/ml 
all generating NAG activity in the proximity of 0.4 units per ml, which was approximately 
half of the activation calculated at 2.5 and 5.0 µg/ml (Figure 5.5).  
 
 
Figure 5.5. Effect of DDA-TDB sample concentration on NAG activation. The BALB/c cell number of 
8x10
4
/ml at DDA-TDB concentrations of 2.5-15.0 µg/ml was tested. The calculated positive and negative 
control values were 45.07 and 0.04 units/ml respectively. Absorbance measurements were made from each 
concentration in triplicate, with mean values and standard error of the calculated NAG activation displayed. 
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5.3.2. Induced phagocytic activity upon replacement of DDA or substitution of DDA-TDB 
Phagocytic activity was ascertained via the NAG assay upon selected DDA-TDB 
replacement and substituted formulations as displayed in Table 5.1 (For a comparison of 
all the outlined DDA-TDB based formulations of this study, see Appendix 1). Together 
with DDA-TDB, partial and complete DDA replacement was tested with an intermediate 
level of substitution in order to cover a wide range of formulations that were 
physicochemically characterised previously (see Chapter 3).   
 
Table 5.1. DDA-TDB based formulations in which the main liposomal adjuvant was either substituted 
or replaced, prior to the evaluation of induced phagocytic activity and macrophage activation. 
 
 
After evaluating the effect of DDA-TDB sample concentration upon NAG activation, as 
previously set for the MTS assay, based on the concentration of the cationic component of 
DDA, the sample concentration of 5.0 µg/ml with 8x10
4
/ml BALB/c cells was applied to 
 
 DDA-TDB                     DDA  volume 
Formulation                       (µg/dose)                  
   
  Lipid volume 
 (µg/dose)    
       
 TDB volume   
        (µg/dose) 
  
   
DDA-TDB                                250 
 
 
             0 
 
50 
DDA/DPPC/TDB                     150 
 
DDA/DSPC/TDB                     150                
 
DDA-TDB-50% DPPC            125 
 
DDA-TDB-50% DSPC            125 
 
DPPC-TDB                                0                       
 
DSPC-TDB                                0 
100 
 
100 
 
165 
 
175 
 
250 
 
250 
50 
 
50 
 
25 
 
25 
 
50 
 
50 
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the outlined formulations in triplicate. This concentration was selected as it provided 
optimal detection of phagocytic activity via the NAG assay. 
 
DDA-TDB was found to stimulate the highest level of activation, producing 
approximately 0.8 units/ml (Figure 5.6). Partial replacement of DDA-TDB with either 
DPPC or DSPC, (DDA/LIPID/TDB at 150/100/50 µg/dose), elicited a significantly (P < 
0.05) lower volume of NAG activation compared to DDA-TDB, at ~0.6 units/ml (Figure 
5.6a). Furthermore, complete removal of DDA, as in the case of the DPPC-TDB and 
DSPC-TDB liposomes, generated a further significant (P < 0.05) reduction in the level of 
measured phagocytic activity, stimulating ~0.2 units/ml (Figure 5.6a), with no significant 
difference apparent between the DPPC and DSPC based formulations.  
 
Interestingly, the absence of DDA in the system did not completely eradicate NAG 
activation with activity remaining significantly higher (P < 0.05) than media alone, which 
may be due to the presence of the immunostimulatory glycolipid TDB and/or the larger 
particle size of the systems. Indeed despite the variation in recorded phagocytic activity in 
these tested liposomal formulations, NAG activation was stimulated by all of the proposed 
immunoadjuvants. As highlighted earlier, vesicle size, especially particles greater than 250 
nm, is a key factor influencing the onset of phagocytic activity (Kaisto, 2003) and the 
observed levels of NAG activation in the present study were stimulated by the proposed 
systems, previously characterised to be within the size range of approximately 500-2000 
nm. 
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Figure 5.6a. Stimulation of NAG activation upon replacement of DDA within DDA-TDB. NAG 
activation was calculated with 8x10
4
/ml BALB/c cells
 
at 5.0 µg/ml. Values represent the volume (µg) of 
DDA, DPPC or DSPC and TDB per 200 μl dose. The positive and negative controls generated 42.35 and 
0.04 units/ml respectively. The mean and standard deviation of three independent experiments are displayed. 
 
In consideration of vesicles where the DDA:TDB ratio was locked but reduced in 
concentration (Fig 5.6b), whereby both DDA and TDB concentrations were reduced  
(DDA/TDB + 50% DPPC or DSPC: which is equivalent to a dose of 125 µg DDA, 25 µg 
TDB and 165 µg DPPC or 175 µg DSPC; Table 5.1), activation levels were also 
significantly (P < 0.05) reduced when compared to the DDA-TDB liposomes, to the 
region of 0.3 units per ml, with no significant difference apparent between the systems 
when either substituting lipid of DPPC or DSPC was used (Figure 5.6b).  
 
Interestingly, this level of activation represents half the recorded level of the partially 
replaced DDA-LIPID-TDB systems (Figure 5.6a) which contained slightly more DDA 
content and twice the volume of TDB (50 µg), and as both these sets of formulations have 
been previously characterised in this study to be of a comparable particle size, the 
difference in response demonstrates the potentiating effect of TDB upon the formulation. 
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Figure 5.6b. NAG activation induced by DDA-TDB and its substitution with DPPC or DSPC. 
Phagocytic activity was indicated by NAG activation with 8x10
4
/ml BALB/c cells at a sample concentration 
of 5.0 µg/ml. Results shown are the mean average and standard deviation of three independent experiments. 
 
5.4. Determination of macrophage activation upon quantification of TNF-α 
In the context of immunisation against TB, the TNF-α cytokine mediates many positive 
factors as it leads to formation and maintenance of granulomas to control the latent TB 
infection, supports apoptosis of macrophages infected with MTB and enhances the 
maturation of APCs, which facilitates antigen presentation to the lymph nodes to then 
prime T cell subsets and ultimately clear the pathogen (Wang et al, 2009). In addition, 
TNF-α increases macrophage function and is therefore an indicative marker of 
macrophage activation and for the present study, the level of TNF-α cytokine secretion 
was quantified in response to varying liposomal sample concentrations and the DDA-TDB 
based formulations. 
 
5.4.1. Effect of sample concentration on mouse TNF-α cytokine production 
The previously observed NAG activation signifies liposomal uptake via the endocytic 
pathway, and the onset of phagocytic activity is determined by attachment to specific 
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PAMPs, ultimately leading to the activation of NF-κB, a protein complex that acts as a 
primary response to harmful cellular stimuli by initiating the transcription of pro-
inflammatory cytokines such as TNF-α (Chandel et al, 2000; Parham, 2005). In the 
present study, a mouse TNF-α ELISA development kit was applied to assess TNF-α 
cytokine release upon introducing the proposed liposomal adjuvants. 
 
Prior to testing the DDA-TDB based systems, the effect of sample concentration was 
determined, as previously conducted for the MTS and NAG assays, with DDA-TDB set to 
a range of concentrations between 2.5-15.0 µg/ml, with 8x10
4
/ml BALB/c cells. At a 
sample concentration of 2.5 µg/ml, DDA-TDB generated approximately 100 pg/ml of 
TNF-α (Figure 5.7). The peak of TNF-α cytokine activation produced by macrophages in 
the presence of DDA-TDB was induced at 5.0 µg/ml with approximately 200 pg/ml, 
generating a significantly (P < 0.05) higher level than the sample concentration of 2.5 
µg/ml (Figure 5.7). This result reinforces the selection of 5.0 µg/ml as the desired sample 
concentration to proceed with and to be applied to all subsequent in vitro ELISA 
experiments involving DDA-TDB based liposomes. In addition, DDA-TDB at 7.5, 10 and 
15 µg/ml resulted in significantly (P < 0.05) reduced levels of TNF-α to within the region 
of 100 pg/ml (Figure 5.7), which was comparable to the levels stimulated at the lowest 
DDA-TDB concentration initially introduced at 2.5 µg/ml.  
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Figure 5.7. Determination of macrophage activation using an enzyme-linked immunosorbent assay 
(ELISA) in the evaluation of the effect of DDA-TDB sample concentration on TNF-α secretion. The 
calculated negative control (DMEM) generated 25 pg/ml. Results represent the mean average for each 
concentration in triplicate, with error bars displaying the standard deviation from the mean. 
 
In general, after the peak of TNF-α release associated to DDA-TDB at 5.0 µg/ml, a 
sample concentration beyond this optimum level stimulated lower levels of activation. 
This can possibly relate to the results of the toxicity studies, indicated by the magnitude of 
cell proliferation, in which fewer cells were able to survive in the DDA-TDB environment 
at higher concentrations. Therefore, these conditions render a diminished macrophage 
presence resultant from increased toxicity, consequently limiting the level of phagocytic 
activity and macrophage activation. 
 
5.4.2. Activation of TNF-α in response to DDA-TDB and its cationic replacement 
Following on from the effect of sample concentration studies, the TNF-α ELISA kit was 
applied to the DDA-TDB based formulations, as previously assessed for toxicity through 
the MTS cell proliferation assay and phagocytic activity via the NAG assay (Table 5.1). 
As reported earlier, DDA-TDB induced TNF-α release in the region of 200 pg/ml (Figure 
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5.8), and further replacement of DDA content stimulated significantly (P < 0.05) reduced 
TNF-α production in the proximity of 160 pg/ml (Figure 5.8), regardless of the replacing 
lipid used. DPPC-TDB and DSPC-TDB liposomes were found to generate comparable 
levels of macrophage activation to the partially replaced systems, quantified at ~140 pg/ml 
of the TNF-α cytokine (Figure 5.8). With DDA-TDB stimulating the peak of activity, 
incorporation of further lipids managed to induce comparable levels of the TNF-α, 
significantly beyond macrophage cells or the DMEM cell culture media alone, displaying 
the potential immunostimulatory adjuvant properties of the liposomal carrier systems.   
 
 
Figure 5.8. Quantification of TNF-α secretion indicative of macrophage activation using an enzyme-
linked immunosorbent assay (ELISA) in response to DDA-TDB and its cationic replacement with 
DPPC or DSPC lipid. All samples were subjected to a BALB/c cell number of 8x10
4
/ml at a sample 
concentration of 5.0 µg/ml. The data displayed is based on the mean average of three independent 
experiments, with error bars displaying the standard deviation from the mean. 
 
 
5.4.3. TNF-α stimulation from DDA-TDB substituted with additional lipids  
For the substituted DDA-TDB liposomes, all samples were set to 5.0 µg/ml as previously 
conducted. Substitution of DDA-TDB with 50 mol% DPPC or DSPC stimulated ~170 
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pg/ml of TNF-α, which was comparable to the levels generated previously in response to 
the partially replaced systems and was similarly lower than the levels produced by DDA-
TDB (Figure 5.9). As seen throughout all of the in vitro experiments conducted in this 
study, no significant difference in the measured outcome was observed regardless of the 
incorporated lipid of DPPC or DSPC to the DDA-TDB liposomes (Figure 5.9). 
 
 
Figure 5.9. Tumour necrosis factor alpha (TNF-α) enzyme-linked immunosorbent assay (ELISA) 
results for DDA-TDB substituted with DPPC or DSPC. All samples were subjected to a BALB/c cell 
number of 8x10
4
/ml at a sample concentration of 5.0 µg/ml. The calculated average was based upon the 
mean of three independent experiments, with error bars displaying the standard deviation from the mean.  
 
Interestingly, all formulations stimulated macrophage activation signified by TNF-α levels 
quantified per system. This was observed in relation to the significantly (P < 0.05) reduced 
cytokine levels produced by the macrophages alone and the negative control of DMEM 
growth media, at 42 pg/ml and 23 pg/ml respectively. One factor that all of the proposed 
adjuvant systems shared was the incorporation of TDB, which advantageously carries 
immunogenic properties that stabilise and enhance the adjuvant potency of DDA vesicles, 
acting as an immune potentiator for DDA response. However, due to the lipidic properties 
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of TDB, co-administration with an adjuvant such as DDA, recognised as a liposomal 
vaccine adjuvant delivery system, is required (Vangala et al, 2007; Davidsen et al, 2005).  
 
Furthermore, DDA is crucial in providing the net cationic charge of the system, yet 
cationic liposomes are recognised for their cytotoxic effect as they attain a higher affinity 
to cell surfaces, demonstrated earlier in this study with elevated levels of macrophage cell 
proliferation observed upon increased cationic replacement with either DPPC or DSPC 
lipid. However, Korsholm et al, (2007) proposed that cationic DDA liposomes promote 
uptake via endocytosis prior to disruption or fusion with internal cellular membranes, and 
that the delivery of associated antigen to cells occurs upon instant contact with the cell 
surface through electrostatic interactions prior to active antigen uptake and presentation, 
which is a key mechanism behind the adjuvant properties of cationic DDA liposomes. In 
addition, previous studies into DDA liposomes incorporating DSPC lipid demonstrated 
that antigen acquisition by APCs was dependent upon DDA concentration (Korsholm et 
al, 2007), whilst in this current study, it was apparent that DDA presence was pivotal to 
the recorded levels of phagocytic activity and macrophage activation in vitro, indicative of 
potential uptake and expression of the proposed liposomal formulations, reiterating the 
necessity of a cationic constituent within the multi-component immunoadjuvant system. 
 
5.5. Further studies into determining whether the in vitro cellular activity is due to DDA 
replacement or removal 
To consider if the above results linking DDA concentration to cellular toxicity and activity 
were due to the replacement of DDA with a zwitterionic lipid or the reduction of DDA 
concentration alone (i.e. the DSPC lipid played no role in the measured outcomes),  the in 
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vitro behaviour of DDA-TDB at a 5:1 (250/50 µg/dose – as previously assessed) and 2:1 
(100/50 µg/dose) weight ratio, in conjunction with a further partially replaced system of 
DDA/DSPC/TDB at 100/150/50 µg/dose, were tested alongside DSPC-TDB, which 
represented complete DDA replacement. DPPC formulations were not tested as no 
significant difference had been observed between the incorporation of DPPC or DSPC. 
 
As can be seen in Figure 5.10 with each of the three markers used, the presence or absence 
of DSPC within the formulations made no significant difference. Indeed, upon assessment 
of cell proliferation, there was no significant difference between DDA/DSPC/TDB at 
100/150/50 µg/dose and DDA-TDB (100/50 µg/dose) with both systems showing ~70% 
cell viability (Figure 5.10a). Although an increased sample concentration of 10.0 µg/ml 
reduced the calculated cell viability to ~60%, for both of these additional systems tested, 
again no significant difference between the two formulations was observed (Figure 5.10a). 
 
Subsequently, when considering induced phagocytic activity, DDA-DSPC-TDB at 100-
150-50 µg/dose and DDA-TDB at 100/50 µg/dose produced levels of NAG activation 
which were not significantly different from one another (0.4-0.5 units/ml; Figure 5.10b). 
This demonstrates that the presence or absence of DSPC makes no significant difference. 
 
Finally, when considering the level of macrophage activation induced (Figure 5.10c), 
TNF-α cytokine production was not significantly different between DDA-DSPC-TDB at 
100-150-50 µg/dose and DDA-TDB at 100/50 µg/dose, again demonstrating that the 
reduced concentration of DDA in the formulation (rather than an increased DSPC 
concentration) is influencing the in vitro parameters evaluated within macrophage cells. 
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Figure 5.10. Cell viability (A) NAG activation (B) and TNF-α secretion (C) upon further replacement 
of DDA within the DDA-TDB adjuvant system. Formulations were set to 5.0 µg/ml (unless otherwise 
stated) with 8x10
4
/ml BALB/c cells. Calculations were made on triplicate wells per formulation (n=3 ± SD). 
C 
B 
A 
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5.6. Conclusions 
The cytotoxic effect of DDA within the main DDA-TDB liposomal immunoadjuvant was 
apparent as an increased concentration of cationic content decreased the measured cell 
viability of BALB/c mice cells. Such a trend was demonstrated upon increased DDA 
replacement within DDA-TDB as complete cationic replacement with DPPC-TDB and 
DSPC-TDB generated elevated levels of macrophage cell proliferation. Additionally, 
DDA-TDB substituted with DPPC or DSPC at 25-75 mol% favourably reduced the 
associated toxicity of DDA-TDB, potentially providing a safer delivery system as cell 
viability increased by 20-30%. 
 
The peak of phagocytic activity and macrophage activation was generated by DDA-TDB, 
and upon adjustment via replacement or substitution, the stimulated activity decreased. 
However, macrophages can be seen to recognise and trigger cellular activity in response to 
the liposomal carrier systems in vitro, demonstrated as macrophage activation signified by 
TNF-α secretion was also induced. Such cellular processes that permits invading material 
to be engulfed and ingested, crucially initiates the primary stages that lead to generating 
targeted immunity, particularly in response to the administration of a liposomal 
immunoadjuvant.  
 
With previous physicochemical characterisation and stability studies, together with 
morphological and thermodynamic analysis, these in vitro experiments add to the profile 
produced for the replaced and substituted DDA-TDB based liposomal adjuvants, required 
in order to ascertain key aspects controlling their efficacy. It is understood that a cationic 
presence increases the associated toxicity, observed through resultant inhibition of cell 
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proliferation. However, from the current data, the addition of zwitterionic lipids in 
conjunction with TDB boosted cell proliferation levels in comparison to DDA-TDB, 
whilst phagocytosis and macrophage activation was also induced, readdressing a balance 
between adjuvant potency and safety. The effectiveness of the BALB/c cell line and its 
use to screen the outlined liposomal adjuvant delivery systems will be evaluated and 
assessed upon future in vivo immunological studies, which may also confirm whether the 
cellular processes stimulated are dependent upon a reduced DDA presence or further lipid 
incorporation.  
 
To conclude, the parameters characterised to date demonstrate the potential of the 
proposed liposomal immunoadjuvants in stimulating an immune response and thus, 
suffice as proficient systems for vaccine delivery in vivo. Indeed, the DPPC based 
liposomal formulations will be considered for potential pulmonary vaccine delivery, and 
the DSPC based systems will be assessed in a mouse model upon intramuscular injection 
as part of an immunisation study involving the novel H56 vaccine for TB.   
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6.1. Introduction 
6.1.1. Hybrid 56 vaccine antigen 
The necessity for preventive, post exposure TB vaccines that can be administered to 
latently infected individuals has been recognised (SSI, 2010). Subunit vaccines based on 
antigens from mycobacterium TB in conjunction with an adjuvant that stimulates a strong 
Th1 type cellular immune response offer promising potential (Aagaard et al, 2011). One 
post exposure vaccine candidate known as Hybrid56 (H56 vaccine) is designed to prevent 
the reactivation of TB to those with the latent form of the TB infection. The H56 vaccine 
consists of the Ag85B-ESAT-6 fusion molecule with the addition of the Rv2660 latency 
antigen (Figure 6.1) (SSI, 2010).   
 
 
 
 
 
Figure 6.1. The post exposure H56 vaccine candidate which combines the fusion protein Ag85B-
ESAT-6 with Rv2660 antigen. (Figure adapted from SSI, 2010). 
 
 
Studies have shown that whole blood from individuals with the latent TB infection (LTBI) 
incubated with the Rv2660 mycobacterial antigen induced elevated levels of the IFN-γ 
cytokine, which is indicative of macrophage activation and a key marker of cell mediated 
immunity, when compared with patients that developed the active form of TB. LTBI 
individuals were also found to preferentially recognise Rv2660 and produced an increased 
number of viable T cells, justifying the use of the Rv2660 latency antigen and its 
integration into candidate TB vaccines (Govender, 2010). 
 
 
Ag85B 
 
 
 
 ESAT-     
6 
 
 
Rv2660 
Hybrid 56 antigen (H56 vaccine) 
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A viable approach for a post exposure vaccine is to specifically target mycobacteria in the 
inactive phase of infection. A vast array of potential latency antigens and numerous 
protein antigens have been assessed for their suitability in providing protective efficacy 
against TB reactivation. One such combination is the H56 vaccine against TB, in which 
post exposure vaccination in a mouse model of latent TB was found to proficiently control 
the infection. Preclinical data has indicated the potential of H56 vaccine delivery for 
protection against mycobacterium TB, as incorporation into the novel IC31 adjuvant 
capably induced T and B cell responses. As a result, the H56 vaccine is being put forward 
into a phase I clinical trial, scheduled for 2011, to test individuals infected with latent TB 
(SSI, 2010). 
 
In the present study, the aim of this chapter was to immunologically characterise the 
DDA-TDB based liposomal formulations as adjuvant delivery systems for the promising 
H56 vaccine candidate against TB. Alongside the assessment of DDA replacement within 
DDA-TDB, as some toxicity was observed for the main adjuvant system, the DDA:TDB 
ratio remained fixed (as this has previously been shown to be an important factor) yet the 
total dose of DDA:TDB was reduced upon substitution with DSPC lipid. Therefore, 
consideration was given to whether just DDA, the ratio of DDA:TDB or both factors were 
crucial to the resultant adjuvanticity of the formulation. 
 
6.2. Preliminary studies – optimisation of the splenocyte proliferation assay 
6.2.1. The effect of cell number and concanavalin A upon splenocyte proliferation 
To investigate the potential of the DDA-TDB based adjuvants in potentiating an immune 
response to the H56 antigen, prior to the immunisation studies including evaluation of 
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splenocyte proliferation, initial studies were conducted to optimise the protocol for this 
assay. Tests were conducted upon albino NMRI mice which were humanely culled before 
their spleens were dissected. Spleen cell numbers were adjusted to a range of 
concentrations from 6.25 X 10
5 
to 4.0 X 10
7 
cells per ml (Table 6.1) in order to ascertain 
an optimum number of cells to be cultured. 
 
Table 6.1. Tested cell numbers in the optimisation of their effect upon splenocyte proliferation.  
 
 
 
 
 
 
 
 
 
 
 
Alongside the assessment of cell number, the effect of concanavalin A (ConA) 
concentration was also observed in order to optimise its use for the main immunisation 
study. ConA is widely applied in biological studies and for these particular in vivo 
experiments, ConA was used as a positive control as it is known to stimulate the 
proliferation of T lymphocytes. Various ConA concentrations ranging between 0-10 µg/ml 
were tested upon the adjusted cell numbers and after culturing the spleen cells in triplicate 
 
Cell number  
per ml 
 
Equivalent number 
of cells per well  
(per 100 μl) 
 
 
0 
 
6.25 X 10
5       
 
 
1.25 X 10
6       
 
 
2.5 X 10
6       
 
 
5.0 X 10
6       
 
 
1.0 X 10
7       
 
 
2.0 X 10
7       
 
 
4.0 X 10
7       
 
 
 
0 
 
6.25 X 10
4       
 
 
1.25 X 10
5       
 
 
2.5 X 10
5       
 
 
5.0 X 10
5      
 
 
1.0 X 10
6      
 
 
2.0 X 10
6      
 
 
4.0 X 10
6       
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per cell number and incubating the samples for 72 hours in RPMI growth medium, all 
wells were pulsed with 0.5 µCi [
3
H]thymidine and incubated for a further 24 hours. 
During this incubation period, the proliferating cells incorporated various levels of 
[
3
H]Thymidine, depending on the number of cell divisions that took place, and thus, the 
measured counts for radioactivity represented the extent of stimulated cell proliferation.  
 
For the tested cell numbers, it was observed that an increase in splenocyte cells in turn 
elevated the level of proliferation (Figure 6.2). This trend continued towards a maximum 
response at the cell number of 5.0 X 10
6 
cells per ml and at a ConA concentration of 2 
µg/ml. Beyond this cell number at 1.0, 2.0 and 4.0 X 10
7 
cells per ml, the increased 
concentration of cells decreased the level of splenocyte proliferation, as beyond the 
observed peak cell number, an increased presence of cells per ml had a detrimental effect. 
 
Furthermore, with the maximum cell number for proliferation coinciding with a ConA 
concentration of 2 µg/ml, ConA at 1 and 3 µg/ml was also found to stimulate comparably 
high levels of splenocyte proliferation for the optimum cell number of 5.0 X 10
6 
cells per 
ml (Figure 6.2). Below and above the positive control concentration range of 1-3 µg/ml, 
the level of splenocyte proliferation was significantly lower (P < 0.05), regardless of the 
cell number (Figure 6.2). 
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Figure 6.2. The effect of cell number and ConA concentration upon the proliferation of splenocyte 
cells. The selected cell numbers ranged from 0-4x10
7
 cells/ml at ConA concentrations of 0-10 µg/ml. 
Results denote the mean and standard error from triplicate wells of naive spleens from albino NMRI mice. 
 
6.2.2. The effect of pulsing activity and incubation time upon splenocyte proliferation 
After establishing an optimised cell number and ConA concentration of 5.0 X 10
6 
cells per 
ml and 2 µg/ml respectively, these parameters were fixed for all future splenocyte 
proliferation assays. Subsequently, the effect of pulsing activity and incubation time was 
analysed after culturing splenocyte cells for 72 hours. A range of [
3
H]thymidine activity 
levels were tested at 0, 0.25, 0.75 and 1.0 µCi, upon 4, 8, 16 and 24 hours of incubation. 
 
It was observed that the lowest amount of [
3
H]Thymidine activity used (0.25 µCi) to pulse 
the splenocytes also coincided with the lowest levels of spleen cell proliferation (Figure 
6.3). However, increasing the pulsing activity to 0.5, 0.75 and 1.0 µCi did increase the 
detection of cell proliferation, represented by higher counts per minute (Figure 6.3). This 
trend generally occurred in conjunction with an increased incubation time. Furthermore, 
great levels of variation was evident in the samples pulsed with 0.75 and 1.0 µCi, with no 
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significant difference displayed between the time points of 16 and 24 hours of incubation, 
particularly for 0.5 µCi activity and beyond (Figure 6.3). Therefore, as 0.5 µCi of 
[
3
H]thymidine activity used to pulse the splenocyte cells provided the least variation 
across all of the tested time points, coupled with relatively high counts indicative of 
splenocyte proliferation, this concentration at a time point of 24 hours was deemed the 
most suitable for the proliferation experiments, when characterising the immunological 
effect of the liposomal systems to be tested in the immunisation study.   
 
 
 
Figure 6.3. The effect of pulsing activity and incubation time upon the proliferation of splenocyte cells. 
The cell number was fixed to 5x10
6
 cells/ml with a ConA concentration of 2 µg/ml. Results denote the mean 
average and standard error from triplicate wells of naive spleens from albino NMRI mice. 
 
To summarise, based upon these preliminary studies using naive NMRI spleens, the 
optimised parameters for the assessment of splenocyte proliferation are as follows:  
 Cell number: 5.0 X 106 cells per ml, 
 ConA positive control: 2 μg/ml, 
 Radioactive pulsing activity of [3H]Thymidine: 0.5 µCi, 
 Incubation time: 24 hours. 
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6.3. Immunisation study: determination of immune responses to a novel TB vaccine 
6.3.1. H56 vaccine groups 
Upon extensive characterisation of the DDA-TDB based systems, a range of replacement 
and substitution formulations were put forward to be evaluated and analysed as part of an 
immunisation study into the immunological efficacy of the proposed liposomal adjuvants. 
The extent of splenocyte proliferation, specific IgG antibody production and cytokine 
secretion was assessed for all of the tested groups. The study was conducted over seven 
weeks with five scheduled bleeds on days 0, 9, 24, 37 and 49 respectively. C57BL/6 mice 
were immunised three times with 5 µg of H56 antigen with injections made 
intramuscularly (0.05 ml/dose) on days 0, 14 & 28, maintaining two week intervals 
between each immunisation, as previously conducted (Christensen et al, 2007a; Agger et 
al, 2008). 
 
Sera from each individual mouse were obtained in order to evaluate the antigen specific 
antibody production stimulated by each vaccine group. Termination of the mice took place 
on day 50 prior to developing spleen cell suspensions for subsequent assessment of 
splenocyte proliferation and antigen specific cytokine responses. A total of 55 female 6-8 
week old C57BL/6 mice under a standard mouse diet were split into 11 vaccine groups 
(n=5 mice per group) as summarised in Table 6.2. The liposomal formulations that formed 
9 of the 11 tested groups were prepared and characterised for their particle size and zeta 
potential before and after antigen adsorption (Table 6.3), prior to each of the three 
intramuscular immunisations that took place. 
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Table 6.2. Immunisation study: vaccine groups tested for immunological analysis with the novel TB 
vaccine candidate, H56 antigen. Female 6-8 week old C57BL/6 mice were split into 11 groups of 5. The 
naive and antigen groups were accompanied by nine DDA-TDB based formulations accommodating various 
levels of DSPC lipid. Weights stated are all in µg per dose and mg per ml of Tris buffer.    
 
 
6.3.2. Characterisation of liposomes upon H56 vaccine antigen adsorption   
The liposomes were produced as previously conducted via lipid hydration and rehydrated 
in Tris buffer. Empty DDA-TDB liposomes were characteristically found to be ~500 nm 
with a cationic zeta potential of 50 mV (Table 6.3). The reduced weight ratio of DDA-
TDB at 2:1 (DDA-DSPC-TDB at 100/0/50 µg/dose), replacement of DDA and further 
replacement within this adjuvant system generated liposomes with a mean particle size of 
600-800 nm, maintaining a zeta potential of 50 mV. Complete cationic replacement with 
the DSPC-TDB liposomes generated significantly larger vesicles (P < 0.05) at two 
micrometres in particle size with a neutral to slightly anionic zeta potential, contrasting the 
formulations that contained DDA (Table 6.3). The systems incorporating 25-75 mol% 
 
Vaccine 
Group 
 
Formulation 
 
DDA/LIPID/TDB 
(µg/dose) 
 
DDA/LIPID/TDB 
(mg/ml) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
Naive 
 
H56 Antigen 
 
DDA-TDB 
 
DDA-DSPC-TDB 
 
DDA-DSPC-TDB 
 
DDA-DSPC-TDB 
 
DDA-DSPC-TDB 
 
DDA-DSPC-TDB 
 
+25% DSPC 
 
+50% DSPC 
 
+75% DSPC 
 
 
/ 
 
/ 
 
250/0/50 
 
 150/100/50 
 
 100/150/50 
 
           100/0/50 
 
         50/200/50 
 
          0/250/50 
 
         188/88/36 
 
        125/175/25 
 
         62/264/14 
 
/ 
 
/ 
 
1.25/0.00/0.25 
 
0.75/0.50/0.25 
 
0.50/0.75/0.25 
 
0.50/0.00/0.25 
 
0.25/1.00/0.25 
 
0.00/1.25/0.25 
 
0.94/0.44/0.18 
 
0.62/0.88/0.13 
 
      0.31/1.32/0.07 
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DSPC were also 600-800 nm in particle size coinciding with a cationic zeta potential also 
measured at 50 mV. The polydispersity of all the unloaded formulations were in the 
proximity of 0.3, suggesting a polydisperse population of liposomes (Table 6.3). Such 
findings for particle size and zeta potential coincide with results previously obtained in 
this study (Chapter 3). 
 
For the proposed in vivo liposomal preparations, the main adjuvant system for example, 
consisted of DDA and TDB at a dose of 250 µg and 50 µg respectively (5:1 weight ratio) 
with H56 antigen adsorbed at 5 µg/50 µl dose. Upon surface adsorption of H56 antigen at 
the fixed dosage form to the cationic systems of DDA-TDB, its reduced weight ratio, the 
partial replacement of DDA and substitution of DDA-TDB with DSPC, the injected 
formulations had all risen significantly (P < 0.05) to a mean particle size of ~1500 nm 
(Table 6.3). The exception to this increase in size was observed with DSPC-TDB, in 
which the addition of antigen produced vesicles just under two microns, displaying no 
significant change in particle size. The polydispersity ranged from 0.2-0.4 for all 
formulations (Table 6.3). Furthermore, the zeta potential of all the liposomal vaccine 
groups was also characterised, representing a key indicating factor into the antigen 
retention properties of the formulations and therefore, their potential in stimulating a 
particular immune response. All of the tested systems exhibited no significant change in 
the measured zeta potential or any difference to one another, as the positively charged 
DDA-TDB based liposomes remained strongly cationic at 50 mV (Table 6.3). The DSPC-
TDB liposomes were also found to remain slightly anionic, showing no apparent 
difference to their empty counterparts upon antigen adsorption in dosage form for the 
immunisation of mice, as summarised in Table 6.3. 
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Table 6.3. Particle size, polydispersity and zeta potential of the liposomal vaccine groups characterised before and after H56 antigen adsorption, applied 
for the three immunisations of mice during the 7 week in vivo study. Results displayed are the mean average from three independent batches produced ± the 
standard deviation. Measurements were made using one i.m. vaccine dose (50 µl) taken from a batch used for each immunisation, per liposome formulation. 
 
 
 
Formulation 
(µg/dose) 
 
PS  
(nm) 
(empty) 
 
 
P.D. 
(empty) 
 
 
ZP 
(mV) 
(empty) 
 
 
PS 
(nm) 
(+H56) 
 
 
P.D. 
(+H56) 
 
 
ZP 
(nm) 
(+H56) 
 
 
DDA-TDB 
(250/50) 
 
 
506.4 ± 73.4 
 
0.32 ± 0.01 
 
48.9 ± 3.7 
 
1019.2 ± 327 
 
0.36 ± 0.01 
 
47.2 ± 3.9 
DDA-DSPC-TDB 
(150/100/50) 
 
813.8 ± 11.9 0.29 ± 0.05 50.8 ± 2.7 1383.3 ± 227.9 0.38 ± 0.02 49.2 ± 2.5 
DDA-DSPC-TDB 
(100/150/50) 
 
644.8 ± 67.3 0.32 ± 0.02 49.9 ± 3.9 1503.0 ± 303.8 0.39 ± 0.04 50.5 ± 2.5 
DDA-DSPC-TDB 
(100/0/50) 
 
559.6 ± 52.6 0.34 ± 0.01 43.7 ± 5.6     1391.6 ± 86.2 0.36 ± 0.11 48.4 ± 6.4 
DDA-DSPC-TDB 
(50/200/50) 
 
559. 9 ± 90.3 0.32 ± 0.01 50.7 ± 2.8 1400.0 ± 364.9 0.43 ± 0.05 47.3 ± 0.9 
DDA-TDB 
+25%DSPC 
 
798.0 ± 30.3 0.34 ± 0.01 50.3 ± 3.1 1589.7 ± 159.2 0.44 ± 0.05 48.9 ± 5.4 
DDA-TDB 
+50%DSPC 
 
653.9 ± 49.5 0.32 ± 0.01 50.1 ± 3.6 1610.5 ± 103.2 0.39 ± 0.01 50.7 ± 2.8 
DDA-TDB 
+75%DSPC 
 
734.1 ± 113.7 0.33 ± 0.02 50.7 ± 3.5 1486.0 ± 183.5 0.33 ± 0.10 51.9 ± 1.9 
DSPC-TDB 
(250/50) 
 
1846.7 ± 115.2 0.24 ± 0.07 -8.0 ± 5.4     1730.8 ± 95.8 0.31 ± 0.05  -7.5 ± 5.2 
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6.3.3. Production of anti-H56 IgG, IgG1 and IgG2b antibodies 
6.3.3.1. Replacement of DDA in DDA-TDB: effect upon H56 specific antibody production 
Sera collected at regular intervals throughout the vaccine immunisation study were 
analysed by an ELISA for antibody mediated H56 specific responses to DDA-TDB and 
the systemic variations of this adjuvant, as outlined in Table 6.3 (for the full immunisation 
schedule, see appendix 2). For IgG and IgG1 isotypes, the liposomal adjuvants stimulated 
comparable serum antibody levels, regardless of the cationic adjustment that took place, 
and were all significantly (P < 0.05) higher than the non adjuvanted H56 antigen group, 
particularly by day 37 and 49, which represented the peak of antibody production (Figures 
6.4 A & B). Additionally, it was observed that mice immunised with DSPC-TDB 
demonstrated an early response with significantly (P < 0.05) elevated IgG and IgG1 
antibody titres compared to all other vaccination groups on day 9 (Figures 6.4 A & B). 
 
In contrast, IgG2b antibody levels showed more dependence on the level of DDA content 
(Figure 6.4 C), as DDA-TDB, its partial replacement with DDA-DSPC-TDB at 
150/100/50 μg/dose and its reduced concentration at 100/0/50 μg/dose, produced the 
highest levels of IgG2b antibody titres, with further and complete cationic replacement of 
the liposomal adjuvant generating significantly (with a probability value of at least P < 
0.01) decreased levels of antibody production (Figure 6.4 C). Additionally, all liposomal 
adjuvants generated a significantly (P < 0.05) higher IgG2b antibody response than the 
H56 antigen group, with the exception of DDA-DSPC-TDB at 50/200/50 μg/dose and 
DSPC-TDB at the later stages of the study (Figure 6.4 C).    
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Figure 6.4. Mean serum H56 specific antibody titres generated by DDA-TDB and its cationic 
replacement with DSPC for A: IgG, B: IgG1 and C: IgG2b subsets. Values represent μg/dose, with sera 
collected before the first immuinsation and on days 9, 24, 37 and 49 thereafter, prior to analysis for anti-H56 
antibodies by ELISA. Results signify the positive reciprocal end point dilution (log10) compared with 
untreated control sera (n=5 +/- SE). Significance is illustrated as n.s. (not significant) or *p<0.05 increase 
compared to H56 vaccination group, with DDA-TDB compared to equivalent IgG2b responses on day 49. 
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6.3.3.2. Substitution of DDA-TDB: effect upon H56 specific antibody production 
After assessing the effect of replacing DDA within DDA-TDB, substitution with DSPC 
represented a reduction in the total dose of DDA:TDB, rather than just a reduced DDA 
concentration. DDA-TDB and substitution with 25, 50 and 75 mol% of DSPC elicited 
comparable levels of IgG and IgG1 antibody production, with all liposomal adjuvants 
generating significantly (P < 0.05) higher antibody titres than delivery of H56 antigen, 
particularly from day 37 onwards (Figures 6.5 A & B). Interestingly, evaluation of IgG2b 
antibodies showed that DDA-TDB and substitution with 25 and 50 mol% DSPC generated 
the highest levels, with no significant difference between these groups, whilst producing 
significantly more IgG2b titres than the H56 group (Figure 6.5 C). However, compared to 
these systems, further DDA-TDB substitution with 75 mol% DSPC generated a highly 
significantly (P < 0.001) reduced level of IgG2b antibody titres, and was not significantly 
different to the response induced upon administration of H56 antigen alone (Figure 6.5 C), 
as seen previously when DDA was further reduced within the formulation (Figure 6.4 C). 
 
From the H56 antigen specific antibody responses observed upon delivery of the proposed 
liposomal adjuvants, the measured levels of IgG2b titres suggest a Th1 type cell mediated 
immune response, induced by partial DDA replacement and substitution of DDA-TDB 
with DSPC and by the reduced concentration of DDA-TDB (at a 2:1 weight ratio), which 
may be administered without greatly compromising the immunogenic effect of DDA-
TDB, recognised as a delivery vehicle capable of inducing cellular immunity vital for 
protection against TB (Ager et al, 2008). However, further spleen cell proliferation and 
cytokine analysis can confirm whether cellular immunity is elicited by these particular 
systems, and to the extent between each liposomal-H56 vaccine adjuvant group. 
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Figure 6.5. Mean serum H56 specific antibody titres generated by DDA-TDB and its substitution with 
DSPC at 25-75 mol% for A: IgG, B: IgG1 and C: IgG2b subsets. Sera was collected prior to the first 
immuinsation and on days 9, 24, 37 and 49 respectively thereafter, prior to analysis for anti-H56 antibodies 
by an ELISA. Values represent the positive reciprocal end point dilution (log10) compared with untreated 
control sera (n=5 +/- SE). Significance is illustrated as n.s. (not significant) or *p<0.05 increase compared to 
the H56 vaccination group, with DDA-TDB compared to equivalent IgG2b isotype responses on day 49. 
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Previous studies have assessed the effect of vesicle size on the immunoadjuvancy of 
DDA-TDB liposomes as experimental adjuvants for subunit TB vaccine delivery 
(Henriksen-Lacey et al, 2011b), observing that the extent of the Th1 type immune 
response, signified by IFN-γ and IgG2b serum antibody levels, was not significantly 
affected by the wide range of DDA-TDB sizes tested. With DDA-TDB consistently 
stimulating cell mediated immunity, such findings indicate that the aforementioned effect 
upon adjuvant potency is dictated more by the immunostimulatory combination of DDA 
and TDB, and is less influenced by liposomal size. 
 
Therefore, in relation to the findings of the present study, the replacement of DDA-TDB 
was found to generate medium sized vesicles in the nanometre range, with the exception 
of complete DDA replacement resulting in a larger system within the micrometre range. 
However, production of IgG and IgG1 antibodies were comparable across all systems 
regardless of the level of cationic adjustment or particle size of the adjuvants, with no 
apparent difference between IgG2b levels for DDA-DSPC-TDB at 50/200/50 μg/dose and 
DSPC-TDB, which represented a significant difference in liposomal size, reaffirming the 
immunostimulatory effect of TDB due to its fixed presence in this set of formulations. 
 
The variation in IgG2b antibody production can be attributed to the varying presence of 
DSPC within the liposomal adjuvants, observed upon further DDA replacement and upon 
substitution of DDA-TDB, as increased DSPC incorporation lowered IgG2b antibody 
levels and thus, the Th1 response. With elevated DDA-TDB substitution coinciding with 
reduced DDA and TDB content, the presence of this cationic lipid in conjunction with the 
immunostimulatory glycolipid plays a pivotal role in the resultant immunogenic effect.  
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6.3.4. H56 antigen specific splenocyte proliferation 
6.3.4.1. The effect of replacing DDA content within the DDA-TDB adjuvant 
The proposed DDA-TDB based adjuvants were also assessed for antigen specific spleen 
cell proliferation upon re-stimulation with H56 antigen at the concentrations of 0, 0.05, 
0.5, 5 and 25 μg/ml. All vaccination groups exhibited a concentration dependent trend, 
with DDA-TDB inducing the peak of proliferation, indicated by elevated levels of 
[
3
H]Thymidine (Figure 6.6). Furthermore, continual cationic replacement stimulated 
significantly (with a probability value of at least P < 0.01) less splenocyte proliferation, 
upon re-stimulation with H56 antigen at 0.05-25 μg/ml (Figure 6.6). More specifically, 
with DDA content being partially replaced out of DDA-TDB with DSPC at 150/100/50 
μg/dose, splenocyte proliferation was reduced, with another significant (P < 0.001) 
reduction observed upon further replacement at 100/150/50 μg/dose (Figure 6.6). 
However, the response is then seen to significantly (P < 0.001) rise again for the lower 
concentration of DDA (100/0/50 μg/dose) and upon higher DSPC incorporation 
(50/200/50 μg/dose), with no significant difference in proliferation levels between these 
two systems and partial DDA replacement (Figure 6.6). 
 
In addition, H56 antigen delivery via DSPC-TDB liposomes, representing complete 
replacement of DDA content, induced the lowest levels of splenocyte proliferation, and 
was not significantly different to the response induced upon further cationic replacement 
with DDA/DSPC/TDB at 100/150/50 μg/dose at all antigen concentrations (Figure 6.6). 
Interestingly, comparing DDA-DSPC-TDB at 100/150/50 μg/dose with the system of 
reduced DDA concentration at 100/0/50 μg/dose, suggests that the presence of DSPC is 
significantly (P < 0.001) reducing the stimulated levels of spleen cell proliferation. This 
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could also possibly be due to the dose of DDA, per adjuvant formulation, actually being 
higher in the DDA-TDB system at its reduced weight ratio of 100/0/50 μg/dose. 
 
With TDB present in all of the tested adjuvant formulations, an immunopotentiating effect 
will be apparent, but the presence of DDA in the liposomal formulation may enhance the 
co-delivery of antigen and adjuvant, ultimately strengthening the resultant immune 
response. This was apparent upon previous related studies into the immunological 
performance of DDA-TDB compared to DSPC-TDB, whereby liposomal cationic charge 
and antigen retention, provided by DDA, were recognised as vital properties for eliciting 
cellular immunity in response to a related Ag85B-ESAT-6 TB vaccine antigen candidate 
(Henriksen-Lacey et al, 2010b). Moreover, the presence of DDA greatly affected antigen 
presentation in vivo, as administration of DDA-TDB resulted in prolonged antigen 
retention at the site of injection compared to DSPC-TDB, possibly providing more 
effective antigen presentation by APCs which resulted in stronger immunity in response to 
DDA-TDB, characterised by elevated IFN-γ and IL-17 cytokine production (Henriksen-
Lacey et al, 2010b). Thus, the reduced response of DSPC-TDB in the present study 
demonstrates the necessity of DDA in the liposomal adjuvant system, not only in 
providing the cationic charge required to retain antigen, but also to elicit the clonal 
expansion of spleen cells in the stimulation of antigen specific immunity. 
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Figure 6.6. Spleen cell proliferation in response to stimulation/re-stimulation with H56 antigen upon 
replacement of cationic content within DDA-TDB. Formulation values represent μg/dose, with DDA-
TDB and DSPC-TDB set to a 5:1 weight ratio (DDA/DSPC/TDB at 250/0/50 and 0/250/50 μg/dose 
respectively). H56 antigen specific splenocyte proliferation was indicated by the level of [
3
H]Thymidine 
incorporation into cultured splenocytes at antigen concentrations of 0-25 μg/ml. ConA was used as a 
positive control at 2μg/ml with all counts in the region of 100,000 CPM. The results displayed denote the 
mean average for each group with associated standard error at n=5. Significance is illustrated between the 
liposomal vaccination groups, and comparisons shown against one another are upon re-stimulation with H56 
vaccine antigen at 25 μg/ml. 
 
6.3.4.2. Substitution of DDA-TDB with varying levels of DSPC lipid 
To investigate if the DDA:TDB ratio was an important factor, DDA-TDB and substitution 
with 25-75 mol% DSPC was also evaluated for H56 specific spleen cell proliferation. 
DDA-TDB was found to generate the highest level of splenocyte proliferation (Figure 
6.7), however, substitution with DSPC significantly (P < 0.05) reduced the recorded levels 
of proliferation compared to DDA-TDB, with no significant difference in the response 
displayed for 25 and 50 mol% DSPC incorporation (Figure 6.7). DDA-TDB substituted 
with 75 mol% DSPC induced a further significant (P < 0.05) reduction in response 
compared to substitution with 25 and 50 mol% DSPC, and was consistently low in terms 
of spleen cell proliferation, even with re-stimulation at higher concentrations of H56 
antigen, as beyond 0.5 μg/ml, cell proliferation was not significantly affected (Figure 6.7). 
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Figure 6.7. Spleen cell proliferation in response to stimulation/re-stimulation with H56 antigen upon 
substitution of DDA-TDB with DSPC. The extent of H56 antigen specific splenocyte proliferation was 
determined by the level of [
3
H]Thymidine incorporation into cultured splenocytes at antigen concentrations 
of 0-25 μg/ml. As a positive control, ConA was used at 2μg/ml which generated approximately 100,000 
CPM. The results displayed denote the mean average for each group together with the calculated standard 
error at n=5. Significance is illustrated between the liposomal vaccination groups, and comparisons shown 
against one another are upon re-stimulation with H56 vaccine antigen at the concentration of 25 μg/ml. 
 
Overall, the liposomal adjuvants were found to promote substantially higher responses 
compared to mice immunised with free H56 antigen. Moreover, DDA-TDB and its 
substitution with DSPC, from as low as 0.5 μg/ml re-stimulation of antigen, induced 
significantly higher levels of proliferation (P < 0.001) in comparison to the non-
adjuvanted H56 group. Such an antigen specific recall response being triggered at low 
concentrations of H56 re-stimulation could be beneficial, and in this regard, the use of a 
liposomal adjuvant was essential to eliciting a response. 
 
Upon extensive examination, the DDA adjuvant has been shown to induce moderate Th2 
type immunity and strong Th1 type immunity (Hilgers & Snippe, 1992), and as 
highlighted earlier, incorporation of TDB potentiates the immune response of DDA, 
eliciting stronger antigen specific Th1 type immunity (Davidsen et al, 2005). Furthermore, 
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studies into the relationship between vesicle charge and immunoadjuvancy have shown 
that cationic liposomes encourage further uptake by DCs, compared to their neutral 
counterparts (Foged et al, 2004). Positively charged liposomes have also demonstrated 
efficient uptake by macrophages, with cationic systems containing OVA found to induce 
higher levels of antibody and antigen-specific cytotoxic T lymphocyte responses than 
equivalent anionic and neutrally charged liposomes (Nakanishi et al, 1997). In addition, 
incorporation of DSPC has impacted upon the adjuvant action of liposomal delivery 
systems, with partial incorporation to DDA-TDB stabilised with cholesterol, reducing 
protective immunity (McNeil et al, 2011), and complete incorporation, in the substitution 
of DDA in DDA-TDB, also found to greatly decrease cellular immune responses upon 
immunisation with the H1 vaccine (Henriksen-Lacey et al, 2010b). 
 
With all the substituted DDA-TDB adjuvants in the present study found to induce antigen 
specific spleen cell proliferation, the variation in response can be attributed to the various 
levels of DDA, TDB and DSPC in the proposed liposomal delivery systems. Substitution 
of DDA-TDB suggests that the observed splenocyte proliferation responses was affected 
by increased DSPC incorporation, as this in turn reduced the DDA adjuvant properties of 
the system and the immunopotentiating affect of TDB. Additionally, the responses 
exhibited were irrespective of the zeta potential of the vesicle composition, as these 
systems were previously characterised for attaining a comparable cationic zeta potential. 
 
6.3.5. Quantification of cytokines   
Having characterised antigen specific spleen cell proliferation and antibody levels, in 
order to fully appreciate the extent and type of immunity stimulated, cytokine levels were 
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subsequently examined. A variety of cytokines were tested for their H56 antigen specific 
responses to the proposed DDA-TDB based vaccine delivery systems. Quantification of 
the cytokines, IL-2, IL-5, IL-6, IL-10 and IFN-γ in the cultured splenocyte cell 
suspensions took place via specific sandwich ELISA experiments. 
 
Cellular immunity is vital to mediating intracellular pathogens such as MTB, with IFN-γ 
believed to be the greatest indicator of a Th1 type immune response (Sable et al, 2007). 
IL-2 is specifically generated by Th1 cells and is essential to T-cell proliferation and its 
consequent differentiation. In the context of in vitro splenocyte re-stimulation, IL-2 is 
indicative of cellular immunity as it is not generated by B cells (Vangala et al, 2007). IL-
6, produced from Th2 type cells and monocytes, can act as both a pro-inflammatory and 
anti-inflammatory cytokine, interchangeable between Th1 and Th2 type immune 
responses. Contrastingly, interleukins 5 and 10 are associated with Th2 type responses. 
IL-5 is known to stimulate the growth and differentiation of B cells and enhance 
immunoglobulin secretion, whilst IL-10 down-regulates the expression of Th1 cytokines.  
 
6.3.5.1. Replacement of DDA in DDA-TDB: effect upon H56 specific cytokine production 
Upon immunisation with DDA-TDB, high levels of IFN-γ were observed with partial 
replacement with DSPC (150/100/50 µg/dose) stimulating comparably high levels in the 
region of 4000 pg/ml (Figure 6.8 A). DDA-TDB at a 2:1 weight ratio also stimulated 
substantial levels of IFN-γ however, further replacement within DDA-TDB coinciding 
with increased DSPC incorporation reduced IFN-γ production (Figure 6.8 A). Notably, 
DSPC-TDB liposomes generated minimal levels of the IFN-γ cytokine, in line with the 
naive and H56 vaccine groups (Figure 6.8 A). Such a trend was mirrored in the quantified 
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levels of IL-2, whereby DDA-TDB at a 5:1 and a 2:1 weight ratio alongside its partial 
replacement (150/100/50 µg/dose) represented the peak of IL-2 production, with DSPC-
TDB stimulating comparatively low levels of this Th1 type cytokine (Figure 6.8 B). 
 
For IL-6 production, reduced levels were seen across the vaccine groups (below 100 
pg/ml) with the exception of DDA-TDB (at a 5:1 or 2:1 weight ratio) together with partial 
DDA replacement at 150/100/50 µg/dose, generating at least 200 pg/ml, with 
immunisation of DDA-TDB-H56 (5:1) found to generate the highest recorded levels at 
400 pg/ml (Figure 6.8 C). Furthermore, quantified levels of IL-5 and IL-10, indicative of a 
potential Th2 type immune response, interestingly provided polarised formulation results, 
determined by levels of these cytokines produced when administered with the variety of 
DDA-TDB based vaccine adjuvants (Figure 6.8 D and E). Both sets of observed cytokine 
levels displayed little variation in the tested vaccine groups despite the level of cationic 
replacement, including the naive and H56 non-adjuvanted groups, until the highest level 
of DSPC was introduced to the formulation (Figure 6.8 D and E). This was evident in IL-5 
and IL-10 production exhibited for DDA-DSPC-TDB at 50-200-50 µg/dose and DSPC-
TDB, whereby significantly (P < 0.05) elevated cytokine levels were detected, particularly 
upon re-stimulation with 5 μg/ml of H56 antigen (Figure 6.8 D and E), suggesting a Th2 
bias for these DSPC enriched systems. 
 
This polarised trend contrasted the effect of DDA-TDB against DSPC-TDB liposomes as 
adjuvants for the immunisation of mice with H1 antigen, whereby no significant 
difference in IL-5 production was apparent (Henriksen-Lacey et al, 2010b). Moreover, an 
interesting significant difference between DDA-TDB and the uppermost levels of DSPC 
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incorporation was observed, specifically for DDA-DSPC-TDB at 50-200-50 μg/dose, 
characterised for attaining a net cationic charge yet shown to favour Th2 type immune 
responses, comparable to the anionic DSPC-TDB liposomes. As a result, it can be deemed 
that the immunological adjuvant effect was indeed influenced by the level of DDA content 
and replacement with DSPC and not by the zeta potential of the liposomes, corroborating 
previously related findings for total DDA replacement shown by Henriksen-Lacey et al, 
(2010b). Consequently, from the findings of this study, DDA-TDB based adjuvants can be 
produced with a comparable zeta potential, but upon further DDA adjustment, can be 
tailored to bias a particular desired immune response, demonstrating the flexibility of such 
liposomes as vaccine delivery systems. 
 
In summary, DDA-TDB displayed a strong Th1 type immune response, characterised by 
elevated levels of IFN-γ and low IL-5 cytokine production, correlating with previous 
studies (Holten-Andersen et al, 2004; Davidsen et al, 2005; Henriksen-Lacey et al, 
2011b). Interestingly, partial cationic replacement produced a formulation that 
successfully incorporated the zwitterionic lipid of DSPC at the expense of DDA content, 
whilst eliciting a Th1 mediating effect comparable to levels induced by DDA-TDB, 
immunologically assessed and confirmed for H56 antigen specific spleen cell 
proliferation, IgG2b antibody production and cytokine secretion. 
 
However, further incorporation of DSPC shifted the bias towards Th2 type immunity, 
indicated by specific cytokine responses and antibody levels recorded in this study. 
Indeed, the choice of adjuvant can greatly impact the immune response, with vaccine 
design intending to induce targeted, efficacious and prolonged immunity upon vaccination 
Chapter 6 - Characterisation and immunological analysis of liposomal TB vaccine delivery systems 
 
 215 
(Lima et al, 2004). With the promising potential of the DDA-TDB adjuvant being 
recognised as a strong Th1 inducer, a switch to a protective Th2 type humoral immunity, 
upon particular levels of DSPC incorporation seen in the current study, can be of value for 
the treatment of other diseases. For example, delivery of Merozoite surface protein 1 
(MSP1) and glutamate rich protein (GLURP) malarial antigens, using DDA and DDA-
TDB adjuvants combined with a non-ionic surfactant of 1-monopalmitoyl glycerol (MP) 
and cholesterol, induced a Th2 type humoral response signified by proficient IgG1 
antibodies, vital for protection against Malaria (Vangala et al, 2006). Partial incorporation 
of DSPC in this study provided elements of a Th1 and Th2 type response, which has been 
induced by other related liposomal vaccine candidates, demonstrating a required 
multifaceted response for protection against Chlamydia (Agger et al, 2008) and Influenza 
(Christensen et al, 2010). 
 
Furthermore, adjustment of the DDA/DSPC content may be favourable for the delivery of 
alternative antigens, particularly for those that possess a high isoelctric point (pI) and 
consequently require an anionic adjuvant to associate to the carrier system via electrostatic 
interaction. Examples of such protein antigens include the model lysozyme antigen and 
the “CTH1” Chlamydia vaccine, which have a pI of 11.0 and 9.0 respectively (Henriksen-
Lacey et al, 2010b), thus at physiological pH, attain a net cationic charge. Therefore, with 
careful manipulation of the liposomal adjuvant formulation, vaccine delivery can be 
accommodated for an array of antigens whilst generating a desired immunological effect. 
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Figure 6.8. Spleen cell cytokine production after re-stimulation with H56 antigen at 0, 0.5 and 5 μg/ml, quantified for A: IFN-γ, B: IL-2, C: IL-6, D: IL-5 
and E: IL-10, upon DDA replacement in DDA-TDB with DSPC. Values represent μg/dose, with results of the mean average of five spleens per group +/- SE.
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Previous studies by McNeil et al, (2011) have also assessed the incorporation of TDB and 
DSPC into cationic DDA liposomes. These systems were further stabilised with 
cholesterol and upon immunisation with H1 antigen, good levels of IFN-γ cytokine release 
were measured but were lower than levels stimulated by DDA-TDB (McNeil et al, 2011). 
Moreover, the incorporation of DDA induced more IFN-γ than their neutral counterparts, 
demonstrating its necessity within the multi-component liposomal adjuvant for eliciting 
cellular immunity, enhanced further with TDB presence. Although the incorporation of 
DSPC and cholesterol decreased the level of protection provided by DDA-TDB, the 
neutral formulation of DSPC-Chol-TDB was found to generate protection upon MTB 
challenge, reiterating that liposomal surface charge was not the overriding factor behind 
adjuvant potency (McNeil et al, 2011). In general, it is understood that cationic liposomal 
adjuvants stimulate elevated IFN-γ cytokine levels and in the present study, adjustment of 
cationic content, by reducing the level of DDA within the formulation, demonstrates that 
increasing DSPC content reduced IFN-γ production (with the exception of initial DDA 
replacement at 150/100/50 μg/dose), and that the incorporation of DSPC allows for the 
liposomal adjuvant to be tuned with regards to the type of immunity required. 
 
Liposomal adjuvants have previously been shown to strengthen the immunogenicity of 
vaccines, with DDA-TDB liposomes desirably eliciting high cellular immunity against the 
subunit Ag85B-ESAT-6 antigen for TB (Davidsen et al, 2005; Vangala et al, 2006). The 
use of DDA-TDB has also been evaluated as an adjuvant delivery system for hepatitis B 
surface antigen, eliciting enhanced T cell derived responses (Vangala et al, 2007), whilst 
upon immunisation, also harbouring the ability to stimulate a combination of cellular and 
humoral immunity required for protection against Chlamydia, demonstrating the 
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versatility of such an adjuvant (Agger et al, 2008). Additionally, for protective efficacy 
against Chlamydia, upon immunisation of C57BL/6 mice with Chlamydia-specific 
membrane proteins in various adjuvants, DDA-TDB displayed the greatest protection 
characterised by higher IFN-γ and interleukin-17 cytokine responses, than the CpG 
oligodeoxynucleotide (CpG-ODN) adjuvant, recognised as a strong Th1 inducing agent, 
and the “AbISCO-100” (AbISCO) immunostimulating complex, which is known to elicit 
both Th1 and Th2 type immunity (Yu et al, 2010). 
 
Upon the replacement of DDA with DSPC assessed in this study, for some of the tested 
formulations, a favoured cell mediated immune response against the promising post 
exposure H56 vaccine antigen was achieved to an equivalent level to that of DDA-TDB. 
In addition, further DSPC incorporation has been shown to reduce the cytotoxicity upon 
macrophages (Chapter 5), which may provide a potentially viable formulation alternative 
to the highly promising DDA-TDB (CAF01) liposomal adjuvant, as a subunit vaccine 
delivery system.  
 
6.3.5.2. Substitution of DDA-TDB: effect upon H56 specific cytokine production 
Immunisation with DDA-TDB liposomes displayed elevated levels of IFN-γ and IL-2 and 
alongside this system, substitution with 25 mol% DSPC lipid induced comparable levels 
of these Th1 type cytokines, quantified between 3000-4000 pg/ml. Further incorporation 
at 50 mol% DSPC resulted in significantly reduced levels (P < 0.05) for both cytokines 
with 75 mol% DSPC incorporation into DDA-TDB inducing little to no IFN-γ or IL-2 
cytokine production, similar to that observed for the non vaccinated and non adjuvanted 
groups (Figure 6.9 A & B). 
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In terms of IL-6 production, with DDA-TDB representing the highest quantified levels, 
DDA-TDB-25 mol% DSPC exhibited significantly (P < 0.05) decreased production to 
almost half the generated level observed for DDA-TDB, with a further reduction seen 
upon 50 and 75 mol% substitution (Figure 6.9 C). Interestingly, for the assessment IL-5 
and IL-10, the naive and H56 non adjuvanted group induced similar levels in line with all 
other immunisation groups displaying little variation between the liposomal adjuvants 
(Figure 6.9 D & E). The exception to this was observed for DDA-TDB-75 mol% DSPC 
producing the highest levels of IL-5, and DDA-TDB substituted with 25 and 75 mol% 
DSPC also representing the peak of IL-10 production (Figure 6.9 D & E). 
 
In summary, the incorporation of 25 mol% DSPC was comparable to DDA-TDB in terms 
of its potential to initiate an antigen specific response in favour of cell mediated immunity. 
Furthermore, for the other immunological parameters characterised in this study, 
particularly for the presence of IgG2b antibodies and key cellular markers associated to a 
desired cellular immunity vital in providing protection against TB, such as IFN-γ and IL-
2, cytokine levels were also relatively as high as the optimum DDA-TDB adjuvant 
formulation, despite partial incorporation of DSPC lipid. 
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Figure 6.9. Spleen cell cytokine production after re-stimulation with H56 antigen at 0, 0.5 and 5 μg/ml, quantified for A: IFN-γ, B: IL-2, C: IL-6, D: IL-5 
and E: IL-10, upon DDA-TDB substitution with DSPC. The results displayed are the mean average of five spleens per vaccination group +/- SE.
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Interestingly, upon incorporation of DSPC at 75 mol%, the findings suggest a tendency 
towards a Th2 type immune response. With all systems found to produce equivalent levels 
of IgG and IgG1 antibodies, the IgG2b antibody subset together with cytokines typical of 
a Th1 type immune response examined in this study, provided key indications of bias 
towards a cell mediated immune response. With the varying levels of DSPC incorporation 
and the resultant immunological performance characterised, DSPC was successfully 
incorporated at a lower level providing a comparable formulation to that of DDA-TDB for 
a strong Th1 type response, whilst at higher levels of DSPC incorporation, producing a 
system skewed towards Th2 type activation, indicative of humoral immunity. Moreover, 
the cationic replacement adjuvant formulations portrayed a DDA dependent 
immunological effect, yet upon substitution with DSPC, in turn reducing both DDA and 
TDB content, the potentiating effect of TDB on the immune response of the adjuvants is 
demonstrated, evident as increased DDA-TDB substitution considerably altered the 
resultant immunological response. 
 
As highlighted earlier, although all of the substituted systems attained a net cationic zeta 
potential, the strength of immune response varied with an increased level of DSPC 
incorporation in the substitution of DDA and TDB, particularly at 75 mol%, generating 
immunity skewed towards a Th2 type response. It has been reported in the literature that 
DDA-TDB generally stimulates reduced levels of Th2 cytokines such as IL-5 (Christensen 
et al, 2007b). Despite the comparable cationic properties of DDA-TDB substituted with 
75 mol% of DSPC to that of DDA-TDB, findings in this study suggest a weak Th1 type 
cellular immune response upon the increased level of substitution. Therefore, the resultant 
Th2 type immune responses observed is stimulated by a heightened level of DSPC 
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incorporation and is not dependent on the zeta potential of the liposomal system, as 
previously demonstrated by the replacement of cationic content in this study and by 
Henriksen-Lacey et al, (2010b), whereby TDB incorporated liposomes were able to 
stimulate comparable levels of IL-5 cytokines, regardless of the zeta potential induced 
upon full incorporation of either DDA or DSPC. 
 
It is widely recognised that live vaccines offer stronger protection against TB in 
comparison to killed microorganisms (Collins, 1984), providing the basis behind increased 
attention towards proteins secreted from live mycobacteria to attain protective antigens 
(Brandt et al, 1996). The live BCG vaccine still remains the only currently available TB 
vaccine, but growing concerns over its safety, waning sensitivity and a highly variable 
efficacy have invigorated a push for a safer, more potent vaccine alternative (Anderson & 
Doherty, 2005). It has been demonstrated previously in the literature that protection 
against TB on par with BCG is achievable via subunit vaccination of a single purified TB 
antigen (Brandt et al, 2000). In this particular instance, C57BL/6 mice immunised with 
purified ESAT-6 emulsified in a DDA adjuvant displayed minimal inherent 
immunogenicity requiring a more effective adjuvant, whilst incorporation of Ag85B 
induced sustained CMI, characterised by higher IFN-γ release and a reduced bacterial load 
upon challenge. Although Ag85B and ESAT-6 are recognised during a natural TB 
infection, they both induced polarising levels of CMI when DDA liposomes were used as 
the adjuvant delivery system, upon which the addition of the immunostimulant MPL to 
DDA elicited ESAT-6-specific T-cell responses (Brandt et al, 2000). Therefore, the 
selection of a powerful immunoadjuvant is a vital influencing factor, even capable of 
boosting compatible molecules of previously decreased inherent immunogenicity. 
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Despite the development of novel TB vaccine candidates, the existing BCG vaccine is far 
from being replaced and with ongoing feedback from early phase clinical trials being 
attained, the efficacy and safety profile of proposed novel vaccine candidates can be 
improved (Kaufmann et al, 2010). H56 vaccine delivery via the established DDA-TDB 
(CAF01) liposomal immunoadjuvant has been shown to deter the maturation of TB to its 
active form, and thus provides the basis of clinical development (Aagaard et al, 2011). 
 
6.4. Conclusions 
The data presented demonstrates the necessity of an adjuvant system, evident from the 
notable levels of H56 specific splenocyte proliferation, particularly induced at low 
concentrations which could be a possible facet of the antigen. Furthermore, DDA presence 
within the adjuvant was a crucial factor as demonstrated upon partial replacement of DDA 
content within DDA-TDB or substitution of DDA and TDB, eliciting antigen specific cell 
mediated immune responses in a mouse model, signified by elevated levels of IgG2b 
antibodies and IFN-γ and IL-2 cytokines, vital for providing protection against TB. In 
addition, as DSPC content within the adjuvant formulation increased, either by DDA 
replacement or reduction of DDA and TDB, the response was skewed towards Th2 type 
immunity, coinciding with reduced IgG2b antibody levels and elevated IL-5 and IL-10 
cytokine production. 
 
Such findings demonstrated that minor adjuvant adjustment was sufficient to influence the 
resultant immune response, even when the DDA-TDB ratio was maintained. Overall, the 
role of DDA presence against DSPC within the DDA-TDB adjuvant was appreciated, 
whilst strengthening the potential shown by the promising H56 vaccine against TB.
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7.1. Introduction: vaccination via the pulmonary route 
Liposomes may be regarded as a potential carrier system for subunit antigen delivery via 
the pulmonary route as they can be produced from phospholipids which are commonly 
found within the respiratory tract as a constituent of pulmonary surfactant (Mihalko et al, 
1988). Furthermore, the use of pharmaceutical aerosols can accommodate competent drug 
delivery directly to the lungs (Crowder et al, 2001) and therapeutic liposomal aerosols 
have been shown to offer sustained drug release, eradicate local irritation, enhance drug 
potency and deliver active drugs locally (Gilbert et al, 1991; Parthasarathy et al, 1999).  
 
Inhalational therapy provides advantages compared to other mucosal pathways for 
immunisation as an increased presence of mucosal antibody titres in the respiratory tract 
may provide immediate protection against pathogens upon targeted delivery of therapeutic 
agents, particularly against those that infiltrate via the lungs, for example in the case of TB 
(Gelperina et al, 2005; Sou et al, 2011). Also, the lungs confer advantageous features such 
as an immense absorptive surface area and thin alveolar epithelium (Hussain et al, 2004). 
 
Indeed upon administration via this route, liposomes are engulfed by phagocytes and 
targeting liposome-encapsulated agents to alveolar macrophages of the lung is possible via 
inhalation (Myers et al, 1993), providing the opportunity of delivering antimicrobials and 
other drugs to such immune system cells intracellularly, which is of great consideration 
particularly for the treatment of pulmonary diseases of an intracellular nature (Thomas et 
al, 1991). Mycobacterium tuberculosis is a pathogenic bacteria species and is the main 
causative agent of TB (Ryan & Ray, 2003), with pulmonary TB constituting over 80% of 
TB infections worldwide. In addition, for protective efficacy against TB, subunit protein 
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vaccine delivery for local activity may induce a desired cellular immune response (Russo 
et al, 2000). Studies have demonstrated the potential of dry powders for pulmonary 
delivery, for example in the treatment of tuberculosis, whereby immunisation via the 
pulmonary route using an aerosolised spray dried form of 85B mycobacterial TB antigen 
microparticles enhanced protection against the infection, reducing the bacterial burden 
within the lungs and the spleen upon challenge in a guinea pig model (Lu et al, 2010). 
 
When designing pulmonary vaccines, the inhalational device must be patient friendly 
whilst cost efficient to manufacture in order to economically scale up production for large 
immunisation projects, without causing any detrimental effects to the potency of the 
vaccine (Sou et al, 2011). Amongst the various methods of delivery, the use of pressurised 
metered dose inhalers (pMDIs) are popular as they offer a reliable, self contained, 
transportable and cheap aerosol delivery mechanism that can accommodate pulmonary 
drug targeting and the application of large and safe medicinal doses (Newhouse, 1991). In 
the present study, the aim of this chapter was to ascertain whether the DPPC based 
liposomal systems characterised earlier could be developed into a potential pulmonary 
vaccine for TB antigen delivery, to localise drug action in the lungs upon delivery via a 
pMDI system. In order to test these proposed liposomal adjuvants for potential pulmonary 
delivery, the formulations must be compatible with a solvent for delivery via a pMDI. 
 
7.2. Liposomal compatibility with ethanol 
To produce a liposomal pMDI sample, formulating liposomes in a solvent form was 
considered. Therefore, prior to testing the potential inhalational system for metered dose 
inhalation, if a medium can be used to transfer the dry pelleted liposome samples, 
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produced upon centrifugation, to a pressurised metered dose inhaler vial, with subsequent 
valve attachment and addition of a hydro-fluoroalkane (HFA) propellant, this would 
produce a suitable pressurised MDI suspension, to be tested and characterised further for 
its unique aerosolisation properties and suitability for pulmonary delivery. Indeed, 
utilisation of HFAs requires co-solvents, for example ethanol (Stefely, 2002) and the 
propellant system is a key constituent of a MDI formulation, acting as both a solvent and 
dispersion medium and an energy source for producing aerosol clouds upon actuation as 
the dose is released from the metering valve (Williams et al, 1998). 
 
Lipids are compatible with solvents such as ethanol and liposomes may be prepared from 
ethanol-based proliposomes, in which a proliposome solution of lipids dissolved in pure 
ethanol is converted to liposomes upon introduction of an aqueous phase (Perrett et al, 
1991). The addition of an aqueous phase beyond the Tm of the lipid produces such 
liposomes (Elhissi et al, 2006) and can be produced with high entrapment efficiencies for 
hydrophilic agents (Perrett et al, 1991). However, most attempts to develop proliposome 
technology for pulmonary delivery involve aerosolising such liposomes via nebulisation. 
Despite additional processing not being required, the aqueous liposomal dispersions 
necessary for nebulisation incur issues of stability, as during storage, the liposomal 
suspensions are subject to physical and chemical modifications that ultimately affect the 
vesicle composition, leading to eventual leakage of entrapped material (Niven et al, 1992; 
Darwis & Kellaway, 2001). Furthermore, recent studies using proliposomes for 
nebulisation achieved a high nebulisation output, yet further work is required to minimise 
losses of drug originally entrapped within such liposomes as sample sizes were reduced 
during nebulisation (Elhissi et al, 2011). 
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In this study, with pMDI selected as the method of liposomal delivery, an ideal solvent to 
be used would be a solution that provides a medium of transfer whilst being able to be 
removed relatively quickly. The use of ethanol allows for rapid vaporisation to occur so 
that contact with the vesicles is minimised, thus reducing possible detrimental effects on 
the system, and was therefore tested as a transfer medium. The chosen systems evaluated 
for their compatibility with ethanol were DDA-TDB (250-50 µg/dose), DDA-DPPC-TDB 
(150-100-50 µg/dose) and DDA-TDB-50%DPPC (125-25-165 µg/dose), as they represent 
the main adjuvant formulation and intermediate replacement or substitution with DPPC, 
the most prevalent phospholipid of pulmonary surfactant (Wright, 1990). These systems 
were tested alongside DDA liposomes and were characterised before and after ethanol 
exposure and upon protein adsorption to ascertain the effect of solvent on the liposomes. 
 
7.3. The effect of ethanol on the particle size and zeta potential of empty liposomes 
The empty liposomes were initially assessed for interactions with ethanol to investigate its 
effect on the lipid bilayers. The liposomes were prepared by lipid hydration and subjected 
to an equal volume of pure ethanol and then assessed for the resultant particle size, 
polydispersity and zeta potential over time (0-60 mins). Liposomes of DDA-TDB and 
partial replacement or substitution with DPPC were 500-700 nm with a polydispersity of 
~0.3 and a zeta potential of 50 mV (Figure 7.1), as previously characterised (Chapter 3). 
 
However, upon exposure to ethanol, all of the liposomal systems became significantly (P 
< 0.01) smaller (200-300 nm; Figure 7.1) compared to their non-exposed counterparts, and 
remained at this reduced size for up to 60 minutes (Figure 7.1). The polydispersity of the 
liposomes ranged between 0.1-0.4, whilst the zeta potential remained in the region of 50 
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mV, until interaction with ethanol for 60 minutes caused a significant (P < 0.05) decrease 
in zeta potential by ~30%, down to 35 mV (Figure 7.1). 
 
 
 
 
 
Figure 7.1. Effect of ethanol upon the particle size, polydispersity and zeta potential of A: DDA-TDB, 
B: DDA-DPPC-TDB (150-100-50 µg/dose) and C: DDA-TDB-50%DPPC liposomes over time. Results 
shown are the mean average of three experiments with error bars of the standard deviation from the mean. 
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It is apparent that upon exposure of the liposomal systems to ethanol, the pure solvent had 
interacted with and affected the vesicular structures as significantly smaller liposomes 
were formed. The effect of ethanol on liposomal permeability was studied by Komatsu & 
Okada, (1995), in which the leakage of fluorescent dye entrapped within the inner aqueous 
core of large unilamellar DPPC vesicles was observed. It is understood that when exposed 
to short chain alcohols, saturated phosphatidylcholines are capable of forming 
interdigitated regions, in which the methyl group within the acyl chains infiltrate the 
opposing monolayer. Moreover, findings indicated that the presence of ethanol at higher 
concentrations induced high permeability with leakage of the dye greatly increased as the 
original bilayer and interdigitated structure coexist with phase separation of the membrane 
and instability of the boundary regions, which is also the case even when the membranes 
were initially stabilised with cholesterol (Komatsu & Okada, 1997). 
 
A breakdown in the spherical geometry of liposomes may also occur upon ethanol 
interaction with small liposomes of saturated phospholipids due to the interdigitation of 
ethanol molecules (Ahl et al, 1994). In the present study, the reduced liposomal particle 
size observed upon ethanol exposure demonstrates the possible effect of ethanol on the 
phospholipid chains of the liposomes, with such intermolecular interactions disrupting and 
altering the original lipid bilayer structure and may be representative of a restructure into 
small unilamellar vesicle formation. 
 
In addition, alcohols have been shown to aggravate chain interdigitation of 
phosphatidylcholines such as DPPC or DSPC (Li et al, 1996), and as ethanol penetrated 
the liposomes, direct interaction with the pure solvent destabilised the vesicle structure 
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and not only affected the phospholipid acyl chain arrangements, it may have caused a 
secondary interaction with ethanol molecules associating to sites at the head groups of the 
bilayer surface (Rowe, 1983), thus affecting the original liposomal structural arrangement. 
 
7.4. Effect of ethanol exposure to liposomes adsorbed with protein 
Given that particulates of a cationic nature (although smaller in size and lower in cationic 
charge) were still formed after exposure to ethanol, studies progressed into considering 
cationic liposomes with adsorbed protein. Therefore, the above outlined liposomal 
systems were mixed with OVA protein (which acts as a model antigen) to a final 
concentration of 1 mg/ml, and again the effect of ethanol exposure was considered. More 
specifically, the liposomal samples were adsorbed with OVA and split into two prior to 
ultracentrifugation, with one resultant pellet redispersed in Tris buffer and the other in 
pure ethanol, which was subsequently removed via nitrogen streaming and resuspended 
back into Tris buffer for comparison, as summarised in Figure 7.2.  
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. A process map summarising the experiment conducted to directly compare the effect of 
Tris buffer vs. ethanol on the cationic liposomes adsorbed with OVA protein. 
Produce liposomes via lipid hydration in Tris buffer 
Surface adsorb 1 mg/ml OVA to the liposomes (split into 2) 
Subject the formulations to ultracentrifugation (2 sets per batch)  
 
Resuspend one pellet in Tris buffer  Suspend the other pellet in pure ethanol 
Evaporate off solvent by nitrogen streaming 
Resuspend back into Tris buffer 
Analyse Tris vs. ethanol exposed samples 
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Prior to ethanol exposure, the vesicles adsorbed with OVA in Tris buffer were between 2-
3 micrometres in particle size with a neutral to slightly anionic zeta potential (Table 7.1), 
whilst no significant difference was apparent between the formulations. However upon 
exposure to ethanol, liposomes of DDA, DDA-TDB and its partial replacement or 
substitution with 50 mol% DPPC were all found to be significantly (P < 0.05) smaller 
(~1500 nm; Table 7.1) than their Tris buffer counterparts. When considering the effect of 
ethanol on the cationic nature of the systems, all liposomes adsorbed with OVA were also 
shown to have a significantly (P < 0.05) increased zeta potential when compared to the 
neutral systems saturated with OVA in Tris buffer, as exposure to ethanol generated 
vesicles in the region of 15-20 mV (Table 7.1), suggesting a possible loss of adsorbed 
protein from the surface of the liposomes and/or a re-organisation of the structures. 
 
Subsequent morphological analysis via TEM demonstrated contrasting vesicle populations 
with an abundance of OVA generating aggregated particles in Tris buffer (Figure 7.3), 
which corroborated with the previously attained sizing data. Contrastingly, the ethanol 
exposed samples displayed more sparsely populated vesicles with more exposed surfaces 
compared to their Tris buffer counterparts (Figure 7.3). In addition, no apparent 
differences were observed between each of the DDA-TDB based cationic systems exposed 
to ethanol, with vesicles predominantly in a sub-micrometre size range, as observed in the 
previous measurements of particle size via DLS, with only minor traces of particle 
aggregation (Figure 7.3).  
 
 
Chapter 7 - The potential of liposomes as systems for pulmonary vaccine delivery 
 
 233 
Table 7.1. Particle size, polydispersity and zeta potential of liposomes adsorbed with OVA at 1 mg/ml in Tris buffer or exposed to ethanol and 
redispersed back into Tris buffer. Results displayed are the mean average +/- the standard deviation of at least three independent experiments. 
 
 
 
Formulation 
 
 
Particle size  
(nm) 
(Tris buffer) 
 
 
Polydispersity 
(Tris buffer) 
 
Zeta potential 
(mV) 
(Tris buffer) 
 
Particle Size 
(nm) 
(ethanol exposed) 
 
Polydispersity 
(ethanol exposed) 
 
Zeta potential 
 (mV) 
(ethanol exposed) 
 
DDA 
 
 
2063.9 ± 383.6 
 
0.60 ± 0.04 
 
6.0 ± 3.8 
 
909.2 ± 169.3 
 
  0.43 ± 0.01 
 
17.6 ± 2.3 
 
DDA-TDB 
(250-50 µg/dose) 
2753.3 ± 410.6 0.24 ± 0.11 3.6 ± 4.3 1315.8 ± 396.7   0.49 ± 0.31 27.2 ± 3.6 
 
DDA-DPPC-TDB  
(150-100-50 µg/dose) 
 
3213.3 ± 370.2 
 
0.59 ± 0.29 
 
-1.9 ± 2.6 
 
1194.1 ± 128.6 
   
 
  0.50 ± 0.18 
 
   
  14.8 ± 11.5                          
 
 DDA-TDB-50% DPPC 
 (125-25-165 µg/dose) 
 
 
3589.0 ± 350.5 
 
0.38 ± 0.15 
 
 
-1.2 ± 2.0 
 
 
1947.5 ± 808.3 
 
 
  0.42 ± 0.13 
 
  19.8 ± 11.4 
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                 Tris                                                                   Ethanol 
 
DDA-TDB + 1 mg/ml OVA 
 
                                
 
 
                 Tris                                                                  Ethanol 
 
DDA-DPPC-TDB + 1 mg/ml OVA 
 
                                              
 
   
                 Tris                                                                  Ethanol 
 
DDA-TDB-50% DPPC + 1 mg/ml OVA 
 
Figure 7.3. TEM micrographs of cationic liposomes with OVA in Tris buffer vs. ethanol exposure. All 
liposomes were surface adsorbed with OVA at 1 mg/ml and were prepared by lipid hydration in Tris buffer.  
1 µm 
1 µm 
1 µm 
1 µm 
1 µm 
1 µm 
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Holte & Gawrisch, (1997) suggested that at higher concentrations of ethanol 
incorporation, such as the pure form used in this study, non-specific surface binding with 
bilayers is induced. Thus, the causation of vesicle instability is also possible, as any bonds 
and intermolecular interactions contributing to maintaining the vesicle structure may be 
disrupted, and it is possible that exposure of the systems to ethanol has caused a 
restructure of the vesicles and affected the associated protein structure, therefore 
potentially reducing the inter particle attraction between the vesicles. 
 
Indeed interactions of ethanol with proteins can affect their structure and function as such 
proteins can become unstable and poorly soluble (Pace et al, 2004). The addition of 
ethanol causes proteins in solution to precipitate out. This process occurs due to a decrease 
in the dielectric constant, in turn decreasing solubility. Ethanol readily associates with 
water to a much greater extent than it does with proteins, effectively causing dehydration 
of proteins at the surface (Oss, 1989). The organic solvent can continue to displace water 
from protein surfaces that binds into hydration layers coating the ethanol molecules. Thus, 
the protein molecules are exposed of hydration layers, yielding protein aggregation. 
Hydrogen bonding is pivotal to protein structure and important to the stabilisation of 
proteins, with the α-helix and β-sheets of protein molecules recognised as fundamental 
structural components in the composition of proteins. Relatively weak intermolecular 
forces, such as hydrogen bonds and van der Vaals forces, facilitate the intricate folding of 
proteins. However, exposure to ethanol can modify this complex protein structure and 
denature its original form (Mirsky & Pauling, 1936; Pauling et al, 1951).  
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Indeed a notable difference in visual appearance between the OVA solutions in Tris buffer 
vs. ethanol was apparent, as precipitates observable in the pure solvent demonstrated the 
immiscibility of protein in pure ethanol, contrasting the miscibility of OVA in Tris buffer, 
as it dissolved into a clear solution (Figure 7.4). When the ethanol was evaporated off and 
redispersed back into Tris buffer, the OVA failed to dissolve into a completely clear 
solution as some precipitates were present. This would suggest that upon exposure of the 
liposomal-protein constructs to ethanol, the proteins become insoluble and precipitate, and 
are therefore possibly lost from the vesicles. To investigate this further, antigen loading of 
the vesicles before and after ethanol exposure was investigated.  
 
 
                                                                      
  
            OVA in Tris                        OVA in Ethanol 
Figure 7.4. Comparison of 1 mg/ml OVA in Tris buffer vs. ethanol. 
 
7.5. Radiolabelled antigen retention 
The effect of ethanol exposure to cationic liposomes was analysed to determine the extent 
of resultant protein adsorption to the vesicles against identical systems in Tris buffer. 
OVA protein was radiolabelled with I
125
 to directly track the level of antigen retained. 
DDA was selected to represent the cationic liposome systems and was surface adsorbed 
with radiolabelled OVA to a final concentration of 1 mg/ml. Upon adsorbing the DDA 
liposomes with OVA-I
125
, subsequent ultracentrifugation separated the samples into 
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liposome associated and non-associated protein. Once the systems had undergone two 
ultracentrifugation steps to remove unbound material, one half of each pelleted batch was 
suspended in either Tris buffer or exposed to pure ethanol. The batch suspended in Tris 
buffer had undergone two further ultracentrifugation steps, with the ethanol samples, upon 
solvent removal via nitrogen streaming and reconstitution in Tris buffer, also centrifuged a 
further two times to allow for a direct comparison to be made between the Tris and 
ethanol exposed DDA-OVA/I
125 
adsorbed
 
systems. Gamma counts for the original total, 
supernatant and pellet samples were used to calculate the level of protein association. 
 
The results in Table 7.2 show that after removal of the initial non-associated OVA, 87% 
of OVA was retained by the DDA liposomes, and this was not significantly changed by 
further incubation in Tris buffer as described above. However after exposure to ethanol, 
OVA retention was significantly reduced (P < 0.001) to 24.4% (Table 7.2), demonstrating 
that exposure to the pure solvent resulted in protein loss from the vesicles and support that 
the change in zeta potential noted in Table 7.1 is a result of protein loss. 
 
Table 7.2. Levels of OVA/I
125
 retention to DDA liposomes before and after exposure to ethanol. Results 
represent the mean average and the standard deviation of three independent experiments. 
 
 
 
Additionally, in the context of the delivery mechanism used for inhalation, ethanol is 
commonly utilised to enhance the drug solubility of formulations for metered dose 
 
 
Formulation 
 
 
OVA retained 
from the initial 
batch in Tris (%) 
 
 
OVA retained after 
being redispersed 
in Tris (%) 
 
OVA retained upon 
exposure to ethanol 
(%) 
 
 
DDA 
 
87.3 ± 2.6 
 
87.2 ± 2.6 
 
 
24.4 ± 11.6 
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inhalation, however, the volume of solvent used must be minimised as when the level of 
solvent introduced to the MDI rises, the aerosol particles become rougher in texture which 
hinders the aerosolisation performance (Johnson, 1997). In the present study, if interaction 
with ethanol maintained a comparable level of antigen retention to Tris buffer, this may 
have facilitated further development into a pulmonary delivery system via metered dose 
inhalation. However this was not the case, and the detrimental effect of ethanol on the 
liposomal structure and associated protein, later confirmed to affect the high retention of 
radiolabelled OVA adsorbed to the cationic vesicles, renders the use of ethanol unviable. 
 
7.6. Drawbacks and disadvantages associated to liposomal pulmonary vaccine delivery 
Prior to continuing the development of a pulmonary TB vaccine and taking into account 
the efficacious potential of aerosolised antigen delivery, the obstacles associated to such a 
route of delivery were considered. For example, despite an immediate onset of action upon 
targeting the respiratory system, this period is typically limited as the delivered material 
may be rapidly cleared from the lung through a variety of clearance mechanisms in the 
upper respiratory region such as impaction, sedimentation and interception, which clears 
particulates and prevents deeper deposition into the lungs. It is also understood that 
regardless of the aerosolisation device used, patients will need regular dosing throughout 
the day to achieve a desired level of protection (Johnson, 1997; Joshi & Misra, 2001). 
 
Crucially, the therapeutic and toxic drug concentration must be considered, with a 
compromise between pharmacological activity and safety of primary importance when 
formulating vaccines (Zeng et al, 1995). Although cationic liposomes can favourably 
enhance antigen retention and the resultant immunostimulatory effect, a major drawback 
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in the use of these cationic systems is the associated cytotoxicity which often suppresses 
their development into pulmonary vaccines. Li & Mitra, (1996) studied pulmonary 
absorption of liposome-insulin complexes and established that the capability of liposomes 
in facilitating pulmonary protein absorption relied upon the surface charge, concentration 
and acyl chain length of the lipids used. Moreover, despite the cationic liposomal systems 
triggering the greatest hypoglycaemic response compared to their anionic and neutral 
counterparts, toxicological studies demonstrated that charge inducing agents such as 
stearylamine, used to provide the liposomes with a positive charge, can result in the 
disruption of pulmonary epithelial cells (Li & Mitra, 1996). Indeed, other pulmonary 
studies involving positively charged liposomes have also concluded that cationic lipids are 
too toxic to the alveolar region (Sheule et al, 1997). 
 
In the present study, although increased lipid incorporation in the reduction of cationic 
content or adjuvant concentration reduced cytotoxicity (chapter 5), the optimum DDA-
TDB formulation induced the least macrophage cell proliferation and these particular 
systems may incur adverse effects upon administration to the respiratory tract. In addition, 
the macrophage cell line was utilised as a general model to consider the viability of the 
proposed immunoadjuvants, yet assessment of nanoparticle toxicity and safety elicited 
upon delivery to the lung provides a great challenge when developing novel systems. 
Indeed, when considering the fate of nanomedicines in the lungs, the use of in vitro cell 
exposure studies using pulmonary cell systems has been recognised for its potential to 
screen nanoparticulate toxicity. However, further development is required in order to 
accurately examine the biological impact of nanoparticulate delivery via the pulmonary 
pathway (Paur et al, 2011). 
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7.7. Conclusions 
It was established from the investigation of ethanol as a possible transfer medium for a 
pMDI system that minimal exposure altered the properties of the liposomes and the 
systems adsorbed with protein. Indeed ethanol caused a restructure of the liposomes and 
the protein induced aggregation displayed in Tris was less apparent upon interaction with 
ethanol, which cleared the protein at the surface and minimised the level of inter particle 
attractions. Subsequent studies of DDA liposomes with radiolabelled OVA confirmed that 
ethanol unfavourably displaced the adsorbed antigen, as equivalent samples in Tris buffer 
showed a high level of radiolabelled OVA retention.  
 
An alternative approach to using a solvent based system for pMDI is the dry powder 
format to produce particulates and allow for performance characterisation and 
development of a potential pulmonary vaccine to commence. Freeze and spray drying are 
two methods that could be considered to prepare liposomal dry powder formulations. 
Freeze drying is regarded as the method of choice for preparing liposomal dry powders, 
especially for liposomes encapsulating proteins, peptides or enzymes (Lu & Hickey, 
2005). Spray drying is also a suitable method for preparing micron-sized powders for 
aerosolisation, as it can control particle formation and be easily translated to large scale 
production. However, upon evaluation of the use of cationic liposomal systems and their 
associated toxic effect upon delivery via the pulmonary route, further work into 
developing an aerosolised pulmonary vaccine delivery system was not undertaken.    
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8. General discussion and conclusions 
The propose of vaccination is to provide effective immunity, and with continual 
elucidation of immunological mechanisms such as pathogen recognition, the role of 
adjuvants and gene expression, an ever increasing immunological understanding has 
paved the way for greater research into vaccination (Bramwell & Perrie, 2005). Indeed, 
considerable progress has lead to the understanding that vaccination is always considered 
as the best control strategy against any disease (Sable et al, 2007a).     
 
Tuberculosis, which is caused by the intracellular pathogen of mycobacterium 
tuberculosis, is no exception as over 80% of the world’s population is already vaccinated 
against TB with the live attenuated BCG vaccine. However despite such efforts, TB is one 
of the most deadly infectious diseases worldwide and this predicament has worsened since 
the onset of the MTB and HIV co-pandemic, intensifying the need for further 
development of new and improved prophylactic and therapeutic interventions (Sable et al, 
2007a). In addition, it is understood that for TB to be completely eradicated, a potent and 
cost effective vaccine for mass immunisation is required, and although BCG is readily 
available, it is estimated to prevent a mere 5% of all potential vaccine-preventable 
fatalities due to tuberculosis (Gupta et al, 2007).   
 
Consequently, TB vaccine development remains high on the global agenda and a major 
advancement towards the end of the 20
th
 century was determination of the genome 
sequence for the best-characterised MTB strain, H37Rv, as it fuelled the conception of 
novel prophylactic and therapeutic interventions. With the understanding that a promising 
antigen does not necessarily correlate to a proficient immunogen (Sable et al, 2007a), the 
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evolution of subunit vaccine design to enhance immunogenicity resulted in the fusion of 
the 6-kilodalton early secretory antigenic target (ESAT-6) to Ag85B, generating the H1 
vaccine. Such a combination is promising as the proteins are highly recognised T-cell 
antigens during the initial stage of infection and have been established to achieve 
protection within animal models (Olsen et al, 2001). This particular fusion protein vaccine 
candidate has been shown to elicit potent antigen specific cellular immunity, inducing Th1 
type cytokines and antibody responses in the C57BL/6 mouse model, stimulating efficient 
immunological memory upon delivery via DDA-MPL (Olsen et al, 2001), and DDA-TDB 
(Davidsen et al, 2005), which was later shown to increase monocyte infiltration at the site 
of injection upon H1 antigen deposition (Henriksen-Lacey et al, 2010a). 
 
Whilst the fusion of early secreted TB antigens have shown potential as an alternative to 
BCG, a post exposure vaccine that can provide protection against the late persistent stage 
of infection remains a high priority (Moreno-Mendieta et al, 2010). The Statens Serum 
Institut has developed a strategy for a post-exposure vaccine by targeting mycobacteria 
during the latent stage of infection. The emergence of one such candidate has been 
established by combining H1 with Rv2660c antigen forming H56 vaccine, a therapeutic 
subunit vaccine that can contain the infection upon challenge (Aagaard et al, 2011). 
 
Taking this into account and given that subunit vaccines can be potentiated by co-delivery 
with adjuvants, coupled with the promising CAF01 cationic liposomal formulation 
established in providing cellular immunity against TB (Davidsen et al, 2005), DDA-TDB 
formed the foundation of liposomal adjuvants tested in this study as subunit delivery 
systems for the H56 vaccine. The aim of this thesis was to further investigate the 
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physicochemical properties of DDA-TDB upon its cationic replacement or reduction in 
concentration by incorporating zwitterionic lipids of DPPC or DSPC, to ascertain the role 
of the cationic DDA lipid in the formulation. Furthermore, the DPPC based systems were 
assessed for possible pulmonary delivery and the characterised physicochemical and in 
vitro properties were correlated with their effectiveness in vivo, using the DSPC based 
formulations as delivery systems for the promising H56 TB vaccine.  
 
Initial work of this thesis concentrated on extensively characterising the DDA-TDB based 
formulations with the key focus at this stage being the evaluation of additional lipid 
incorporation and its resulting physicochemical properties. With the DDA liposomal 
adjuvant being previously optimised for TDB incorporation at 11 mol% (5:1 weight ratio) 
(Davidsen et al, 2005), this standard formulation was retained as TDB has been shown to 
potentiate DDA response and outperform an aluminium based adjuvant, which still 
remains one of the most widely used vaccine adjuvants (Davidsen et al, 2005). 
 
Our data had shown that DPPC or DSPC incorporation led to the formulations retaining a 
sub-micrometre particle size and a cationic zeta potential until complete DDA replacement 
took place. Furthermore, no difference at this stage was apparent upon the introduction of 
either supplementary lipid. Whilst DDA-TDB liposomes provide a cationic charge ideal 
for antigen absorption, possible issues of long term colloidal stability with such a 
combination have been countered upon TDB incorporation (Davidsen et al, 2005), yet 
despite a vast array of literature highlighting the potential of liposomal drug delivery, a 
lack of liposome based vaccines are currently available due to their weak physical stability 
in solution (Mohammed et al, 2010). Therefore, with incorporation of additional lipids at 
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the expense of DDA-TDB concentration, these formulations were subjected to stability 
trials, in which we observed the retention of vesicle size and zeta potential over time. The 
lack of aggregation or visible precipitates in both temperature conditions demonstrated 
that even upon increased lipid incorporation (up to 75 mol% of DPPC or DSPC), the 
physical stability of the systems could still be maintained. Such findings provided the 
springboard for further physicochemical investigation where we also discovered that the 
high retention of radiolabelled OVA associated to DDA-TDB, used as OVA is established 
as a protein standard (Huntington & Stein, 2001) and was utilised in this study as a model 
antigen, was reduced upon partial DDA replacement or substitution within DDA-TDB, yet 
upon an initial burst of protein release, levels were retained for the remainder of the 
experiment. In addition, the necessity of DDA in retaining antigen was clear when DSPC-
TDB liposomes failed to retain OVA over time. Also, dialysis of the liposome-OVA 
protein complexes provided a suitable means of assessing the proposed nano-particulate 
systems, with iodine labelling to OVA allowing for protein release to be tracked, whilst 
demonstrating the level of protein retention from the systems that were not subjected to 
any centrifugation methods to separate liposome associated and non-associated protein, 
thus, mimicking an in vivo preparation prior to administration. 
 
Subsequent assessment of liposomal interactions with serum proteins also demonstrated 
instantaneous serum induced aggregation in line with previous studies for related cationic 
systems (Henriksen-Lacey et al, 2010a; McNeil & Perrie, 2006). When DDA-TDB 
incorporated DPPC or DSPC, the liposomal complexes exhibited a charge dependent 
reaction as complete DDA replacement displayed no significant change in particle size or 
zeta potential upon exposure to serum proteins. These findings indicate that as a result of 
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serum interactions and the consequent switch to an anionic zeta potential, particularly for 
the cationic formulations, exposure to serum most likely induced liposome-serum 
complexes as opposed to serum induced vesicle disruption.   
 
With the understanding that efficient liposome delivery is influenced by the level of 
protein association (Korsholm et al, 2007), further examination of protein adsorption 
properties took place after saturating the systems with 1 mg/ml OVA. Whilst all cationic 
systems demonstrated particle aggregation, quantification of non-adsorbed protein did 
differentiate between the formulations, with SDS-PAGE confirming that either 
incremental replacement of DDA content or DDA and TDB substitution continually 
decreased the level of OVA associated to the system. Korsholm et al, (2007), when testing 
the adsorption capabilities of OVA to DDA vesicles, established a high level of adsorption 
to such liposomes which subsequently generated active protein uptake by DCs of murine 
bone marrow in vivo, with vesicles favourably delivering antigen to the cell membranes of 
APCs. The targeted antigen delivery achievable demonstrates the principal role of such 
cationic adjuvant systems, ultimately enhancing antigen uptake and submission. 
 
Microscopic analysis was conducted via TEM in order to examine the morphology of the 
liposomal systems, with images corroborating with earlier particle size analysis, 
displaying a heterogeneous population of spherical vesicle structures. However, whilst 
DPPC or DSPC lipid was assumed to be incorporated into DDA-TDB, thermodynamic 
analysis via DSC confirmed the nature of interactions between the multiple lipid 
components, as single broadened main melting peaks symptomatic of lipid interdigitation 
were apparent. Furthermore, DSC studies showed the first key difference between DPPC 
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or DSPC incorporation, with the formulations incorporating DSPC demonstrating elevated 
phase transition temperatures at approximately 10 °C higher than the DPPC equivalents, 
which can be attributed to the longer 18-carbon alkyl chains of DSPC. Interestingly, 
partial incorporation of DSPC, with DDA/DSPC/TDB dispersions at 150/100/50 µg/dose 
and substitution with 50 mol%, displayed an absence of detectable thermal events, which 
can be attributed to attaining an organised, intermediate liquid-ordered phase. We 
therefore learnt that with the behaviour observed for DDA-TDB, followed by its partial 
replacement or substitution, incorporation of additional lipids to a particular level was 
achievable without substantially hindering the resultant physicochemical properties, and at 
this particular stage, displayed characteristics of potential vaccine delivery systems. 
 
The in vitro studies conducted strengthened the potential of the proposed liposomal 
immunoadjuvants as a reduced net sample concentration, DDA lipid presence and DDA-
TDB concentration was observed to increase macrophage cell proliferation, and such a 
response is advantageous as toxicity limits the volume of cationic lipid that is offered to 
cells (Hofland et al, 1996). Therefore in this regard, although reduced cationic content and 
DDA-TDB dose had shown decreased antigen retention, the reduced cytotoxicity may in 
fact harbour an increased propensity of liposome-cell interactions and thus, increase the 
potential efficiency of the proposed immunoadjuvants. In addition, with an observed 
cationic DDA lipid and DDA-TDB concentration dependent effect upon induced 
phagocytic activity, levels of TNF-α cytokine secretion in response to the various 
liposomal formulations showed less variation, particularly upon DDA adjustment, as 
continual cationic replacement with either additional lipid elicited comparable levels of 
TNF-α. This tells us that whilst DDA presence undeniably impacts the adjuvant properties 
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of the formulation, as potential vaccine delivery systems, the immunopotentiating affect of 
TDB can still be retained within the formulation, despite further lipid incorporation and a 
reduced cytotoxicity, which Numata et al, (1985) shown in vivo, when TDB, a derivative 
of TDM, was compared to its synthetic analogue, demonstrating a reduced toxic effect 
whilst maintaining adjuvanticity. 
 
The various DDA-TDB based liposomes replaced or substituted with DSPC were 
considered as viable subunit vaccine delivery systems to be tested in vivo. In consideration 
of the route of administration, for a targeted cell mediated immune response, it has been 
reported that intramuscular injection of DDA based liposomes can promote a depot effect, 
crucially retaining antigen-liposome complexes at the site of injection, promoting 
monocyte infiltration (Henriksen-Lacey et al, 2010a). In contrast, liposomal vaccine 
delivery systems applied via intravenous injection have been restricted by poor stability in 
the blood stream and clearance by mononuclear phagocytic system (MPS) cells of the 
liver and spleen (Moghimi & Patel, 1989). Taking this into account and based on 
previously related immunisation studies involving the H1 subunit TB vaccine adsorbed to 
cationic DDA based liposomes stimulating powerful Th1 type immune responses 
(Henriksen-Lacey et al, 2010a; Henriksen-Lacey et al, 2010b), whilst also providing 
additional humoral immunity specific to hepatitis B surface antigen (Vangala et al, 2007), 
intramuscular injections of the outlined DDA-TDB based systems, surface adsorbed with 
the proposed H56 vaccine, was the route of choice for immunological characterisation. 
 
Having established the route of immunisation, the systems were characterised for 
interactions with H56 vaccine antigen prior to each immunisation. It was observed that in 
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dosage form, the cationic characteristics of the adjuvant delivery systems were crucially 
maintained (with the exception of the anionic DSPC-TDB liposomes). Indeed, the surface 
charge of a liposomal delivery system is a key factor influencing vital cellular interactions 
with such adjuvants. Hsu & Juliano, (1982) reported that an anionic charge can promote 
liposome-cell complexes when assessing the extent of liposomal interactions with mouse 
peritoneal macrophages. In this instance, macrophages interacted more favourably with 
negatively charged multilamellar vesicles than their cationic or neutral counterparts. In 
contrast, Magee et al, (1974) observed interactions of positively charged vesicles with 
cells in culture and hypothesised that cationic liposomes electrostatically bound to anionic 
cells, which encouraged uptake of the systems by fusion or endocytosis.  
 
The immunisation data demonstrated the immunoadjuvant capability of the proposed 
subunit vaccine delivery systems, with the role of DDA presence against DSPC and the 
effect of DDA-TDB concentration appreciated, suggesting that even minor adjuvant 
adjustment was sufficient to significantly impact the resultant immune responses. 
Moreover, with DDA-TDB providing the peak of cellular immune responses, depending 
on the extent of adjuvant adjustment, polarised responses were enthused. Indeed, results 
were dependent upon DDA lipid presence and independent of the system’s zeta potential. 
With DSPC continually replacing DDA or substituting DDA and TDB in the formulation, 
either cellular immunity, signified by IgG2b antibodies and IFN-γ and IL-2 cytokines, or 
humoral, Th2 type immunity, characterised by a strong antibody response and elevated IL-
5 and IL-10 cytokine production, was elicited. 
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Liposomal composition undoubtedly affects resultant interactions with immune system 
cells such as cells involved with antigen presentation (Bramwell & Perrie, 2006). The 
results of this thesis indicates the variety in induced immune responses from the liposomal 
systems, dictated by the level of DDA/DSPC incorporation, whilst initiating adaptive 
immunity and immunological memory, portrayed in the stronger secondary and tertiary 
antibody responses upon repeated immunisations of mice. 
 
The necessity of DDA within the formulation was also recognised as DDA fused with the 
antigen, ensuring that activated APCs were introduced to the related antigen, 
differentiating effector T cells accordingly to provide a desired adaptive immune response. 
DDA has previously been identified as an adjuvant capable of providing protective 
immunity in mice upon delivery of a TB subunit vaccine (Lindblad et al, 1997). 
Furthermore, DDA based adjuvants have been tested upon the addition of selected 
immunostimulatory components due to their Th1 inducing capabilities for example, with 
MPL (Brandt et al, 2000), whereby vaccination of mice with a DDA based subunit TB 
vaccine of ESAT-6 encouragingly stimulated strong antigen specific T-cell responses 
together with protective immunity on par with the BCG vaccine. Later studies by Holten-
Anderson et al, (2004), screened a variety of immunomodulators and identified DDA co-
administered with TDB as a strong Th1 promoting adjuvant alongside DDA-MPL, 
signified by elevated ESAT-6 antigen specific interferon gamma secretion, rendering 
DDA an efficient adjuvant for TB subunit vaccine delivery. Recent studies have also 
tested additional immunopotentiators alongside DDA-TDB, whereby incorporation of a 
TLR3 ligand of polyinosinic–polycytidylic acid (Poly I:C) induced high CD8+ T-cell 
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responses and thus, may be catered for subunit vaccination against viral pathogens 
(Nordly et al, 2011). 
 
Despite the impressive success of currently approved adjuvants for generating immunity 
to viral and bacterial infections, there is a necessity for improved adjuvants that enhance 
protective antibody responses, especially in populations that respond poorly to current 
vaccines. It also remains a great challenge to develop vaccines that generate strong T cell 
immunity using purified or recombinant vaccine antigens (Coffman et al, 2010). From the 
initial recognition of TDB potentiating DDA response and harbouring the ability to act as 
a subunit vaccine adjuvant delivery system, the expansion of DDA-TDB’s application has 
continued to develop (as highlighted in chapter 1, Table 1.6) and promisingly provide 
protection against a variety of disease targets.  
 
In terms of TB and the H56 vaccine antigen, it is apparent that the latency expressed 
protein can advantageously be maximised when combined with the H1 vaccine, as such 
early expressed antigens provide clonal expansion for the development of T-cell mediated 
immunity and protective efficacy against the advanced form of TB (Aagaard et al, 2011). 
Whilst the immunisation study conducted in this thesis strengthens the preclinical profile 
of this post exposure vaccine, if we compare back to the main identified vaccination 
strategies against TB (Chapter 1, Table 1.8), by targeting latently infected patients and 
combining early and latently expressed antigens, this particular candidate goes some way 
towards improving efficacy and preventing TB infection. However, we remain far from 
replacing the current live BCG vaccine in the near future, and only adjuvants that are 
approved and licensed for administration as vaccine products can be regarded as 
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successful (O’Hagan & Gregorio, 2009). Consequently, the promising immunological data 
attained in this thesis comes at an interesting time as we anticipate results of currently 
initiated clinical trials involving H56 vaccine, to establish its validity for use in humans. 
 
Having established the immunoadjuvant capabilities of the DSPC based liposomes in an 
animal model, the DPPC based systems were proposed for potential pulmonary vaccine 
delivery. The accessibility of the lungs, coupled with the ability to prepare liposomes 
within a broad particle size range, whilst integrating hydrophilic or lipophilic drugs, make 
pulmonary vaccination via liposomal systems a potentially favourable means of therapy 
(Taylor & Newton, 1992; Zeng et al, 1995). In this study, the use of ethanol was regarded 
as an unsuitable transfer medium for the DPPC based cationic liposome-protein 
complexes and some of the formulations may be too cytotoxic if an aerosolised system 
was to be achieved and targeted to the respiratory tract, making application potentially 
unviable for pulmonary delivery and hence, further work in this area was not carried out. 
Indeed, current systems utilised for parenteral vaccine delivery may not be appropriate for 
delivery to the respiratory tract as their safety profile has yet to be established for 
pulmonary use, requiring further research to evaluate whether adjuvants can be safely 
administered to the lung (Sou et al, 2011). 
 
Despite not being taken forward as a potential pulmonary vaccine in the current study, 
further studies of the proposed DPPC based formulations could be beneficial if 
alternatively developed into a dry powder format, in which case evaluating the main 
methods of developing dry powders such as spray and freeze drying would be of interest. 
Indeed, spray drying is a straightforward process that offers reasonable costs and potential 
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scalability (Fourie et al, 2008) and can be optimised to generate an abundance of stable 
protein based aerosolised powders, and is therefore well suited to produce antigen 
containing dry powdered pulmonary vaccines (Sou et al, 2011). In addition, freeze drying 
is the primary technique applied to create stable proteins and polypeptides that are 
otherwise physically or chemically unstable in fluid form (Manning et al, 1989), and when 
freeze drying DDA-TDB liposomes, trehalose has been shown to be an appropriate 
cryoprotectant providing protection during the freeze drying process and crucially, 
retaining its adjuvanticity (Christensen et al, 2007). Characterisation of the particle 
aerodynamic diameter is crucial (Johnson, 1997), and consideration into particle 
deposition within the lungs, which can be assessed in vitro using liquid impingers or 
cascade impactors (Waldrep et al, 1997), alongside evaluation of a suitable delivery 
device, would also be of great interest. Indeed, advancement of a suitable formulation for 
the administration of candidate antigens via inhalational vaccine delivery is still required 
to produce pulmonary vaccines for commercial use (Sou et al, 2011). 
 
To conclude, from the results obtained in this thesis, we have shown that DDA-TDB 
based liposomes can be adjusted to incorporate additional lipids with varying lipid chain 
lengths and melting points, and suffice as competent immunoadjuvant subunit delivery 
systems, meeting the objective of physicochemically characterising the proposed 
liposomal adjuvants and testing their viability in an animal model. In addition, the 
viability of the proposed systems was successfully examined using a macrophage cell line 
to screen selected in vitro characteristics, prior to elucidating their resultant 
immunological behaviour. With immune responses invariably dictated by DDA lipid 
content and DDA-TDB concentration, the DSPC based liposomes retained an 
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extraordinary ability to elicit antigen specific cell mediated immunity, stimulating either 
Th1 type immune responses, vital in providing protective efficacy against TB, or upon 
further adjustment, Th2 type humoral immune responses. Whilst appreciating the role of 
DDA vs. DSPC content, it was evident that even a minimal reduction in DDA-TDB 
concentration can significantly alter the resultant immune response. 
 
Overall, the results of this project suggest that we can incorporate DSPC lipid into the 
main DDA-TDB adjuvant yet maintain stability in terms of particle size and zeta potential, 
the system’s structural rigidity and favourably reduce cytotoxicity. Subsequently, upon 
conducting the immunisation study, the adjuvant effect of DDA, immunopotentiating 
necessity of TDB and the ability to customise resultant immune responses based on DSPC 
content was appreciated, displaying the multifaceted attributes of the formulations, 
demonstrating that liposomes can be regarded not only as delivery systems, but also as 
immunostimulatory adjuvants that increase the immunogenicity of antigens (Rongen, 
1997). The versatility and scope to tune the proposed adjuvant formulations provide a 
potential platform to facilitate the delivery of alternative subunit antigens and may be 
developed for other disease targets that require cell mediated or humoral immune 
responses. With currently ongoing clinical development of the H56 vaccine, we await 
results of the performance and applicability of the main DDA-TDB adjuvant, and should 
any issues arise, the promising immunological data obtained in this study for the DSPC 
based systems offer viable alternative adjuvant formulations that may be used. 
 
Hopefully the findings presented in this thesis have increased our knowledge of 
physicochemical liposomal characteristics that dictate the efficacy of such subunit vaccine 
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delivery systems, and provided some valuable formulation advantages whilst readdressing 
a balance between adjuvant potency and safety. The associated stability infers longer shelf 
life and lessens the need for controlled conditions during storage and distribution, which 
can ultimately reduce production costs. In addition, a reduced cytotoxicity could signify 
fewer local reaction events and less pain and discomfort upon injection, while facilitating 
better production and transport of the formulation. Such improvements provide further 
possible systems to the highly promising DDA-TDB adjuvant formulation and strengthen 
its pre-clinical profile and possible clinical acceptability, in this particular instance, for 
eliciting protection against TB in response to the novel H56 vaccine.  
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Table A.1. DDA-TDB based immunoadjuvant formulations in which the main liposomal system was 
either substituted or replaced with DPPC or DSPC lipid. The formulations are displayed in order of 
DDA content, with the highest level of cationic presence at the top. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
 
DDA/Lipid/TDB 
(µg/dose) 
 
DDA/Lipid/TDB 
(mg/ml) 
 
 
DDA-TDB 
 
+25% DPPC 
 
+25% DSPC 
 
DDA-LIPID-TDB 
 
+50% DPPC 
 
+50% DSPC 
 
DDA-LIPID-TDB 
 
DDA-LIPID-TDB 
 
+75% DPPC 
 
+75% DSPC 
 
DDA-LIPID-TDB 
 
DDA-LIPID-TDB 
 
DDA-LIPID-TDB 
 
 
250/0/50 
 
188/82/36 
 
188/88/36 
 
150/100/50 
 
125/165/25 
 
125/175/25 
 
100/150/50 
 
100/0/50 
 
62/246/14 
 
62/264/14 
 
50/200/50 
 
10/240/50 
 
0/250/50 
 
 
1.25/0.00/0.25 
 
0.94/0.41/0.18 
 
0.94/0.44/0.18 
 
0.75/0.50/0.25 
 
0.62/0.83/0.13 
 
0.62/0.88/0.13 
 
0.50/0.75/0.25 
 
0.50/0.00/0.25 
 
0.31/1.23/0.07 
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Figure A.1. Full vaccine immunisation study timeline. Vaccine preparations were made with liposomes incorporating H56 vaccine. All mice, with the exception of the 
naive group, were immunised intramuscularly with the proposed vaccine three times, with two week intervals between each immunisation, prior to termination after 7 weeks.  
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